



**CONSOLIDATED FINANCIAL STATEMENTS**  
**December 31, 2023**

# TABLE OF CONTENTS

<b>1. CONSOLIDATED FINANCIAL STATEMENTS.....</b>	<b>3</b>
Consolidated income statement .....	3
Consolidated statement of comprehensive income .....	3
Consolidated statement of financial position .....	4
Consolidated cash flow statement.....	5
Consolidated statement of changes in equity.....	6
<b>2. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS .....</b>	<b>7</b>

## 1. Consolidated financial statements

Unless otherwise stated, the consolidated financial statements are presented in millions of euros, rounded to the nearest hundred thousand euros. Rounding differences may therefore occur in the financial statements presented.

### Consolidated income statement

<i>(in millions of euros)</i>	Notes	2023	2022 Restated (a)
Gross rental income		363.9	364.0
Income from construction and off-plan sale contracts		1,073.9	1,059.3
Income from services provided		89.8	31.6
Other income from operating activities		129.3	113.6
<b>Income from operating activities</b>	9.1.	<b>1,656.9</b>	<b>1,568.5</b>
Purchases used		(946.1)	(861.1)
Outside services		(223.3)	(213.4)
Taxes, duties and similar payments		(7.4)	(5.0)
Staff costs, performance incentive scheme and profit sharing		(143.7)	(147.7)
Other operating expenses		(56.0)	(27.3)
<b>Expenses from operating activities</b>		<b>(1,376.5)</b>	<b>(1,254.4)</b>
<b>EBITDA</b>		<b>280.4</b>	<b>314.1</b>
Depreciation charges net of government investment grants		(22.8)	(21.8)
Change in fair value of investment property	6.3.	(1,466.2)	(387.3)
Charges and reversals related to impairment of tangible, financial and other current assets		0.2	3.0
Profit/(loss) from acquisitions		(1.7)	(0.7)
Profit/(loss) on asset disposals		(0.8)	(1.0)
Goodwill impairment	10.1.	(54.9)	-
Share of net profit/(loss) of equity-accounted companies	10.2.	(2.9)	14.0
<b>OPERATING PROFIT/(LOSS)</b>		<b>(1,268.8)</b>	<b>(79.8)</b>
<b>Cost of net financial liabilities</b>		<b>(49.7)</b>	<b>(72.7)</b>
Other finance income and expenses		(19.7)	(28.0)
<b>FINANCE INCOME/(EXPENSE)</b>	7.1.4.	<b>(69.4)</b>	<b>(100.7)</b>
Tax expense	11.1.	9.2	(22.2)
Net profit/(loss) from continuing operations		(1,329.0)	(202.7)
Profit/(loss) from discontinued operations	3.2.	38.4	424.6
<b>NET PROFIT/(LOSS)</b>		<b>(1,290.6)</b>	<b>221.9</b>
<b>Including net profit/(loss) attributable to the Group</b>		<b>(1,250.3)</b>	<b>54.1</b>
- Including continuing operations		(1,213.6)	(178.7)
- Including discontinued operations	3.2.	(36.7)	232.7
<b>Including net profit/(loss) attributable to non-controlling interests</b>		<b>(40.3)</b>	<b>167.8</b>
<b>Basic earnings per share attributable to the Group (in €)</b>	8.4.1.	<b>(€16.50)</b>	<b>€0.71</b>
- Including continuing operations per share		(€16.02)	(€2.36)
- Including discontinued operations per share		(€0.48)	€3.08
<b>Diluted earnings per share attributable to the Group (in €)</b>	8.4.2.	<b>(€16.48)</b>	<b>€0.71</b>
- Including continuing operations per share		(€16.00)	(€2.36)
- Including discontinued operations per share		(€0.48)	€3.07

(a) Reclassification of the Healthcare Property Investment business as discontinued operations in accordance with IFRS 5 (see note 3.3).

### Consolidated statement of comprehensive income

<i>(in millions of euros)</i>	2023	2022 Restated (a)
<b>NET PROFIT/(LOSS) FOR THE PERIOD</b>	<b>(1,290.6)</b>	<b>221.9</b>
<b>Other comprehensive income:</b>		
- <b>Recyclable to the income statement – cash flow hedges:</b>	<b>(29.9)</b>	<b>166.5</b>
- Change in fair value	(30.0)	167.6
- Tax on changes in fair value	0.3	(0.1)
- Recycling to the income statement	(0.2)	(1.0)
- <b>Non-recyclable to the income statement</b>	<b>0.3</b>	<b>2.9</b>
- Actuarial gains and losses	0.4	3.4
- Taxes on actuarial gains and losses	(0.1)	(0.5)
<b>Total other comprehensive income</b>	<b>(29.6)</b>	<b>169.4</b>
- Including transfer to net profit/(loss)	(0.2)	(1.0)
<b>COMPREHENSIVE INCOME FOR THE PERIOD</b>	<b>(1,320.2)</b>	<b>391.3</b>
- <b>Including comprehensive income attributable to the Group</b>	<b>(1,276.6)</b>	<b>185.6</b>
- Including continuing operations	(1,238.8)	(94.5)
- Including discontinued operations	(37.8)	280.1
- <b>Including comprehensive income attributable to non-controlling interests</b>	<b>(43.5)</b>	<b>205.7</b>

(a) Reclassification of the Healthcare Property Investment business as discontinued operations in accordance with IFRS 5 (see note 3.3).

## Consolidated statement of financial position

### ASSETS

<i>(in millions of euros)</i>	Notes	12/31/2023	12/31/2022
Goodwill	10.1.	-	54.9
Other intangible fixed assets	10.1.1.	31.5	29.4
Tangible fixed assets	10.1.2.	55.9	53.6
Net investment property	6.1.1.	6,646.8	14,834.4
Equity-accounted investments	10.2.	111.5	128.3
Financial assets at fair value through profit or loss	7.1.5.	18.8	23.0
Financial assets at amortised cost	7.1.5.	17.1	82.0
Derivative assets	7.1.3.	63.0	155.1
Deferred tax assets	11.3.	18.8	11.0
<b>NON-CURRENT ASSETS</b>		<b>6,963.4</b>	<b>15,371.8</b>
Inventories and work in progress	9.2.2.	742.2	816.2
Contract assets	9.2.3.	204.3	122.7
Accounts receivable	9.2.3.	168.9	173.5
Tax receivables		8.7	9.8
Miscellaneous receivables	9.2.4.	342.5	377.8
Other financial assets at fair value through profit or loss	7.1.5.	0.1	0.1
Financial assets at amortised cost	7.1.5.	358.5	114.1
Derivative assets	7.1.3.	0.6	0.1
Cash and cash equivalents	7.1.6.	1,620.2	1,084.6
Investment property held for sale	6.1.2.	62.0	147.5
Financial assets held for sale	2.1.	1,129.7	-
<b>CURRENT ASSETS</b>		<b>4,637.7</b>	<b>2,846.4</b>
<b>TOTAL ASSETS</b>		<b>11,601.0</b>	<b>18,218.2</b>

### LIABILITIES

<i>(in millions of euros)</i>	Notes	12/31/2023	12/31/2022
Share capital	8.1.1.	116.2	116.2
Share premium		2,387.4	2,514.3
Treasury shares		(33.9)	(33.9)
Revaluation reserves	7.1.3.	61.8	125.7
Other reserves		3,704.7	3,811.5
Net profit/(loss) attributable to the Group		(1,250.3)	54.1
<b>Equity attributable to the Group</b>		<b>4,985.9</b>	<b>6,587.9</b>
Non-controlling interests	8.3.1.	81.8	2,096.6
<b>EQUITY</b>		<b>5,067.7</b>	<b>8,684.5</b>
Provisions	12.1.	18.5	22.2
Financial liabilities at amortised cost	7.1.1.	4,519.5	6,815.4
Lease liabilities	9.3.	48.3	54.2
Tax liabilities		-	7.8
Deferred tax liabilities	11.3.	21.4	28.6
Other financial liabilities		59.0	74.6
Derivative liabilities	7.1.3.	1.3	0.8
<b>NON-CURRENT LIABILITIES</b>		<b>4,668.0</b>	<b>7,003.5</b>
Provisions	12.1.	57.3	59.9
Financial liabilities at amortised cost	7.1.1.	547.8	1,144.6
Lease liabilities	9.3.	12.2	8.7
Tax liabilities		2.9	11.4
Contract liabilities	9.2.3.	65.4	69.4
Accounts payable		692.2	680.8
Miscellaneous payables	9.2.4.	486.0	549.9
Other financial liabilities		0.7	3.1
Derivative liabilities	7.1.3.	0.0	0.1
Liabilities from discontinued operations	6.1.2.	0.8	2.3
<b>CURRENT LIABILITIES</b>		<b>1,865.3</b>	<b>2,530.1</b>
<b>TOTAL LIABILITIES AND EQUITY</b>		<b>11,601.0</b>	<b>18,218.2</b>

## Consolidated cash flow statement

<i>(in millions of euros)</i>	Notes	2023	2022
<b>I) OPERATING ACTIVITIES</b>			
Net profit/(loss)		(1,290.6)	221.9
Net depreciation and provision charges		118.5	34.4
Change in fair value of investment property		1,457.7	267.1
Unrealised gains and losses due to changes in fair value		18.2	(1.6)
Other non-cash income and expenses		3.2	16.2
Capital gains or losses on asset disposals		(5.6)	(20.7)
Capital gains or losses on disposals of investments in consolidated companies		119.8	(0.4)
Share of profit/(loss) of equity-accounted companies		2.9	(14.0)
Dividends received		(13.5)	(0.2)
<b>Cash flow from operating activities after cost of net financial liabilities and tax</b>		<b>410.6</b>	<b>502.7</b>
Cost of net financial liabilities		107.1	93.4
Tax expense		(10.9)	26.5
<b>Cash flow from operating activities before cost of net financial liabilities and tax</b>		<b>506.8</b>	<b>622.6</b>
Interest paid		(106.2)	(99.7)
Tax paid		(12.9)	(19.3)
Change in working capital requirement related to operating activities	9.2.1.	(79.5)	(190.8)
<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>		<b>308.2</b>	<b>312.9</b>
<i>Including net cash flow from operating activities – Discontinued operations</i>	3.2.	126.2	97.5
<b>II) INVESTING ACTIVITIES</b>			
Other intangible and tangible fixed assets and investment property			
- acquisitions		(304.6)	(547.1)
- disposals		148.3	653.1
Change in security deposits paid and received		17.2	(5.6)
Change in financial receivables		2.2	2.0
<b>Operating investments</b>		<b>(136.8)</b>	<b>102.4</b>
Investments in subsidiaries			
- acquisitions		(7.9)	(33.2)
- disposals		1,400.5	0.0
- impact of changes in scope of consolidation		(272.2)	16.6
Investments in equity-accounted companies and unconsolidated companies			
- acquisitions		11.3	10.1
- disposals		0.8	0.7
Dividends received and profit/(loss) of tax-transparent equity-accounted companies		14.7	(5.2)
<b>Financial investments</b>		<b>1,147.1</b>	<b>(10.9)</b>
<b>NET CASH FLOW FROM INVESTING ACTIVITIES</b>		<b>1,010.3</b>	<b>91.5</b>
<i>Including net cash flow from investing activities – Discontinued operations</i>	3.2.	(314.2)	(149.1)
<b>III) FINANCING ACTIVITIES</b>			
Amounts received from non-controlling interests on capital increases		7.1	89.8
- final and interim dividends paid to Icade SA shareholders	2.4.	(328.1)	(317.8)
- final and interim dividends paid to non-controlling interests		(95.4)	(95.9)
Repurchase of treasury shares		0.0	(0.1)
<b>Change in cash from capital activities</b>		<b>(416.4)</b>	<b>(324.0)</b>
Bond issues and new financial liabilities		253.1	1,771.6
Bond redemptions and repayments of financial liabilities		(832.0)	(1,426.8)
Repayments of lease liabilities		(11.6)	(8.7)
Acquisitions and disposals of current financial assets and liabilities		129.3	7.6
<b>Change in cash from financing activities</b>	7.1.1.	<b>(461.2)</b>	<b>343.7</b>
<b>NET CASH FLOW FROM FINANCING ACTIVITIES</b>		<b>(877.6)</b>	<b>19.7</b>
<i>Including net cash flow from financing activities – Discontinued operations</i>	3.2.	(227.7)	295.4
<b>NET CHANGE IN CASH (I) + (II) + (III)</b>		<b>440.9</b>	<b>424.1</b>
<b>CHANGES IN CASH FROM DISCONTINUED OPERATIONS</b>		<b>(70.7)</b>	<b>(71.2)</b>
<b>OPENING NET CASH</b>		<b>966.3</b>	<b>542.3</b>
<b>CLOSING NET CASH</b>		<b>1,407.2</b>	<b>966.3</b>
Cash and cash equivalents (excluding interest accrued but not due)		1,609.4	1,084.0
Bank overdrafts (excluding interest accrued but not due)		(202.3)	(117.7)
<b>NET CASH</b>		<b>1,407.2</b>	<b>966.3</b>

## Consolidated statement of changes in equity

<i>(in millions of euros)</i>	Share capital	Share premium	Treasury shares	Revaluation reserves	Other reserves and net profit/(loss) attributable to the Group	Equity attributable to the Group	Non-controlling interests	Total equity
<b>EQUITY AS OF 12/31/2021</b>	116.2	2,593.5	(39.1)	(3.0)	4,054.1	6,721.8	1,917.5	8,639.4
<b>Net profit/(loss)</b>					54.1	54.1	167.8	221.9
<b>Other comprehensive income:</b>								
<b>Cash flow hedges:</b>								
- Changes in value				129.6		129.6	38.0	167.6
- Tax on changes in fair value				(0.1)		(0.1)	(0.0)	(0.1)
- Recycling to the income statement				(0.9)		(0.9)	(0.1)	(1.0)
<b>Other non-recyclable items:</b>								
- Actuarial gains and losses					3.3	3.3	0.1	3.4
- Taxes on actuarial gains and losses					(0.5)	(0.5)		(0.5)
<b>Comprehensive income</b>				128.7	57.0	185.6	205.7	391.3
Dividends paid		(79.3)			(238.6)	(317.8)	(98.0)	(415.8)
Capital increases (a)					0.0	0.0	89.8	89.8
Treasury shares			5.2		(5.3)	(0.1)		(0.1)
Other (b)					(1.6)	(1.6)	(18.5)	(20.1)
<b>EQUITY AS OF 12/31/2022</b>	116.2	2,514.3	(33.9)	125.7	3,865.6	6,587.9	2,096.6	8,684.5
<b>Net profit/(loss)</b>					(1,250.3)	(1,250.3)	(40.3)	(1,290.6)
<b>Other comprehensive income:</b>								
<b>Cash flow hedges:</b>								
- Changes in value				(26.4)		(26.4)	(3.6)	(30.0)
- Tax on changes in fair value				0.2		0.2	0.1	0.3
- Recycling to the income statement				(0.4)		(0.4)	0.3	(0.2)
<b>Other non-recyclable items:</b>								
- Actuarial gains and losses					0.4	0.4	0.0	0.4
- Taxes on actuarial gains and losses					(0.1)	(0.1)		(0.1)
<b>Comprehensive income</b>				(26.6)	(1,250.0)	(1,276.6)	(43.5)	(1,320.2)
Dividends paid		(126.9)			(201.2)	(328.1)	(98.0)	(426.1)
Capital increases (a)							7.7	7.7
Treasury shares (c)			0.0			0.0		0.0
Other (d)				(37.3)	40.0	2.7	(1,880.9)	(1,878.2)
<b>EQUITY AS OF 12/31/2023</b>	116.2	2,387.4	(33.9)	61.8	2,454.4	4,985.9	81.8	5,067.7

(a) In 2022 and 2023, the change in non-controlling interests mainly related to the recognition of the capital increases completed by OPPCI IHE.

(b) In 2022, other factors related primarily to changes in scope of consolidation, more specifically Icade's exchange with another entity of their respective interests in two assets, namely Orianz and Factor E, and the acquisition of the M&A Group.

(c) Treasury shares decreased from 456,679 as of December 31, 2022 to 456,244 as of December 31, 2023.

(d) Other factors mainly related to the Healthcare Property Investment Division no longer being consolidated into the Group.

## 2. Notes to the consolidated financial statements

<b>NOTE 1 . GENERAL PRINCIPLES.....</b>	<b>8</b>
1.1. General information.....	8
1.2. Accounting standards .....	8
1.3. Basis of preparation and presentation of the consolidated financial statements.....	9
<b>NOTE 2 . HIGHLIGHTS OF THE FINANCIAL YEAR 2023 .....</b>	<b>11</b>
2.1. Divestment of the Healthcare Property Investment Division.....	11
2.2. Investments and disposals by the Commercial Property Investment Division .....	11
2.3. Changes in net financial liabilities .....	11
2.4. Dividend distribution .....	11
<b>NOTE 3 . DISCONTINUED OPERATIONS.....</b>	<b>12</b>
3.1. Icade's divestment of its healthcare business.....	12
3.2. Financial statements for discontinued operations.....	12
3.3. Restatement of comparative information.....	13
<b>NOTE 4 . SCOPE OF CONSOLIDATION .....</b>	<b>14</b>
<b>NOTE 5 . SEGMENT REPORTING .....</b>	<b>16</b>
5.1. Segmented income statement.....	16
5.2. Segmented statement of financial position .....	17
5.3. Segmented cash flow from fixed assets and investment property .....	17
<b>NOTE 6 . PROPERTY PORTFOLIO AND FAIR VALUE .....</b>	<b>18</b>
6.1. Property portfolio .....	18
6.2. Valuation of the property portfolio: methods and assumptions.....	21
6.3. Change in fair value of investment property.....	24
<b>NOTE 7 . FINANCE AND FINANCIAL INSTRUMENTS .....</b>	<b>25</b>
7.1. Financial structure and contribution to profit/(loss).....	25
7.2. Management of financial risks .....	31
7.3. Fair value of financial assets and liabilities.....	34
<b>NOTE 8 . EQUITY AND EARNINGS PER SHARE .....</b>	<b>35</b>
8.1. Share capital and shareholding structure .....	35
8.2. Dividends .....	35
8.3. Non-controlling interests .....	36
8.4. Earnings per share .....	37
<b>NOTE 9 . OPERATIONAL INFORMATION .....</b>	<b>38</b>
9.1. Income from operating activities .....	38
9.2. Components of the working capital requirement .....	39
9.3. Lease liabilities .....	42
<b>NOTE 10 . OTHER NON-CURRENT ASSETS.....</b>	<b>43</b>
10.1. Goodwill, other intangible and tangible fixed assets .....	43
10.2. Equity-accounted investments.....	46
<b>NOTE 11 . INCOME TAX.....</b>	<b>48</b>
11.1. Tax expense .....	49
11.2. Reconciliation of the theoretical tax rate to the effective tax rate .....	49
11.3. Deferred tax assets and liabilities .....	49
<b>NOTE 12 . PROVISIONS .....</b>	<b>50</b>
12.1. Provisions.....	50
12.2. Contingent liabilities .....	50
<b>NOTE 13 . EMPLOYEE REMUNERATION AND BENEFITS.....</b>	<b>51</b>
13.1. Short-term employee benefits.....	51
13.2. Post-employment benefits and other long-term employee benefits.....	52
13.3. Share-based payments.....	54
13.4. Staff.....	55
<b>NOTE 14 . OTHER INFORMATION .....</b>	<b>56</b>
14.1. Related parties.....	56
14.2. Off-balance sheet commitments.....	57
14.3. Events after the reporting period .....	59
14.4. Statutory Auditors' fees .....	59
14.5. Scope of consolidation .....	60

## Note 1 . General principles

### 1.1. General information

Icade ("the Company") is a French public limited company (SA, *société anonyme*). Its registered office is situated at 27 rue Camille Desmoulins, 92130 Issy-les-Moulineaux, France.

The Company's consolidated financial statements as of December 31, 2023 reflect the financial position and profits and losses of the Company and its subsidiaries ("the Group"), as well as the Group's investments in equity-accounted companies (joint ventures and associates). They were prepared in euros, which is the Company's functional currency.

As of December 31, 2023, the Group was an integrated real estate player operating as a commercial property investor and a developer of residential and office properties as well as large-scale public amenities.

### 1.2. Accounting standards

The Group's consolidated financial statements as of December 31, 2023 have been prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the European Union as of December 31, 2023, pursuant to European Regulation No. 1606/2002 dated July 19, 2002, and include comparative information as of December 31, 2022 prepared in accordance with the IFRS applicable at the reporting date.

The international accounting standards are issued by the IASB (International Accounting Standards Board) and have been adopted by the European Union. They include the IFRS, the IAS (International Accounting Standards) and their interpretations. These standards are available for viewing on the European Commission's website.

The accounting policies and measurement bases used by the Group in preparing the consolidated financial statements as of December 31, 2023 are identical to those used for the consolidated financial statements as of December 31, 2022, except for those mandatory standards, interpretations and amendments to be applied for annual periods beginning on or after January 1, 2023, which are detailed in note 1.2.1 below.

These consolidated financial statements were approved by the Board of Directors on February 16, 2024.

#### 1.2.1. Mandatory standards, amendments and interpretations adopted by the European Union which became effective for annual periods beginning on or after January 1, 2023

- ◆ Amendments to IAS 1 – Disclosure of Accounting Policies.  
These amendments aim to clarify the disclosures to be made in the financial statements regarding material accounting policies ("material" as defined in IAS 1). IFRS Practice Statement 2: Making Materiality Judgements has been amended by adding guidance on how to identify material accounting policy information and examples of how to apply IAS 1 as amended.
- ◆ Amendments to IAS 8 – Definition of Accounting Estimates.  
The objective of these amendments is to define accounting estimates as "monetary amounts in financial statements that are subject to measurement uncertainty". They also specify that entities develop accounting estimates if accounting policies require items in financial statements to be measured in a way that involves measurement uncertainty (monetary amounts that are not directly observable).
- ◆ Amendments to IAS 12 – Deferred Tax related to Assets and Liabilities arising from a Single Transaction.  
These amendments specify how companies should recognise deferred tax when they account for transactions, such as leases, by recognising both an asset and a liability.

These amendments have had no impact on the Group.

- ◆ International Tax Reform – Pillar Two Model Rules.  
The 2024 Finance Act transposed Council Directive (EU) 2022/2523 of December 15, 2022 into French law. This directive aims to ensure a global minimum level of taxation of 15% for multinational enterprise groups and large-scale domestic groups in the European Union, known as "Pillar Two".  
However, uncertainties remain as to how it should be applied, and the OECD regularly publishes administrative guidance on this subject. This guidance is expected to be transposed into French law by an ordinance, since the July 2023 and December 2023 guidance is not at present covered by the 2024 Finance Act.

"Transitional Safe Harbour", i.e. a temporary simplification measure, has been introduced for the financial years 2024 to 2026. This measure enables groups to comply with their GloBE obligations gradually by not having to perform all the calculations required to determine their tax liability for GloBE purposes from the outset in countries where their presence is not significant or where taxation is high.

The Group has applied the amendment to IAS 12 providing for a mandatory temporary exception from accounting for deferred tax associated with top-up tax arising from the Pillar Two rules.

The first impact assessments for this directive were still ongoing at the end of the reporting period. At present, the Group does not expect any significant impact in terms of top-up tax from the entry into force of the Pillar Two framework.

- ◆ IFRS 17 – Insurance Contracts (replacing IFRS 4).



- ◆ Initial Application of IFRS 17 and IFRS 9 – Comparative Information.

These amendments are not applicable to the Group.

### 1.2.2. Standards, amendments and interpretations issued but not yet mandatory for annual periods beginning on or after January 1, 2023

**Standards, amendments and interpretations issued by the IASB effective for annual periods beginning on or after January 1, 2024 but not yet adopted by the European Union**

- ◆ Amendments to IAS 1 – Classification of Liabilities as Current or Non-current.  
These amendments aim to clarify the criteria for the classification of a liability as either current or non-current.
- ◆ Amendment to IFRS 16 – Lease Liability in a Sale and Leaseback.
- ◆ Amendments to IAS 7 and IFRS 7 – Supplier Finance Arrangements.
- ◆ Amendments to IAS 21 – Lack of Exchangeability.

## 1.3. Basis of preparation and presentation of the consolidated financial statements

### 1.3.1. Measurement bases

The consolidated financial statements have been prepared according to the amortised cost method, with the exception of investment property and certain financial assets and liabilities measured at fair value.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. IFRS 13 – Fair Value Measurement utilises a fair value hierarchy across three levels:

- ◆ level 1: fair value measured based on unadjusted prices quoted in active markets for identical assets or liabilities;
- ◆ level 2: fair value measured based on models using observable data, either directly (i.e. prices), or indirectly (i.e. data derived from prices);
- ◆ level 3: fair value measured based on market data not directly observable.

According to the principle of relevance and the ensuing materiality notion, only information deemed relevant and useful to the users' understanding of the consolidated financial statements is reported.

### 1.3.2. Use of judgement and estimates

The preparation of consolidated financial statements requires the Group's management to use estimates and assumptions to determine the value of certain assets, liabilities, income and expenses, as well as for the information provided in the notes to the consolidated financial statements.

Due to the uncertainties inherent in any measurement process, the Group revises its estimates on the basis of regularly updated information. The future results of the operations concerned may differ from the estimates made at the reporting date of the consolidated financial statements.

The main estimates made by the Group related to the following measurements:

- ◆ the fair value of investment property determined based on the valuations carried out by independent property valuers (*see note 6.2*);
- ◆ measurement of credit risk arising from accounts receivable (*see note 9.2*);
- ◆ measurement of revenue based on the percentage of completion method for construction and off-plan sale contracts following the review of property developments whose land is controlled by the Group (*see note 9.1*).

The accounting estimates used to prepare the financial statements as of December 31, 2023 were made amid a complex and volatile economic environment with persistent inflation and rising interest rates. In 2023, the Group was able to withstand these elevated interest rates through its high levels of fixed rate or hedged debt. However, the Group will continue to pay particular attention to the short- and medium-term outlook for rising interest rates in the financial markets and their impact on financing costs. For the period ended December 31, 2023, the Group considered the reliable information at its disposal with respect to the impact of this situation.

In addition to using estimates, the Group's management used its judgement to define the appropriate accounting treatment for certain operations and transactions where current IFRS and their interpretations did not specifically address the accounting issues raised.

Management exercised its judgement in:

- ◆ determining the degree of control (sole or joint) by the Group over its investments or the existence of significant influence;
- ◆ measuring the right-of-use assets and lease commitments that were used in applying IFRS 16 – Leases and, in particular, in determining lease terms;
- ◆ determining the classification of leases in which the Group is the lessor between operating and finance leases;
- ◆ recognising deferred tax assets, in particular tax loss carry forwards;
- ◆ determining whether certain assets and related liabilities meet the criteria to be classified as held for sale in accordance with IFRS 5.

### 1.3.3. Effects of climate change

The 2015 Paris Climate Agreement has stepped up the fight against climate change which lies at the heart of the environmental and societal concerns of major European economic players.

As such, in order to reduce its greenhouse gas emissions, the Group has been on a very ambitious low-carbon pathway for several years and set even higher goals by defining an objective for each business line by 2030 (-60% for Commercial Property Investment and -41% for Property Development).

The Group has also integrated this into its investment and expenditure policy in line with applicable regulations and its strategy to reduce its carbon footprint. As such, funds have been allocated on a yearly basis to finance projects to be undertaken.

For this purpose, when determining the fair value of investment properties, planned investments, including climate-related ones, are reported to the independent property valuers. Such property valuers carry out their work in accordance with their professional standards, as described in note 6.2.1 "Valuation assignments". Based on their knowledge of the market, they found no evidence that sustainability criteria had a material impact on transaction prices in 2023. However, they remain attentive to any changes in the real estate market in this regard.

As of December 31, 2023, the inclusion of climate change effects has had no significant impact on the judgement and key estimates required to prepare the financial statements.

In addition, the Group has continued its sustainable financing strategy following the adoption, at the end of 2021, of a new Green Bond Framework as detailed in note 7.1 "Financial structure and contribution to profit/(loss)".

## Note 2 . Highlights of the financial year 2023

### 2.1. Divestment of the Healthcare Property Investment Division

On June 13, 2023, Icade signed a sale and purchase agreement with Primonial REIM and the minority shareholders of both Praemia Healthcare (formerly Icade Santé) and IHE. This agreement provides for the three-stage sale of its entire healthcare property portfolio worth a total of €2.6 billion based on EPRA NTA as of December 31, 2022.

The first stage of the transaction was completed on July 5, 2023. It involved the sale of 63% of Icade's stake in Praemia Healthcare for €1.4 billion, based on a valuation in line with EPRA NTA as of December 31, 2022, after adjusting for the 2022 dividend.

As part of this first stage, Primonial REIM took over management of Praemia Healthcare's property assets as well as IHE's portfolio. In particular, it is responsible for selling the assets in this portfolio at times that optimise their value.

As provided for in the agreements, Icade's remaining stake in Praemia Healthcare is scheduled to be acquired by the end of 2025 by funds managed by Primonial REIM France using their inflows, based on the most recently published EPRA NTA.

On July 5, 2023, Praemia Healthcare also repaid the outstanding balance of its €50.0 million shareholder loan from Icade and exited the cash pooling arrangement in place.

In the Group's financial statements, the Healthcare Property Investment Division's contribution for FY 2022 and H1 2023 was presented in "Profit/(loss) from discontinued operations" under IFRS 5.

In 2023, "Profit/(loss) from discontinued operations" also included the impact of recognising the full gain or loss on the disposal of Praemia Healthcare. Note 3 details the impact of applying IFRS 5 on the financial statements.

Following the completion of the first stage and Icade's loss of control, the Healthcare Property Investment Division was deconsolidated from the Group's financial statements.

As of December 31, 2023, the remaining interests in the Healthcare Property Investment Division were measured at fair value through profit or loss and presented under "Financial assets held for sale" in the consolidated statement of financial position pending completion of the next two stages of the disposal. The change in fair value of the remaining interests in the Healthcare Property Investment Division as of December 31, 2023 was a negative €14 million. It was recognised as a finance expense.

### 2.2. Investments and disposals by the Commercial Property Investment Division

- ♦ The Commercial Property Investment Division invested a total of €259.0 million. These investments related to the acquisition of Ponant B and ongoing development projects such as the Olympic Village, Next, Jump and Grand Central.
- ♦ The Commercial Property Investment Division sold assets for a total of €146.2 million. These disposals related to a residual residential portfolio sold to the RLF Group for nearly €40 million and the Eko Active and Grand Central office buildings.

For further information about investments and disposals completed during the period, an analysis has been provided in note 6.1.1 "Investment property".

### 2.3. Changes in net financial liabilities

The Group's net financial liabilities decreased from €6,573.7 million as of December 31, 2022 to €3,015.9 million as of December 31, 2023, mainly due to the divestment of the Healthcare Property Investment Division as described in note 2.1.

For further information about changes in the Group's finance during the period, a complete review has been provided in note 7 "Finance and financial instruments".

### 2.4. Dividend distribution

The General Meeting held on April 21, 2023 approved a gross dividend of €4.33 per share for the financial year 2022 and the following payment terms:

- ♦ Payment of an interim dividend of €2.16 per share in cash on March 2, 2023 totalling €163.7 million, after taking into account treasury shares; and
- ♦ A final dividend payment of €2.17 per share on July 6, 2023 totalling €164.4 million, after taking into account treasury shares.

For further information about the dividends paid out by the Group during the year, an analysis has been provided in note 8 "Equity and earnings per share".

## Note 3 .Discontinued operations

### 3.1. Icade's divestment of its healthcare business

The divestment of the Healthcare Property Investment Division's business as described in note 2.1 led the Group to account for the contribution of this division as discontinued operations under IFRS 5:

- Net profit/(loss) from discontinued operations for H1 2023 and FY 2022 is presented in the income statement as "Net profit/(loss) from discontinued operations" (see note 3.3);
- Net profit/(loss) from discontinued operations for the period includes the full gain or loss on disposal of the healthcare business less the costs associated with its sale;
- Net cash flow from operating, investment and financing activities from discontinued operations for the period is presented in the Group's cash flow statement for the current period and comparative period.

### 3.2. Financial statements for discontinued operations

The financial statements of the Healthcare Property Investment Division, which has been reclassified as discontinued operations, are detailed below:

#### Income statement for discontinued operations – Healthcare Property Investment

(in millions of euros)	2023	2022
<b>Income from operating activities</b>	<b>187.3</b>	<b>360.7</b>
<b>EBITDA</b>	<b>178.3</b>	<b>336.2</b>
Change in fair value of investment property	8.5	120.1
Profit/(loss) on disposal of investment property	(0.0)	6.0
<b>OPERATING PROFIT/(LOSS)</b>	<b>186.7</b>	<b>462.3</b>
<b>FINANCE INCOME/(EXPENSE)</b>	<b>(22.1)</b>	<b>(33.5)</b>
Tax expense	1.6	(4.3)
Profit/(loss) on asset disposals	(127.9)	-
<b>NET PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS</b>	<b>38.4</b>	<b>424.6</b>
<b>NET PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS ATTRIBUTABLE TO THE GROUP</b>	<b>(36.7)</b>	<b>232.7</b>

(in millions of euros)	2023	2022
<b>NET PROFIT/(LOSS)</b>	<b>38.4</b>	<b>424.6</b>
<b>Other comprehensive income:</b>		
- <b>Recyclable to the income statement – cash flow hedges:</b>	<b>(1.9)</b>	<b>81.1</b>
- Change in fair value	(2.0)	81.5
- Recycling to the income statement	0.1	(0.4)
- <b>Non-recyclable to the income statement</b>	<b>0.0</b>	<b>0.1</b>
- Actuarial gains and losses	0.0	0.1
<b>Comprehensive income recognised in equity</b>	<b>(1.9)</b>	<b>81.2</b>
- Including transfer to net profit/(loss)	0.1	(0.4)
<b>COMPREHENSIVE INCOME FROM DISCONTINUED OPERATIONS</b>	<b>36.5</b>	<b>505.8</b>
- <b>Attributable to the Group</b>	<b>(37.8)</b>	<b>280.1</b>

### Cash flow statement for discontinued operations – Healthcare Property Investment

(in millions of euros)	2023	2022
<b>I) OPERATING ACTIVITIES</b>		
<b>Net profit/(loss)</b>	<b>38.4</b>	<b>424.6</b>
Cash flow from operating activities before cost of net financial liabilities and tax	167.2	305.0
Interest paid	(16.2)	(29.2)
Tax paid	(3.5)	(10.3)
Change in working capital requirement related to operating activities	(8.6)	(68.0)
<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>	<b>126.2</b>	<b>97.5</b>
<b>II) INVESTING ACTIVITIES</b>		
Other intangible and tangible fixed assets and investment property		
- acquisitions	(57.3)	(242.6)
- disposals	1.0	95.2
Change in security deposits paid and received	12.7	(1.9)
<b>Operating investments</b>	<b>(43.6)</b>	<b>(149.3)</b>
<b>Financial investments</b>	<b>(270.6)</b>	<b>0.3</b>
<b>NET CASH FLOW FROM INVESTING ACTIVITIES</b>	<b>(314.2)</b>	<b>(149.1)</b>
<b>III) FINANCING ACTIVITIES</b>		
<b>Change in cash from capital activities</b>	<b>(215.7)</b>	<b>(0.9)</b>
Bond issues and new financial liabilities	8.4	418.0
Bond redemptions and repayments of financial liabilities	(20.2)	(48.9)
Repayments of lease liabilities	(0.0)	(0.0)
Acquisitions and disposals of current financial assets and liabilities	(0.2)	(0.1)
<b>Change in cash from financing activities</b>	<b>(12.0)</b>	<b>369.0</b>
<b>NET CASH FLOW FROM FINANCING ACTIVITIES</b>	<b>(227.7)</b>	<b>295.4</b>

### 3.3. Restatement of comparative information

The comparative period has been restated in the income statement by reclassifying the Healthcare Property Investment Division's contribution to "Profit/(loss) from discontinued operations", with the following impact:

(in millions of euros)	2022 reported	IFRS 5 adjustments	2022 restated
Gross rental income	723.9	(359.9)	364.0
Income from construction and off-plan sale contracts	1,059.3	-	1,059.3
Income from services provided	32.4	(0.8)	31.6
Other income from operating activities	145.8	(32.2)	113.6
<b>Income from operating activities</b>	<b>1,961.4</b>	<b>(392.9)</b>	<b>1,568.5</b>
Expenses from operating activities	(1,311.1)	56.7	(1,254.4)
<b>EBITDA</b>	<b>650.3</b>	<b>(336.2)</b>	<b>314.1</b>
Change in fair value of investment property	(267.1)	(120.1)	(387.3)
Other operating income/(expenses)	(0.6)	(6.0)	(6.6)
<b>OPERATING PROFIT/(LOSS)</b>	<b>382.5</b>	<b>(462.3)</b>	<b>(79.8)</b>
<b>FINANCE INCOME/(EXPENSE)</b>	<b>(134.1)</b>	<b>33.5</b>	<b>(100.7)</b>
Tax expense	(26.5)	4.3	(22.2)
Profit/(loss) from discontinued operations	-	424.6	424.6
<b>NET PROFIT/(LOSS)</b>	<b>221.9</b>	<b>-</b>	<b>221.9</b>
<b>NET PROFIT/(LOSS) ATTRIBUTABLE TO THE GROUP</b>	<b>54.1</b>	<b>-</b>	<b>54.1</b>

## Note 4 . Scope of consolidation

### ACCOUNTING PRINCIPLES

#### Consolidation principles

The consolidated financial statements include the financial statements of fully consolidated subsidiaries as well as the Group's investments in joint ventures and associates, which are accounted for using the equity method. The consolidation method is determined in accordance with the degree of control by the Group.

#### ◆ Subsidiaries

A subsidiary is an entity that is directly or indirectly controlled by the Group. Control exists when the Group:

- has power over the entity in terms of voting rights;
- has rights to variable returns from its involvement with the entity;
- has the ability to use its power to affect the amount of these returns.

Potential voting rights as well as the power to govern the financial and operating policies of the entity are also among the factors taken into account by the Group in order to assess control.

Subsidiaries are fully consolidated from the date the latter acquires control over them until the date that such control ceases.

Non-controlling interests represent the share of interest which is not directly or indirectly attributable to the Group. These are presented in equity as "Non-controlling interests" and in the income statement as "Net profit/(loss) attributable to non-controlling interests".

All intragroup transactions and balances between the Group's subsidiaries are eliminated on consolidation.

#### ◆ Joint ventures and associates

A joint venture is an entity over which the Group exercises joint control by virtue of a contractual agreement. Joint control exists where unanimous consent of the parties that have joint control is required in the choice of financial and operating policies relating to the entity.

An associate is an entity in which the Group has significant influence over the financial and operating policies but not control or joint control.

Joint ventures and associates are consolidated using the equity method from the date on which joint control (for joint ventures) or significant influence (for associates) commences until the date on which joint control or significant influence ceases.

The consolidated financial statements include the Group's share of changes in the net assets of equity-accounted companies and its share of the net profit/(loss) of these companies. Only intragroup profits and dividends are eliminated based on the Group's ownership interest.

#### ◆ Other investments

Where the Group holds an investment in a company in which it does not have direct, indirect or joint control, or significant influence over its financial and operating policies, the investment is recognised as a financial asset at fair value through profit or loss and presented under the relevant heading of the consolidated statement of financial position. The method used for measuring other investments is presented in note 7.1.5.

#### Business combinations

To determine whether a transaction is a business combination under the revised IFRS 3, the Group analyses whether an integrated set of activities and assets has been acquired and not just property and whether this integrated set includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output.

The consideration transferred must include any contingent consideration, which must be measured at fair value.

According to the acquisition method, the acquirer must, at the acquisition date, recognise the identifiable assets, liabilities and contingent liabilities of the acquiree at fair value at that date.

Goodwill is measured as the difference between, on the one hand, the fair value of the consideration transferred and, on the other hand, the net of the acquisition-date amounts of the identifiable assets and liabilities assumed measured at fair value. If positive, goodwill is accounted for on the asset side of the balance sheet. If negative, goodwill may be referred to as "negative goodwill" or "badwill" or "bargain purchase gain" (arising as a result of a bargain purchase) and is recognised immediately in the income statement under the heading "Profit/(loss) from acquisitions".

For business combinations in which the acquirer holds less than 100% of the equity interests in the acquiree, the fraction of interests that were not acquired (i.e. the amount of non-controlling interests) in the acquiree is measured and recognised:

- ◆ either at acquisition-date fair value; goodwill is therefore recognised for the portion attributable to non-controlling interests in accordance with the full goodwill method;
- ◆ or on the basis of the acquirer's share of the acquiree's identifiable net assets; no goodwill is therefore recognised for the portion attributable to non-controlling interests in accordance with the partial goodwill method.

The Group has 12 months from the acquisition date to definitively determine the fair value of the assets acquired and liabilities assumed. Any adjustment to the fair value of these assets and liabilities which occurred during that period is recognised against goodwill. Beyond that period, any adjustment to the fair value of assets and liabilities is recognised directly through profit or loss.

Costs of business acquisitions are recorded as expenses in “Profit/(loss) from acquisitions” in the consolidated income statement.

**Change in the Group’s ownership interest in an investment**

Changes in ownership interest that do not affect control (additional acquisition or disposal) shall result in a new apportionment of equity between the Group’s share and the share of non-controlling interests.

Changes in ownership interest resulting in a change in the nature of control over an entity shall give rise to the recognition of a profit or loss on the disposal and remeasurement of the fair value of the ownership interest retained as a corresponding entry of the profit or loss.

**Discontinued operations**

According to IFRS 5, a discontinued operation is a component of the Group which has been disposed of or is classified as held for sale, and which represents either a separate major line of business or a geographical area of operations.

If the component qualifies as a discontinued operation, the profit or loss as well as the capital gain or loss from the sale of this operation are also shown, net of taxes and actual or estimated selling costs, as a separate line item in the consolidated income statement.

Cash flow from discontinued operations is also shown separately in the consolidated cash flow statement.

The same accounting treatments are applied to the consolidated income statement and consolidated cash flow statement for the preceding financial year, which are shown as comparative information.

The companies included in the scope of consolidation are listed in note 14.5.

The impact of these changes in scope of consolidation on the main line items of the consolidated statement of financial position is shown in the corresponding notes.

- ◆ The divestment of the Healthcare Property Investment Division as described in note 2.1 led to this division’s entities being deconsolidated on July 5, 2023, upon completion of the first stage of the transaction under the sale and purchase agreement signed with Primonial REIM;
- ◆ Other changes in the scope of consolidation during the financial year mainly resulted from the creation and dissolution of legal entities during the financial year.

## Note 5 . Segment reporting

### ACCOUNTING PRINCIPLES

In accordance with IFRS 8 – Operating segments, segment information must be structured according to the operating segments for which results are regularly reviewed by the chief operating decision maker in order to assess their performance and make decisions about resources to be allocated to such segments. Segment information must be consistent with internal reporting to the chief operating decision maker.

As a result of the divestment of the Healthcare Property Investment Division, the Group is now structured around two business lines, each having its own specific risks and advantages. These two business lines, which constitute the Group's two operating segments under the standard, are as follows:

- ♦ the **Commercial Property Investment** business, which focuses primarily on holding and developing office properties and business parks for the rental of these assets and active management of this asset portfolio. Holding company activities are presented in the Commercial Property Investment segment;
- ♦ the **Property Development** business, which focuses primarily on building property assets with a view to selling them (office and residential properties, large-scale public amenities and healthcare facilities).

The **Intersegment transactions and other items** column includes discontinued operations as well as eliminations and reclassifications relating to transactions between business lines.

The following information is presented in accordance with the same accounting principles as those used in preparing the Group's consolidated financial statements.

The Healthcare Property Investment Division's contribution in FY 2022 and H1 2023 is shown in the column "Intersegment transactions and other items".

### 5.1. Segmented income statement

	Notes	Commercial Property Investment		Property Development		Intersegment transactions and other items		Total	
		2023	2022 Restated (a)	2023	2022	2023	2022 Restated (a)	2023	2022 Restated (a)
		(in millions of euros)							
INCOME FROM OPERATING ACTIVITIES	9.1.	516.5	489.1	1,139.2	1,081.7	1.3	(2.2)	1,656.9	1,568.5
EBITDA		281.6	283.5	(5.4)	43.7	4.2	(13.1)	280.4	314.1
OPERATING PROFIT/(LOSS)		(1,208.5)	(122.7)	(66.6)	53.8	6.3	(10.9)	(1,268.8)	(79.8)
FINANCE INCOME/(EXPENSE)		(53.3)	(86.6)	(21.1)	(14.2)	5.0	0.1	(69.4)	(100.7)
Profit/(loss) from discontinued operations						38.4	424.6	38.4	424.6
NET PROFIT/(LOSS)		(1,262.0)	(224.7)	(78.2)	32.8	49.6	413.8	(1,290.6)	221.9
Net profit/(loss) attributable to non-controlling interests		(109.7)	(4.8)	3.8	6.6	65.6	166.0	(40.3)	167.8
NET PROFIT/(LOSS) ATTRIBUTABLE TO THE GROUP		(1,152.3)	(219.9)	(82.0)	26.3	(16.0)	247.7	(1,250.3)	54.1

(a) Reclassification of the Healthcare Property Investment business as discontinued operations in accordance with IFRS 5 and its presentation, including the associated impacts, in the column "Intersegment transactions and other items" as a result of the divestment in 2023 (see note 2.1).

In 2023, 100% of revenue was generated in France.



## 5.2. Segmented statement of financial position

	Commercial Property Investment		Property Development		Intersegment transactions and other items		Total	
(in millions of euros)	12/31/2023	12/31/2022	12/31/2023	12/31/2022	12/31/2023	12/31/2022 Restated (a)	12/31/2023	12/31/2022
Investment property	6,646.8	7,902.0	-	-		6,932.4	6,646.8	14,834.4
Financial assets held for sale (b)		-		-	1,129.7	-	1,129.7	-
Other assets	2,435.2	3,744.4	1,690.4	1,742.8	(301.1)	(2,103.5)	3,824.5	3,383.7
<b>TOTAL ASSETS</b>	<b>9,082.0</b>	<b>11,646.4</b>	<b>1,690.4</b>	<b>1,742.8</b>	<b>828.6</b>	<b>4,828.9</b>	<b>11,601.0</b>	<b>18,218.2</b>
Equity attributable to the Group	3,635.8	5,314.8	35.0	115.9	1,315.1	1,157.2	4,985.9	6,587.9
Non-controlling interests	74.6	179.6	7.2	11.1		1,906.0	81.8	2,096.6
Financial liabilities	4,856.4	5,677.7	718.6	630.1	(507.7)	1,652.2	5,067.3	7,960.0
Other liabilities	515.2	474.3	929.6	985.7	21.2	113.5	1,466.0	1,573.7
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>9,082.0</b>	<b>11,646.4</b>	<b>1,690.4</b>	<b>1,742.8</b>	<b>828.6</b>	<b>4,828.9</b>	<b>11,601.0</b>	<b>18,218.2</b>

(a) The Healthcare Property Investment Division is presented in the column "Intersegment transactions and other items" as a result of the divestment in 2023 (see note 2.1).

(b) Relates to the remaining interests in the Healthcare Property Investment Division held for sale.

## 5.3. Segmented cash flow from fixed assets and investment property

	Commercial Property Investment		Property Development		Intersegment transactions and other items		Total	
(in millions of euros)	2023	2022	2023	2022	2023	2022 Restated (a)	2023	2022
<b>CASH FLOW:</b>								
- acquisitions	(241.3)	(293.9)	(6.0)	(10.6)	(57.3)	(242.6)	(304.6)	(547.1)
- disposals	145.2	557.9	1.1	-	2.0	95.2	148.3	653.1

(a) The Healthcare Property Investment Division is presented in the column "Intersegment transactions and other items" as a result of the divestment in 2023 (see note 2.1).

## Note 6 . Property portfolio and fair value

### 6.1. Property portfolio

#### 6.1.1. Investment property

##### ACCOUNTING PRINCIPLES

IAS 40 – Investment property defines investment property as property held by the owner to earn rentals or for capital appreciation or both. This category of property cannot be held for use in the production or supply of goods or services or for administrative purposes. Furthermore, the existence of building rights, leasehold rights or building leases also falls within the definition of investment property.

Property that is being developed for future use as investment property is classified as investment property.

In accordance with the option offered by IAS 40, investment property is measured at fair value.

##### Investment property excluding right-of-use assets relating to building leases

Investment property is initially recognised at cost, which includes:

- ◆ the purchase price stated in the deed of acquisition or the construction costs, including non-refundable taxes, after deducting any trade discounts, rebates or cash discounts;
- ◆ the cost of restoration work;
- ◆ all directly attributable costs incurred in order to put the investment property in a condition to be leased in accordance with the use intended by management. Thus, transfer duties, fees, commissions and fixed legal expenses related to the acquisition, and leasing commissions are included in the cost;
- ◆ costs of bringing the property into compliance with safety and environmental regulations;
- ◆ capitalised borrowing costs.

Following initial recognition, investment property is measured at fair value.

The fair value of investment property is measured based on independent property valuations whose methods and assumptions are described in note 6.2. The fair values are appraised values excluding duties, except for those assets acquired at the end of the year for which the fair value is measured based on the acquisition price.

Investment property under construction, or undergoing major renovation, is valued according to the general principle of fair value unless it is not possible to determine its fair value reliably and continuously. In the latter case, the property is provisionally valued at cost less any impairment losses.

In accordance with IAS 36, investment property whose fair value cannot be determined reliably and which is provisionally measured at cost is tested for impairment as soon as an indication of impairment is identified (event leading to a decrease in the asset's market value and/or a change in the market environment). If the net carrying amount of the asset exceeds its recoverable amount (market value excluding duties, determined by independent property valuers) and if the unrealised capital loss exceeds 5% of the net carrying amount before impairment, the difference is recognised as an impairment loss.

Investment property which meets the criteria to be classified as non-current assets held for sale is presented as a separate line item in the consolidated statement of financial position (*see note 6.1.2*) but remains measured at fair value under IAS 40.

The change in fair value of the property portfolio during the period is recognised in the income statement, after deducting capital expenditure and other capitalised costs, such as capitalised borrowing costs and broker fees.

Gains or losses on disposal are calculated as the difference between the proceeds from the sale net of selling costs and the carrying amount of the asset.

##### Right-of-use assets relating to building leases

For the investment assets whose land base is subject to a building lease the fair value is determined by the property valuers as if the assets were a single building complex, in accordance with the fair value model under IAS 40 and with IFRS 13.

The fair value of the complex is determined on the basis of the expected net cash flows, including the expected cash outflows under the building lease. The latter are also recognised as part of the lease liability measured in accordance with IFRS 16, as described in note 9.3. The Group adds back the value of the lease liability to the value of the investment assets so as not to recognise this liability twice, in accordance with IAS 40.

### Borrowing costs

Borrowing costs directly attributable to the construction or production of an asset are included in the cost of that asset until work is completed.

Capitalised borrowing costs are determined as follows:

- ◆ where funds are borrowed in order to build a specific asset, the borrowing costs that are eligible for capitalisation are the costs actually incurred over the financial year less any investment income on the temporary investment of those borrowings;
- ◆ where the borrowed funds are used to build several assets, the borrowing costs that are eligible for capitalisation are determined by applying a capitalisation rate to the construction costs. This capitalisation rate is equal to the weighted average of current borrowing costs for the financial year other than those of borrowings taken out for the purpose of building specific assets. The capitalised amount may not exceed the amount of costs actually borne.

The Commercial Property Investment portfolio consists primarily of investment property. It is valued as described in note 6.2.

Changes in the property portfolio can be broken down as follows:

<i>(in millions of euros)</i>	Notes	12/31/2022	Acquisitions	Construction work (a)	Disposals	Changes in fair value recognised in the income statement	Changes in scope of consolidation (b)	Other changes (c)	12/31/2023
Investment property measured at fair value		14,834.4	48.7	195.4	(1.9)	(1,494.5)	-	(6,935.3)	6,646.8
<b>INVESTMENT PROPERTY</b>	<b>6.3.</b>	<b>14,834.4</b>	<b>48.7</b>	<b>195.4</b>	<b>(1.9)</b>	<b>(1,494.5)</b>	<b>-</b>	<b>(6,935.3)</b>	<b>6,646.8</b>
Investment property of equity-accounted companies (d)	10.2.	100.8	-	0.1	-	(9.6)	-	-	91.3
Investment property held for sale (IFRS 5) (e)	6.1.2.	147.5	-	14.9	(139.7)	36.5	-	2.8	62.0
Financial receivables and other assets		72.8	-	-	-	-	-	(2.2)	70.6
Investment property held for sale – Healthcare Property Investment	2.1.	-	25.6	32.6	(1.0)	9.6	(6,999.2)	6,932.4	-
<b>VALUE OF THE PROPERTY PORTFOLIO</b>		<b>15,155.4</b>	<b>74.3</b>	<b>243.1</b>	<b>(142.6)</b>	<b>(1,458.1)</b>	<b>(6,999.2)</b>	<b>(2.2)</b>	<b>6,870.7</b>
<b>Portfolio distribution:</b>									
Offices		6,101.2	48.7	121.9	(99.8)	(1,215.3)	-	-	4,956.6
Business parks		1,802.9	-	83.5	-	(241.5)	-	(0.0)	1,644.8
<b>Other assets</b>		<b>318.9</b>		<b>5.1</b>	<b>(41.8)</b>	<b>(10.8)</b>	<b>-</b>	<b>(2.2)</b>	<b>269.2</b>
<b>Commercial Property Investment</b>		<b>8,223.0</b>	<b>48.7</b>	<b>210.5</b>	<b>(141.6)</b>	<b>(1,467.6)</b>	<b>-</b>	<b>(2.2)</b>	<b>6,870.7</b>
<b>Healthcare Property Investment (discontinued operations)</b>	<b>2.1.</b>	<b>6,932.4</b>	<b>25.6</b>	<b>32.6</b>	<b>(1.0)</b>	<b>9.6</b>	<b>(6,999.2)</b>	<b>0.0</b>	<b>(0.0)</b>
<b>VALUE OF THE PROPERTY PORTFOLIO</b>		<b>15,155.4</b>	<b>74.3</b>	<b>243.1</b>	<b>(142.6)</b>	<b>(1,458.1)</b>	<b>(6,999.2)</b>	<b>(2.2)</b>	<b>6,870.7</b>

(a) The Commercial Property Investment Division's construction work included €5.4 million in capitalised finance costs.

(b) The Healthcare Property Investment Division is no longer consolidated (see note 2.1).

(c) Other changes primarily related to reclassifications of investment property to investment property held for sale, the divestment of the Healthcare Property Investment Division and repayments of financial receivables.

(d) Investment property of equity-accounted property investment companies is measured at fair value and shown on a proportionate consolidation basis.

(e) Assets held for sale related to Commercial Property Investment assets subject to preliminary sale agreements.

The appraised value of the property portfolio broke down as follows:

<i>(in millions of euros)</i>	Notes	12/31/2023	12/31/2022
<b>VALUE OF THE PROPERTY PORTFOLIO</b>		<b>6,870.7</b>	<b>15,155.4</b>
Lease liabilities	9.3.	(29.2)	(31.7)
Unrealised capital gains on other appraised assets		5.5	6.4
<b>APPRAISED VALUE OF THE PROPERTY PORTFOLIO</b>		<b>6,847.0</b>	<b>15,130.1</b>
<b><u>Portfolio distribution:</u></b>			
Offices		4,951.2	6,095.7
Business parks		1,644.8	1,802.9
Other assets		250.9	302.4
<b>Commercial Property Investment</b>		<b>6,847.0</b>	<b>8,201.0</b>
<b>Healthcare Property Investment (discontinued operations)</b>	<b>2.1.</b>	<b>-</b>	<b>6,929.0</b>
<b>APPRAISED VALUE OF THE PROPERTY PORTFOLIO</b>		<b>6,847.0</b>	<b>15,130.1</b>

### Investments/Acquisitions

Investments made by the **Commercial Property Investment Division** amounted to €259.0 million during the period and primarily included the following:

- ♦ the acquisition of the remaining sections of the Ponant B building in Paris for €48.7 million;
- ♦ projects under development for €125.1 million including the Athletes Village (€18.8 million), Jump (€20.2 million), Next (€22.9 million), Défense 2 (€23.6 million), Grand Central (€15.0 million) and M Factory (€9.7 million).
- ♦ other investments, encompassing “Other capex” and “Other” for €85.2 million, related mainly to building maintenance work and tenant improvements.

### Disposals

**Disposals** totalled €146.2 million during the period and mainly related to Grand Central, Eko Active and the residual residential portfolio.

## 6.1.2.Assets held for sale and discontinued operations

### ACCOUNTING PRINCIPLES

In accordance with IFRS 5, where the Group has decided to dispose of an asset or group of assets, it should classify it as “Assets held for sale” within the current asset section of the consolidated statement of financial position, if:

- ◆ the asset or group of assets is available for immediate sale in its present condition, subject only to terms that are usual and customary for sales of such assets; and if
- ◆ it is highly likely to be sold within 12 months.

The liabilities related to this asset or group of assets are also shown separately as “Liabilities related to assets held for sale”.

Given the nature of its assets and based on its market experience, the Group generally considers that the only assets or groups of assets falling within this category are those under a preliminary sale agreement.

Assets held for sale relate to:

- ◆ Financial assets held for sale, consisting of unconsolidated companies, which are carried at fair value through profit or loss at the end of the reporting period, in accordance with IFRS 9. Their fair value is determined using recognised valuation techniques (net asset value).
- ◆ Other assets or groups of assets classified as held for sale are measured in accordance with IFRS 5 at their fair value, which is usually the amount set out in the preliminary sale agreement, net of expenses.

<i>(in millions of euros)</i>		12/31/2023	12/31/2022
Financial assets held for sale at fair value through profit or loss	7.1.5.	1,129.7	
Investment property held for sale		62.0	147.5
<b>Assets held for sale</b>		<b>1,191.7</b>	<b>147.5</b>
<b>Liabilities from discontinued operations</b>		<b>0.8</b>	<b>2.3</b>

Financial assets measured at fair value through profit or loss that are held for sale related to remaining interests in the Healthcare Property Investment Division (see note 2.1).

Investment property held for sale related to property assets subject to preliminary sale agreements (including Nautilus as of December 31, 2023).

Liabilities related to assets held for sale mainly come from the remaining balance of provisions made for discontinued operations.

## 6.2. Valuation of the property portfolio: methods and assumptions

### 6.2.1.Valuation assignments

The Group’s property assets are valued twice a year by independent property valuers for the publication of the half-year and annual consolidated financial statements, according to a framework consistent with the SIIC Code of Ethics (*sociétés d’investissement immobilier cotées*, French listed real estate investment companies) published in July 2008 by the French Federation of Real Estate Companies (*Fédération des sociétés immobilières et foncières*).

Valuers are regularly selected through a competitive process. They are chosen from among members of the French Association of Property Valuation Companies (*Association Française des Sociétés d’Expertise Immobilière*, AFREXIM).

In accordance with the SIIC Code of Ethics, after seven years Icade shall ensure that there is an internal turnover of the teams responsible for the valuation of its assets in the selected property valuation company. The valuer signing the valuation may not be appointed for more than two consecutive terms of four years except where the valuer has met the requirement with regard to the internal turnover of the teams.

Property valuations were entrusted to Jones Lang LaSalle Expertises, Cushman & Wakefield Valuation France, CBRE Valuation, Catella Valuation and BNP Paribas Real Estate Valuation. Property valuation fees are billed on the basis of a fixed service fee that takes into account the specificities of the properties (number of units, floor area, number of existing leases, etc.) and that is not based on the value of the assets.

The assignments of the property valuers, whose main valuation methods and conclusions are presented hereafter, are performed according to professional standards, in particular:

- ◆ The French Property Valuation Charter (*Charte de l’expertise en évaluation immobilière*), fifth edition, published in March 2017;
- ◆ The Barthès de Ruyter report from the French Securities and Exchange Commission (COB), which is part of the French Financial Markets Authority (AMF), dated February 3, 2000, on the valuation of the property assets of publicly traded companies;
- ◆ On an international level, TEGoVA’s (The European Group of Valuers’ Associations) European Valuation Standards as set out in the ninth edition of its Blue Book published in 2020, as well as the Red Book standards of the Royal Institution of Chartered Surveyors (RICS).

These various texts specify the required qualifications for the property valuers, a code of conduct and ethics, and the main definitions (values, floor areas, rates and main valuation methods).

During each valuation session and when valuers submit their valuation reports, the Group makes sure that the methods used by the different property valuers to value its assets are consistent.

Valuations are presented both inclusive and exclusive of duties, the values excluding duties being net of duties and fixed legal expenses calculated by the property valuers.

Operating properties of significant value, business parks and the Le Millénaire shopping centre are subject to a double appraisal approach. Until their completion, this approach is also applied to the Commercial Property Investment Division's office projects under development (excluding off-plan acquisitions) with a valuation or capex budget over €10 million.

On-site inspections are systematically conducted by the property valuers for all new assets added to the portfolio. Further on-site inspections are then organised according to a multi-year schedule or each time that a specific event in the life of the building requires it (occurrence of significant changes in its structure or environment).

All the assets, including the land bank and projects under development, were valued as of December 31, 2023 according to the procedures currently in place within the Group, with the exception of:

- ◆ Properties subject to a preliminary sale agreement as of the end of the reporting period that are valued based on the contractual sale price (or the price agreed as part of exclusive talks if applicable);
- ◆ Public properties and projects held as part of public-private partnerships (PPP) which are not subject to a formal valuation due to the fact that ownership ultimately returns to the State at the end of these contracts. These assets are included in the value of the Group's property portfolio based on their net carrying amount;
- ◆ Properties acquired less than three months before the end of the reporting period, which are valued at their acquisition price.

The Group has also implemented a process of internal valuation by its asset management teams in order to verify the asset values obtained by the property valuers and to gain a better understanding of the future performance of the portfolio on the basis of the business plans defined. This process is updated on a yearly basis.

### 6.2.2. Methods used by the property valuers

Investment property is valued by the property valuers who use two methods simultaneously: the net income capitalisation method and the discounted cash flow method (the property valuer may use the mean of the two methods or the most appropriate method, as the case may be). The direct sales comparison method, which is based on the prices of transactions noted on the market for assets equivalent in type and location, is also used to verify these valuations.

The net income capitalisation method involves applying a yield to income streams, whether that income is reported, existing, theoretical or potential (estimated rental value). This approach may be implemented in different ways depending on the type of income considered (effective rent, estimated rental value or net rental income), as different yields are associated with each type.

The discounted cash flow method assumes that the value of the assets is equal to the present value of the cash flows expected by the investor, including the sale at the end of the holding period. In addition to the resale value obtained by applying a yield to the previous year's rents, cash flows include rents, the different service charges not recovered by the owner and the major maintenance and repair work. The discount rate to be applied to the cash flows is calculated based either on a risk-free rate plus a risk premium (related both to the property market and to the building considered taking into account its characteristics in terms of location, construction and security of income) or on the weighted average cost of capital.

The land bank and properties under development are also appraised. The methods used by the property valuers primarily include the residual method and/or the discounted cash flow method, and also in certain cases the sales comparison method.

The residual method involves calculating the residual value of a project from the point of view of a property developer to whom the land has been offered. From the sale price of the building at the time of completion, the property valuer deducts all the costs to be incurred, including construction costs, fees and profit, finance costs and any land-related costs.

For properties under development, all outstanding costs linked to the completion of the project, along with carrying costs until completion, must be deducted from the buildings' estimated sale price. Projects under development are valued on the basis of a clearly identified and approved project, as soon as the building permit can be processed and implemented.

Regardless of the method used to determine their estimates, property valuers set a value and discount rate in line with the risks inherent in each project and, in particular, the state of progress of the various approval and construction stages (demolition permit, building permit, objections, stage of completion of work, any pre-commitment, or rent guarantee). From the exit value, the property valuers must explain which procedure they followed in estimating the degree of risk and the change in valuation for the building in the light of the circumstances under which they worked and the information made available to them.

It should be noted that, for all of its properties, Icade informs its property valuers of the work scheduled to be carried out over the next 10 years (maintenance, development, refurbishment). In particular, this scheduled work includes the investments needed to implement Icade's carbon reduction strategy and comply with the French decree on the energy efficiency of service sector properties (Décret Éco Énergie Tertiaire) by 2030. Whether using the net income capitalisation method or the discounted cash flow method, these investments have a direct impact on property valuation.

In addition to this scheduled work, valuers rely on their own assumptions regarding the work required to re-let an asset if they presuppose that it will be vacated in their valuation.

Icade also gives the valuers the information they need to correctly assess the fair value of the buildings: leases, occupancy statuses, service charge budgets, etc. Since 2023, Icade has also provided all CSR criteria for its office properties, as defined in the ESG assessment framework

published in 2023 by the French Association of Property Valuation Companies (AFREXIM). These criteria cover levels of electricity consumption, GHG emissions, environmental certification of buildings, proximity to public transport, etc.

Beyond taking into account the impact of work dedicated to sustainable development, the valuers have not, to date, found any evidence that ESG matters are reflected in the prices obtained or obtainable for offices on the French market. The information provided by Icade is nonetheless likely to enhance the valuers' understanding of the properties under review and to reinforce their conclusions about their fair value.

### 6.2.3. Main valuation assumptions for investment property

Given the limited availability of public data, the complexity of property valuations and the fact that property valuers use the Group's confidential occupancy statuses for their valuations, the Group considered Level 3, within the meaning of IFRS 13 (*see note 1.3.1*), to be the classification best suited to its assets. In addition, unobservable inputs such as discount rate assumptions and capitalisation rates are used by the property valuers to determine the fair values of the Group's assets.

Asset types	Methods generally used	Rates for discounting cash flows (DCF)	Exit yields (DCF)	Market yields (income capitalisation)	Estimated rental value (in €/sq.m)
<b>OFFICES AND BUSINESS PARKS</b>					
<b>Offices</b>					
Paris	Capitalisation and DCF	5.0% - 7.6%	3.8% - 6.1%	3.8% - 6.3%	270 - 1000
La Défense/Peri-Défense	Capitalisation and DCF	6.0% - 8.0%	5.3% - 8.0%	5.0% - 7.7%	250 - 450
Other Western Crescent	Capitalisation and DCF	5.0% - 5.7%	4.8% - 5.0%	4.3% - 4.8%	470 - 550
Inner Ring	Capitalisation and DCF	5.5% - 8.0%	5.5% - 7.5%	5.3% - 7.8%	230 - 370
Outer Ring	Capitalisation and DCF	6.0% - 7.8%	7.5% - 8.0%	7.0% - 9.3%	220 - 230
France outside the Paris region	Capitalisation and DCF	5.7% - 10.7%	5.5% - 10.1%	5.3% - 9.5%	125 - 350
<b>Business parks</b>					
Inner Ring	DCF	5.0% - 10.0%	5.5% - 8.9%	N/A	110 - 330
Outer Ring	DCF	5.8% - 10.0%	5.3% - 9.0%	N/A	55 - 270
<b>Other Commercial Property Investment assets</b>					
Hotels	Capitalisation	N/A	N/A	5.4% - 6.1%	(a)
Retail	Capitalisation and DCF	8.0% - 10.0%	7.3% - 8.5%	7.5% - 9.3%	90 - 270
Warehouses	Capitalisation and DCF	9.5% - 10.5%	N/A	11% - 13%	45 - 55

(a) Not subject to the traditional rules for determining the estimated rental value, due to the layout and highly specific use of the premises.

#### 6.2.4. Fair value sensitivity of property assets

The impact of changes in yields, all else being equal, on the fair value of property assets is presented in the table below. For example, a 50-bp increase in office yields would reduce office values by around 7.1%, i.e. -€307.9 million.

(calculated for the operating property portfolio)	Yields (a)			
	+50 bps		+100 bps	
	As a % of fair value as of 12/31/2023	in millions of euros	As a % of fair value as of 12/31/2023	in millions of euros
<b>Offices</b>	<b>(7.1%)</b>	<b>(307.9)</b>	<b>(13.2%)</b>	<b>(573.6)</b>
- Paris	(8.2%)	(68.5)	(15.2%)	(126.4)
- La Défense/Peri-Défense	(6.7%)	(131.2)	(12.5%)	(245.5)
- Other Western Crescent	(9.0%)	(23.8)	(16.5%)	(43.7)
- Inner Ring	(5.9%)	(36.8)	(11.2%)	(69.2)
- Outer Ring	(4.8%)	(6.9)	(9.2%)	(13.1)
- France outside the Paris region	(7.6%)	(40.8)	(14.1%)	(75.7)
<b>Business parks</b>	<b>(5.8%)</b>	<b>(88.0)</b>	<b>(10.9%)</b>	<b>(166.1)</b>
- Inner Ring	(5.7%)	(44.6)	(10.7%)	(84.2)
- Outer Ring	(5.9%)	(43.5)	(11.2%)	(81.9)
<b>Other assets</b>	<b>(5.2%)</b>	<b>(9.0)</b>	<b>(9.7%)</b>	<b>(16.9)</b>
<b>TOTAL</b>	<b>(6.7%)</b>	<b>(405.0)</b>	<b>(12.5%)</b>	<b>(756.6)</b>

(a) Yield on the operating property portfolio, including duties.

### 6.3. Change in fair value of investment property

The change in fair value of investment property for the financial years 2023 and 2022 broke down as follows:

(in millions of euros)	Notes	2023	2022 Restated (a)
Offices		(1,218.7)	(349.7)
Business parks		(243.1)	(37.9)
Other assets		(4.4)	0.4
<b>CHANGES IN VALUE RECOGNISED IN THE INCOME STATEMENT</b>		<b>(1,466.2)</b>	<b>(387.3)</b>
Other (b)		8.1	(6.2)
<b>CHANGE IN FAIR VALUE OF INVESTMENT PROPERTY</b>	<b>6.1.1.</b>	<b>(1,458.1)</b>	<b>(393.5)</b>

(a) Reclassification of the Healthcare Property Investment business as discontinued operations in accordance with IFRS 5 (see note 3.3).

(b) Mainly relates to the straight-lining of assets and liabilities associated with investment property.

The €1,458.1 million decrease in fair value is mainly due to adjusting market values as risk-free rates and financing costs sharply increased.



## Note 7 . Finance and financial instruments

### 7.1. Financial structure and contribution to profit/(loss)

#### 7.1.1. Change in net financial liabilities

##### ACCOUNTING PRINCIPLES

##### Financial liabilities

Borrowings and other interest-bearing financial liabilities are valued, after their initial recognition, according to the amortised cost method using the effective interest rate of the borrowings. Issue costs and premiums affect the opening value and are spread over the life of the borrowings using the effective interest rate.

For financial liabilities resulting from the recognition of finance leases, the financial liability recognised as the corresponding entry of the asset is initially carried at the fair value of the leased asset or, if lower, the present value of the minimum lease payments.

##### Hedging instruments

The Group uses financial derivatives to hedge its exposure to market risk stemming from interest rate fluctuations. Derivatives are used as part of a policy implemented by the Group on interest rate risk management. The financial risk management strategies and methods used to determine the fair value of financial derivatives are set out in notes 7.2.2 and 7.3.

Financial derivatives are recorded at fair value in the consolidated statement of financial position.

The Group uses derivatives to hedge its variable rate debt against interest rate risk (cash flow hedging) and applies hedge accounting where documentation requirements are met. In this case, changes in fair value of the financial derivative are recognised net of tax in “Other items” in the consolidated statement of comprehensive income until the hedged transaction occurs in respect of the effective portion of the hedge. The ineffective portion is recognised immediately in the income statement for the period. Gains and losses accumulated in equity are reclassified to the income statement under the same heading as the hedged item for the same periods during which the hedged cash flow has an impact on the income statement.

Where financial derivatives do not qualify for hedge accounting under the standard, they are classified under the category of trading instruments and any changes in their fair value are recognised directly in the income statement for the period.

The fair value of derivatives is measured using commonly accepted models (discounted cash flow method, Black and Scholes model, etc.) and based on market data.

### Breakdown of net financial liabilities at end of period

Net financial liabilities as of December 31, 2023 and 2022 broke down as follows:

(in millions of euros)	12/31/2022	Cash flow from financing activities		Changes in scope of consolidation (d)	Fair value adjustments and other changes (e)	12/31/2023
		New financial liabilities (c)	Repayments (c)			
Bonds	4,650.0	-	-	(1,100.0)	-	3,550.0
Borrowings from credit institutions	2,336.3	19.7	(265.9)	(1,093.9)	(0.0)	996.2
Finance lease liabilities	201.4	8.4	(13.1)	(196.8)	0.1	0.0
Other borrowings and similar liabilities	0.1	0.0	(0.0)	-	(0.0)	0.1
NEU Commercial Paper	553.0	225.0	(553.0)	-	-	225.0
<b>Total borrowings</b>	<b>7,740.8</b>	<b>253.1</b>	<b>(832.0)</b>	<b>(2,390.7)</b>	<b>0.1</b>	<b>4,771.3</b>
Payables associated with equity investments	107.2			(15.9)	(2.0)	89.3
Bank overdrafts	117.7			200.0	(115.4)	202.3
<b>Total gross interest-bearing financial liabilities</b>	<b>7,965.7</b>	<b>253.1</b>	<b>(832.0)</b>	<b>(2,206.5)</b>	<b>(117.3)</b>	<b>5,062.8</b>
Interest accrued and amortised issue costs	(5.7)			0.2	10.0	4.5
<b>GROSS FINANCIAL LIABILITIES (a)</b>	<b>7.1.2. 7,960.0</b>	<b>253.1</b>	<b>(832.0)</b>	<b>(2,206.3)</b>	<b>(107.4)</b>	<b>5,067.3</b>
Interest rate derivatives	7.1.3. (154.3)			63.4	28.5	(62.4)
Financial assets (b)	7.1.5. (147.4)			(378.8)	157.3	(368.9)
Cash and cash equivalents	7.1.6. (1,084.6)			70.7	(606.2)	(1,620.2)
<b>NET FINANCIAL LIABILITIES</b>	<b>6,573.7</b>	<b>253.1</b>	<b>(832.0)</b>	<b>(2,451.1)</b>	<b>(527.7)</b>	<b>3,015.9</b>

(a) Including, as of December 31, 2023, €547.8 million in current financial liabilities and €4,519.5 million in non-current financial liabilities.

(b) Excluding security deposits paid and security deposits received and held in an escrow account and excluding financial assets at fair value through profit or loss as of December 31, 2023.

(c) Cash flow from financing activities.

(d) The Healthcare Property Investment Division is no longer consolidated (see note 2.1).

(e) Other changes related primarily to cash flow from bank overdrafts and cash and cash equivalents.

The €2,892.6 million year-on-year change in gross debt (excluding derivatives) stemmed primarily from:

- ◆ the divestment of the Healthcare Property Investment Division (€2.2 billion);
- ◆ changes in borrowings from credit institutions and other borrowings:
  - credit lines secured and drawn down for €19.7 million,
  - repayments worth €265.9 million, including €252.0 million in early repayments (€110.9 million relating to Icade and €67.8 million to SAS Tour Equo, as well as €73.3 million in loans converted into bank overdrafts relating to SAS Neuilly Victor Hugo and SCCV 86 Félix Eboué).
- ◆ net decrease in outstanding NEU Commercial Paper for €328.0 million.

The change in cash flow from financing activities in the cash flow statement was a negative €461.2 million. It mainly included cash flow relating to net financial liabilities (€382.4 million increase and €832.0 million decrease) and repayments of lease liabilities recognised under IFRS 16 (€11.6 million).

## 7.1.2.Components of financial liabilities

### Gross financial liabilities: type of rate, maturity and fair value

Gross financial liabilities at amortised cost, excluding issue costs and premiums and the impact of amortising them by applying the effective interest method, stood at €5,062.8 million as of December 31, 2023. They broke down as follows:

	Balance sheet value	Current						Non-current		Fair value
	12/31/2023	< 1 year	1 to 2 years	2 to 3 years	3 to 4 years	4 to 5 years	> 5 years			12/31/2023
<i>(in millions of euros)</i>										
Bonds	3,550.0	-	500.0	750.0	600.0	600.0	1,100.0			3,164.2
Borrowings from credit institutions	702.9	2.8	3.1	350.1	53.0	3.2	290.7			625.9
Finance lease liabilities	0.0	0.0	0.0	-	-	-	-			0.0
Other borrowings and similar liabilities	0.1	0.0	0.0	-	-	-	-			0.1
Payables associated with equity investments	16.4	16.4	-	-	-	-	-			16.4
NEU Commercial Paper	225.0	225.0	-	-	-	-	-			225.0
<b>Fixed rate debt</b>	<b>4,494.3</b>	<b>244.2</b>	<b>503.1</b>	<b>1,100.1</b>	<b>653.0</b>	<b>603.2</b>	<b>1,390.7</b>			<b>4,031.6</b>
Borrowings from credit institutions	293.3	4.5	66.2	42.5	2.1	1.0	177.0			289.6
Payables associated with equity investments	72.9	72.9	-	-	-	-	-			72.9
Bank overdrafts	202.3	202.3	-	-	-	-	-			202.3
<b>Variable rate debt</b>	<b>568.5</b>	<b>279.7</b>	<b>66.2</b>	<b>42.5</b>	<b>2.1</b>	<b>1.0</b>	<b>177.0</b>			<b>564.9</b>
<b>TOTAL GROSS INTEREST-BEARING FINANCIAL LIABILITIES</b>	<b>5,062.8</b>	<b>523.8</b>	<b>569.4</b>	<b>1,142.6</b>	<b>655.1</b>	<b>604.2</b>	<b>1,567.6</b>			<b>4,596.4</b>

The average debt maturity (excluding NEU Commercial Paper) was 4.6 years as of December 31, 2023 (5.3 years as of December 31, 2022).

As of December 31, 2023, the average maturity was 4.4 years for variable rate debt and 5.5 years for the related hedges, allowing adequate hedging and anticipating coverage of future financing needs.

### Characteristics of the bonds

ICADE	Issue date	Maturity date	Nominal value on the issue date		Rate	Repayment profile	Nominal value as of 12/31/2023
FR0013181906	06/10/2016	06/10/2026	750.0	Fixed rate	1.75%	Bullet	750.0
FR0013218393	11/15/2016	11/17/2025	500.0	Fixed rate	1.125%	Bullet	500.0
FR0013281755	09/13/2017	09/13/2027	600.0	Fixed rate	1.5%	Bullet	600.0
FR0013320058	02/28/2018	02/28/2028	600.0	Fixed rate	1.625%	Bullet	600.0
FR0014001IM0	01/18/2021	01/18/2031	600.0	Fixed rate	0.625%	Bullet	600.0
FR0014007NF1	01/19/2022	01/19/2030	500.0	Fixed rate	1%	Bullet	500.0
<b>Bonds</b>							<b>3,550.0</b>

### 7.1.3. Derivative instruments

#### Presentation of derivatives in the consolidated statement of financial position

Derivative instruments consist of interest rate cash flow hedges.

As of December 31, 2023, the fair value of these instruments was a net asset position of €62.4 million vs. €154.3 million as of December 31, 2022.

The detailed changes in fair value of derivatives were as follows for the financial year ended December 31, 2023:

(in millions of euros)	12/31/2022	Acquisitions	Changes in fair value recognised in the income statement	Changes in fair value recognised in equity	Changes in scope of consolidation (a)	12/31/2023
<b>Cash flow hedges</b>	<b>154.3</b>	<b>0.7</b>	<b>0.6</b>	<b>(29.8)</b>	<b>(63.4)</b>	<b>62.4</b>
Interest rate swaps – fixed-rate payer	145.9	-	0.6	(27.2)	(61.0)	58.3
Interest rate options – caps	8.4	0.7	0.0	(2.6)	(2.4)	4.1
<b>INTEREST RATE DERIVATIVES EXCLUDING MARGIN CALLS</b>	<b>154.3</b>	<b>0.7</b>	<b>0.6</b>	<b>(29.8)</b>	<b>(63.4)</b>	<b>62.4</b>
<b>TOTAL INTEREST RATE DERIVATIVES</b>	<b>154.3</b>	<b>0.7</b>	<b>0.6</b>	<b>(29.8)</b>	<b>(63.4)</b>	<b>62.4</b>
Including derivative assets	155.2	0.7	0.5	(28.8)	(63.9)	63.7
Including derivative liabilities	(0.9)	-	0.1	(1.0)	0.6	(1.3)

(a) The Healthcare Property Investment Division is no longer consolidated (see note 2.1).

#### Changes in hedge reserves

Hedge reserves consisted exclusively of fair value adjustments to financial instruments used by the Group for interest rate hedging purposes (effective portion). They totalled €63.7 million as of December 31, 2023.

Hedge reserves as of December 31, 2023 are shown in the table below:

(in millions of euros)	Total	Attributable to the Group	Attributable to non-controlling interests
<b>REVALUATION RESERVES AS OF 12/31/2022</b>	<b>157.6</b>	<b>125.7</b>	<b>31.9</b>
Changes in value of cash flow hedges	(30.0)	(26.4)	(3.6)
Revaluation reserves for cash flow hedges recycled to the income statement	(0.2)	(0.4)	0.3
Deferred tax on changes in value of cash flow hedges	0.3	0.2	0.1
<b>Other comprehensive income</b>	<b>(29.9)</b>	<b>(26.6)</b>	<b>(3.3)</b>
Impact of changes in scope of consolidation (a)	(64.0)	(37.3)	(26.7)
<b>REVALUATION RESERVES AS OF 12/31/2023</b>	<b>63.7</b>	<b>61.8</b>	<b>1.9</b>

(a) The Healthcare Property Investment Division is no longer consolidated (see note 2.1).

#### Derivatives: analysis of notional amounts by maturity

The derivative portfolio as of December 31, 2023 was as follows:

(in millions of euros)	12/31/2023			
	Total	< 1 year	> 1 year and < 5 years	> 5 years
	Amount	Amount	Amount	Amount
Interest rate swaps – fixed-rate payer	426.9	-	38.1	388.8
Interest rate options – caps	181.4	52.0	115.2	14.2
<b>TOTAL INTEREST RATE DERIVATIVES AS OF 12/31/2023</b>	<b>608.3</b>	<b>52.0</b>	<b>153.3</b>	<b>403.0</b>
<b>TOTAL INTEREST RATE DERIVATIVES AS OF 12/31/2022</b>	<b>1,499.7</b>	<b>23.5</b>	<b>793.6</b>	<b>682.7</b>

These derivatives are used as part of the Group's interest rate hedging policy (see note 7.2.2).

#### 7.1.4. Finance income/(expense)

Finance income/(expense) consists primarily of:

- ◆ cost of gross financial liabilities (mainly interest expenses on financial liabilities and derivatives) adjusted for income from cash, related loans and receivables;
- ◆ other finance income and expenses (primarily including restructuring costs for financial liabilities and commitment fees).

The Group recorded a net finance expense of €69.4 million for the financial year 2023 vs. a net finance expense of €100.7 million for 2022.

<i>(in millions of euros)</i>	2023	2022 Restated (a)
Interest expenses on financial liabilities	(104.5)	(76.4)
Interest expenses on derivatives	11.8	(0.3)
Recycling to the income statement of interest rate hedging instruments	0.8	0.8
<b>COST OF GROSS FINANCIAL LIABILITIES</b>	<b>(91.8)</b>	<b>(75.9)</b>
Interest income from cash and cash equivalents	27.2	1.7
Income from receivables and loans	12.7	1.2
Changes in fair value of cash equivalents recognised in the income statement	2.3	0.5
<b>Net income from cash and cash equivalents, related loans and receivables</b>	<b>42.2</b>	<b>3.3</b>
<b>COST OF NET FINANCIAL LIABILITIES</b>	<b>(49.7)</b>	<b>(72.7)</b>
Income/(expense) from financial assets at fair value through profit or loss (b)	(18.4)	1.8
Changes in fair value of derivatives recognised in the income statement	(0.5)	(0.4)
Commitment fees	(6.1)	(6.1)
Restructuring costs for financial liabilities (c)	(1.3)	(16.5)
Finance income/(expense) from lease liabilities	(2.4)	(2.2)
Other finance income and expenses	8.9	(4.6)
<b>Total other finance income and expenses</b>	<b>(19.7)</b>	<b>(28.0)</b>
<b>FINANCE INCOME/(EXPENSE)</b>	<b>(69.4)</b>	<b>(100.7)</b>

(a) Reclassification of the Healthcare Property Investment business as discontinued operations in accordance with IFRS 5 (see note 3.3).

(b) Relates mainly to the changes in fair value of the remaining interests in the Healthcare Property Investment Division as of December 31, 2023.

(c) Includes prepayment penalties for bonds (call premiums) and other borrowings.

#### 7.1.5. Financial assets and liabilities

##### ACCOUNTING PRINCIPLES

Under IFRS 9, financial assets are classified and measured either at amortised cost or fair value. In order to determine how best to classify and measure financial assets, the Group has taken into consideration its business model for managing such assets and analysed the characteristics of their contractual cash flows. The Group's financial assets fall into two categories:

- ◆ financial assets carried at fair value through profit or loss:

These assets relate to investments in unconsolidated companies carried at fair value through profit or loss at the end of the reporting period. Fair value is determined using recognised valuation techniques (reference to recent market transactions, discounted cash flows, net asset value, quoted prices if available, etc.);

- ◆ financial assets carried at amortised cost:

They consist primarily of receivables associated with equity investments, loans, deposits and guarantees paid, contract assets and accounts receivable carried at amortised cost at the reporting date (the latter two categories of other financial assets are detailed in note 9.2.3).

In accordance with IFRS 9, the Group applies the expected loss model for financial assets that requires expected losses and changes in such losses to be accounted for as soon as the financial asset is recognised at each reporting date to reflect the change in credit risk since initial recognition.

## Changes in financial assets and liabilities during the period

Changes in other financial assets during the financial year 2023 broke down as follows:

(in millions of euros)	12/31/2022	Acquisitions	Disposals / Repayments	Impact of changes in fair value recognised in the income statement	Net charges related to impairment losses recognised in the income statement	Changes in scope of consolidation (a)	Other changes	12/31/2023
Receivables associated with equity investments and other related parties	88.1	24.8	(59.9)	-	0.8	50.0	1.3	105.1
Loans	0.3	-	-	-	-	-	-	0.3
Shareholder loans	21.3	-	(106.3)	-	-	328.8	6.4	250.2
Deposits and guarantees paid	65.4	4.9	(18.9)	-	0.4	(46.2)	(0.0)	5.6
Other (b)	21.1	1.6	(0.0)	-	-	(6.0)	(2.2)	14.5
<b>FINANCIAL ASSETS AT AMORTISED COST</b>	<b>196.1</b>	<b>31.2</b>	<b>(185.2)</b>	<b>-</b>	<b>1.3</b>	<b>326.6</b>	<b>5.6</b>	<b>375.6</b>
Financial assets at fair value through profit or loss (c)	23.1	1.1	(0.8)	(4.5)	-	-	(0.0)	18.8
<b>Financial assets held for sale at fair value through profit or loss (d)</b>	<b>-</b>	<b>1,143.6</b>	<b>-</b>	<b>(13.9)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,129.7</b>
<b>TOTAL FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS</b>	<b>23.1</b>	<b>1,144.7</b>	<b>(0.8)</b>	<b>(18.4)</b>	<b>-</b>	<b>-</b>	<b>(0.0)</b>	<b>1,148.6</b>
<b>TOTAL FINANCIAL ASSETS</b>	<b>219.2</b>	<b>1,175.9</b>	<b>(186.0)</b>	<b>(18.4)</b>	<b>1.3</b>	<b>326.6</b>	<b>5.5</b>	<b>1,524.1</b>

(a) The Healthcare Property Investment Division is no longer consolidated (see note 2.1).

(b) Includes escrowed funds.

(c) Financial assets at fair value mainly consisted of investments in unconsolidated companies.

(d) Financial assets held for sale at fair value related to the Group's remaining interests in the Healthcare Property Investment Division (see note 2.1).

Other financial liabilities consisted mostly of deposits and guarantees received from tenants for €59.6 million as of December 31, 2023. The non-current portion represents €58.9 million, including €56.7 million for the portion maturing in more than five years.

## Maturity analysis of financial assets

A maturity analysis of other financial assets at amortised cost as of the end of the financial year 2023 is shown in the table below:

(in millions of euros)	12/31/2023	Current			Non-current	
		< 1 year	> 1 year and < 5 years	> 5 years		
Receivables associated with equity investments and other related parties	105.1	105.1	-	(0.0)		
Loans	0.3	0.1	0.0	0.2		
Shareholder loans	250.2	250.2	-	-		
Deposits and guarantees paid	5.6	1.2	1.2	3.1		
Other	14.5	1.9	12.5	-		
<b>FINANCIAL ASSETS AT AMORTISED COST</b>	<b>375.6</b>	<b>358.5</b>	<b>13.7</b>	<b>3.4</b>		

## 7.1.6.Cash and cash equivalents

### ACCOUNTING PRINCIPLES

Cash includes current bank accounts and demand deposits. Cash equivalents consist of money-market undertakings for collective investment in transferable securities (UCITS) and investments maturing in less than three months, readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, held for the purpose of meeting short-term cash commitments.

Overdrafts are recognised as current financial liabilities.

(in millions of euros)	12/31/2023	12/31/2022
Cash equivalents (a)	788.7	245.3
Cash on hand and demand deposits (including bank interest receivable)	831.5	839.4
<b>CASH AND CASH EQUIVALENTS</b>	<b>1,620.2</b>	<b>1,084.6</b>

(a) Comprising term deposits and money market UCITS.

## 7.2. Management of financial risks

The monitoring and management of financial risks are centralised within the Financing and Treasury Division of the Group's Finance Department. The Group's Risk, Rates, Treasury and Finance Committee meets on a regular basis with the Group's CEO, Head of Risk and CFO to discuss all matters relating to the management of the Group's liabilities and associated risks.

The Audit and Risk Committee is also informed at least once a year of the Group's financial policy and the monitoring of the various financial risk management policies.

### 7.2.1. Liquidity risk

A liquidity risk policy provides a framework and limits to the Group's Finance Department in order to ensure that the Group is adequately protected from this risk.

In a still highly volatile market environment in 2023, the Group cautiously strengthened its liquidity position and remains fully able to raise more funds if necessary.


The breakdown of the Group's liquidity position as of December 31, 2023 is as follows:

- an undrawn amount of €1,680.0 million from credit lines (excluding credit lines for property development projects),
- €1,415.6 million in closing net cash.

Excluding NEU Commercial Paper, since it is a short-term source of financing, liquidity amounted to €2,870.6 million as of December 31, 2023 and covered the Group's debt payments up to 2028.

In addition, Icade ensures disciplined management and monitoring of the maturities of its main credit lines as shown in the bar chart below. This chart presents the cumulative future principal repayments on financial liabilities and interest payments as estimated up to their maturity dates.

**Maturity analysis for gross interest-bearing financial liabilities**  
(in €m)



## 7.2.2. Interest rate risk

Interest rate risk is also governed by a specific policy set out by the Group's Finance Department and reported on a regular basis to the Audit and Risk Committee. This risk includes, in the event of increased interest rates, the risk of increased finance expenses related to variable rate financial liabilities and, in the event of reduced interest rates, the risk of reduced finance income related to variable rate financial assets.

To finance its investments, the Group may use variable rate debt, thus remaining able to prepay debt without penalty.

For the past several years, the Group has pursued a prudent interest rate risk management policy with over 90% of its debt at fixed rate or hedged.

12/31/2023				
(in millions of euros)	Notes	Fixed rate	Variable rate	Total
Gross interest-bearing financial liabilities	7.1.2.	4,494.3	568.5	5,062.8
Payables associated with equity investments	7.1.2.	(16.4)	(72.9)	(89.3)
Debt treated as variable rate debt: NEU Commercial Paper (a)	7.1.2.	(225.0)	225.0	-
<b>Total</b>		<b>4,253.0</b>	<b>720.6</b>	<b>4,973.6</b>
<b>Breakdown before hedging (in %)</b>		<b>86%</b>	<b>14%</b>	<b>100%</b>
Impact of outstanding interest rate hedges (b)	7.1.3.	608.3	(608.3)	-
<b>Breakdown after hedging</b>		<b>4,861.3</b>	<b>112.3</b>	<b>4,973.6</b>
<b>Breakdown after hedging (in %)</b>		<b>98%</b>	<b>2%</b>	<b>100%</b>

(a) Despite having a fixed interest rate, NEU Commercial Paper creates exposure to interest rate risk due to its average maturity of only 3 months. As a result, these securities are included in the hedging strategy and are hedged using derivatives in the same way as variable rate debt.

(b) Taking into account outstanding hedges for calculating interest rate risk (see note 7.1.3).

As of December 31, 2023, the Group's total debt (excluding debt associated with equity interests) consisted of 86% fixed rate debt and 14% variable rate debt, with fixed rate and hedged debt representing 98% of the total.

The average maturity was 4.4 years for variable rate debt (excluding NEU Commercial Paper) and 5.5 years for the associated hedges.

It should be noted that the Group favours designating its hedging instruments as "cash flow hedges" according to IFRS 9; therefore, any changes in fair value of such instruments are recognised in equity (for the effective portion).

The changes in fair value of hedging instruments, arranged prior to the interest rate increases that began in 2022, had a positive impact on "Other comprehensive income" of €30.0 million as of December 31, 2023.

The accounting impact of a -1% or +1% change in interest rates on the value of derivatives and the Group's finance expense is described below:

12/31/2023	
(in millions of euros)	Impact on equity before tax
<b>Derivative instruments</b>	
Impact of a +1% change in interest rates	26.0
Impact of a -1% change in interest rates	(28.3)

## 7.2.3. Currency risk

Since the Group does not enter into any foreign currency transactions, it is not exposed to currency risk.

## 7.2.4. Credit risk

In the course of its business, the Group is exposed to two major types of counterparties: financial institutions and its tenants.

Regarding financial institutions, credit and/or counterparty risk relates to cash and cash equivalents, and to the banks where they are deposited. The investments chosen have maturities of less than one year with a very low risk profile. They are monitored daily and a regular review of authorised investments complements the control process. Additionally, in order to limit its counterparty risk, the Group only enters into financial transactions with major banking institutions and applies a principle of risk dispersion, avoiding concentration of exposure to any single counterparty. These principles are set out in the Counterparty Risk Policy managed by the Group's Finance Department.

As regards its tenants, the Group believes that it is not exposed to significant credit risk thanks to its diversified tenant portfolio in terms of location and individual size of lease commitments. In addition, the Group has introduced procedures to verify the creditworthiness of tenants prior to signing leases and on a regular basis thereafter. In particular, a customer solvency analysis is carried out for the Property Investment business and a check is made on the financing of insurance and guarantees for the Property Development business. These procedures are subject to regular monitoring.



The Group's exposure to credit risk corresponds primarily to the net carrying amount of receivables less deposits received from tenants, i.e. €39.6 million as of December 31, 2023.

### 7.2.5.Covenants and financial ratios

In addition, the Group is required to comply with the financial covenants listed below, which are covered by the Group's financial risk monitoring and management processes.

Covenants			12/31/2023
LTV bank covenant	Maximum	< 60%	35.1%
"Bank" ICR	Minimum	> 2	5.59x
CDC's stake	Minimum	34%	39.2%
Value of the property portfolio	Minimum	> €5bn	€6.8bn
Security interests in assets	Maximum	< 25% of the property portfolio	8.4%

Loans taken out by the Group may be subject to financial covenants—loan-to-value (LTV) ratio and interest coverage ratio (ICR)—and to a clause on the level of control by Caisse des dépôts, the Group's major shareholder, which may trigger early repayment. All covenants were met as of December 31, 2023.

As of December 31, 2023, Caisse des dépôts held 39.44% of voting rights and a 39.20% stake in Icade SA.

#### LTV bank covenant

The definition of the LTV (loan-to-value) bank covenant was amended in H2 2023 to bring it into line with the definition of the LTV ratio excluding duties. The LTV bank covenant is thus the ratio of the Group's net financial liabilities to the sum of the latest valuation of the property portfolio (excluding duties) and (i) equity-accounted investments (excluding duties), (ii) the value of property development companies, and (iii) financial assets at fair value through profit or loss (on a full consolidation basis). It stood at 35.1% as of December 31, 2023 (vs. 43.5% as of December 31, 2022, based on the former definition). This level is well below the covenant of 60%.

#### Interest coverage ratio (ICR)

The interest coverage ratio, which is the ratio of EBITDA plus the Group's share of net profit/(loss) of equity-accounted companies to the interest expense for the period, was 5.59x for the financial year 2023 (6.42x in 2022). This ratio has remained high, well above the limit set out in the bank agreements.

## 7.3. Fair value of financial assets and liabilities

### 7.3.1. Reconciliation of the net carrying amount to the fair value of financial assets and liabilities

Below is the reconciliation of the net carrying amount to the fair value of financial assets and liabilities as of the end of the financial year 2023:

<i>(in millions of euros)</i>	Carrying amount as of 12/31/2023	Amortised cost	Fair value through equity	Fair value through profit or loss	Fair value as of 12/31/2023
<b>ASSETS</b>					
Financial assets held for sale (a)	1,129.7			1,129.7	1,129.7
Financial assets	394.4	375.6	-	18.8	394.4
Derivative instruments	63.7	0.0	63.6	-	63.7
Contract assets	204.3	204.3			204.3
Accounts receivable	168.9	168.9			168.9
Other operating receivables (b)	66.3	66.3			66.3
Cash equivalents	788.7	615.9		172.8	788.7
<b>TOTAL FINANCIAL ASSETS</b>	<b>2,816.0</b>	<b>1,431.0</b>	<b>63.6</b>	<b>1,321.4</b>	<b>2,816.0</b>
<b>LIABILITIES</b>					
Financial liabilities	5,067.3	5,067.3		-	4,596.4
Lease liabilities	60.4	60.4			60.4
Other financial liabilities	59.6	59.6			59.6
Derivative instruments	1.3	-	1.3	-	1.3
Contract liabilities	65.4	65.4			65.4
Accounts payable	692.2	692.2			692.2
Other operating payables (b)	251.6	251.6			251.6
<b>TOTAL FINANCIAL LIABILITIES</b>	<b>6,198.0</b>	<b>6,196.7</b>	<b>1.3</b>	<b>-</b>	<b>5,727.1</b>

(a) Includes financial assets held for sale at fair value through profit or loss which related to the Group's remaining interests in the Healthcare Property Investment Division (see note 2.1).

(b) Excluding agency transactions, prepaid expenses/income and social security and tax receivables/payables.

### 7.3.2. Fair value hierarchy of financial instruments

The three levels in the fair value hierarchy of financial instruments which are used by the Group in accordance with IFRS 13 are presented in note 1.3.1 on measurement bases.

The financial instruments whose fair value is determined using a valuation technique based on unobservable data are investments in unconsolidated, unlisted companies.

As of December 31, 2023, the Group's financial instruments consisted of:

- ♦ derivative assets and liabilities measured based on observable data (Level 2 of the fair value hierarchy);
- ♦ financial assets at fair value through profit or loss, measured based on market data not directly observable (Level 3 of the fair value hierarchy);

As of December 31, 2023, the Group did not hold any financial instruments measured based on unadjusted prices quoted in active markets for identical assets or liabilities (level 1 of the fair value hierarchy).

Below is a summary table of the fair value hierarchy of financial instruments as of December 31, 2023:

		12/31/2023			
<i>(in millions of euros)</i>	Notes	Level 1: quoted price in an active market	Level 2: valuation technique based on observable data	Level 3: valuation technique based on unobservable data	Fair value
<b>ASSETS</b>					
Derivatives excluding margin calls	7.1.3.	-	63.7	-	63.7
Financial assets at fair value through profit or loss	7.1.5.	-	-	1,148.6	1,148.6
Cash equivalents	7.1.6.	172.8	-	-	172.8
<b>LIABILITIES</b>					
Derivative instruments	7.1.3.	-	1.3	-	1.3

## Note 8 . Equity and earnings per share

### 8.1. Share capital and shareholding structure

#### 8.1.1.Share capital

As of December 31, 2023, the share capital was unchanged compared to December 31, 2022 at €116.2 million and consisted of 76,234,545 ordinary shares. All the shares issued are fully paid up.

As of December 31, 2023, no shares registered directly with the Company (not with an agent of Icade) were pledged.

#### 8.1.2.Shareholding structure

The Company's shareholding structure (number of shares and percentage of share capital) as of December 31, 2023 and 2022 was as follows.

Shareholders	12/31/2023		12/31/2022	
	Number of shares	% of capital	Number of shares	% of capital
Caisse des dépôts	29,885,064	39.20%	29,885,064	39.20%
Crédit Agricole Assurances Group	14,373,960	18.85%	14,565,910	19.11%
Public	31,226,943	40.96%	31,079,420	40.77%
Employees	292,334	0.38%	247,472	0.32%
Treasury shares	456,244	0.60%	456,679	0.60%
<b>TOTAL</b>	<b>76,234,545</b>	<b>100.00%</b>	<b>76,234,545</b>	<b>100.00%</b>

### 8.2. Dividends

Dividends distributed in 2023 and 2022 in respect of profits for the financial years 2022 and 2021, respectively, were as follows:

(in millions of euros)	2023	2022
Payment (a) to Icade SA shareholders for the previous financial year deducted from:		
- Tax-exempt fiscal profit (in accordance with the SIIC tax regime)	202.0	249.0
- Profit taxable at the standard rate	-	-
- "Merger premium" – Return of capital	126.1	68.8
<b>Total distribution</b>	<b>328.1</b>	<b>317.8</b>

(a) The 2022 dividend was paid as follows (see note 2.4):

- an interim dividend payment of €2.16 per share on March 2, 2023 totalling €163.7 million, after taking into account treasury shares;
- a final dividend payment of €2.17 per share on July 6, 2023 totalling €164.4 million, after taking into account treasury shares.

Dividends per share distributed in the financial years 2023 and 2022 in respect of profits for 2022 and 2021 were €4.33 and €4.20, respectively.

## 8.3. Non-controlling interests

### 8.3.1. Change in non-controlling interests

<i>(in millions of euros)</i>	12/31/2023	12/31/2022
<b>OPENING POSITION</b>	<b>2,096.6</b>	<b>1,917.5</b>
Capital increases and reductions	7.7	89.7
Changes in fair value of derivatives	(3.2)	37.9
Impact of changes in scope of consolidation (a)	(1,880.9)	(18.4)
Profit/(loss)	(40.3)	167.8
Dividends	(98.0)	(98.0)
<b>CLOSING POSITION</b>	<b>81.8</b>	<b>2,096.6</b>
Including Commercial Property Investment	74.6	179.6
Including Property Development	7.2	11.1
Including Healthcare Property Investment (a)	-	1,906.0

(a) The Healthcare Property Investment Division is no longer consolidated (see note 2.1).

### 8.3.2. Financial information on non-controlling interests

The main line items of the consolidated statement of financial position, consolidated income statement and consolidated cash flow statement of subsidiaries with non-controlling interests are presented below on a proportionate consolidation basis:

<i>(in millions of euros)</i>	12/31/2023			12/31/2022			
	Commercial Property Investment	Property Development (a)	Total (a)	Commercial Property Investment	Property Development (a)	Healthcare Property Investment	Total (a)
Investment property	373.6	-	373.6	470.8	-	2,878.4	3,349.2
Other assets	31.9	209.9	241.7	38.3	203.1	92.7	334.1
<b>TOTAL ASSETS</b>	<b>405.5</b>	<b>209.9</b>	<b>615.4</b>	<b>509.1</b>	<b>203.1</b>	<b>2,971.1</b>	<b>3,683.3</b>
Financial liabilities	312.3	97.5	409.8	320.7	96.9	1,020.3	1,437.9
Other liabilities	18.6	92.9	111.5	8.9	86.1	44.8	139.8
<b>TOTAL LIABILITIES</b>	<b>330.9</b>	<b>190.4</b>	<b>521.3</b>	<b>329.5</b>	<b>183.1</b>	<b>1,065.1</b>	<b>1,577.7</b>
<b>NET ASSETS</b>	<b>74.6</b>	<b>19.5</b>	<b>94.1</b>	<b>179.6</b>	<b>20.0</b>	<b>1,906.0</b>	<b>2,105.6</b>

(a) Non-controlling interests are presented excluding the impact of purchase options.

<i>(in millions of euros)</i>	2023			2022		
	Commercial Property Investment	Property Development	Total	Commercial Property Investment	Property Development	Total restated (a)
Income from operating activities	17.1	122.4	139.4	16.2	103.5	119.8
EBITDA	(104.2)	7.7	(96.5)	0.4	8.0	8.4
Operating profit/(loss)	(104.2)	7.6	(96.6)	0.4	7.9	16.7
Finance income/(expense)	(5.4)	(4.2)	(9.6)	(5.1)	(1.9)	1.3
<b>Net profit/(loss) from continuing operations</b>	<b>(109.7)</b>	<b>3.8</b>	<b>(105.9)</b>	<b>(4.8)</b>	<b>6.6</b>	<b>1.8</b>
Profit/(loss) from discontinued operations (a)			65.6			166.0
<b>NET PROFIT/(LOSS)</b>			<b>(40.3)</b>			<b>167.8</b>

(a) Profit/(loss) from discontinued operations related to profit/(loss) from the Healthcare Property Investment Division. 2022 figures were restated to reclassify the Healthcare Property Investment business as discontinued operations in accordance with IFRS 5 (see note 3.3).

<i>(in millions of euros)</i>	2023	2022
Net cash flow from operating activities	69.1	22.7
Net cash flow from investing activities	(144.8)	(80.4)
Net cash flow from financing activities	(133.3)	160.1
<b>NET CHANGE IN CASH</b>	<b>(209.0)</b>	<b>102.5</b>
Opening net cash	218.2	116.6
Closing net cash	9.2	219.1

## 8.4. Earnings per share

### ACCOUNTING PRINCIPLES

Basic earnings per share are equal to net profit/(loss) for the period attributable to holders of the Company's ordinary shares divided by the weighted average number of ordinary shares outstanding during the period. The weighted average number of ordinary shares outstanding during the period is the average number of ordinary shares outstanding at the beginning of the financial year, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.

In calculating diluted earnings per share, the average number of shares outstanding is adjusted to take into account the diluting effect of equity instruments issued by the Company and likely to increase the number of shares outstanding.

Below are the detailed figures for basic and diluted earnings per share for the financial years 2023 and 2022:

#### 8.4.1. Basic earnings per share

<i>(in millions of euros)</i>	2023	2022 Restated (a)
Net profit/(loss) attributable to the Group from continuing operations	(1,213.6)	(178.7)
Net profit/(loss) attributable to the Group from discontinued operations	(36.7)	232.7
<b>Net profit/(loss) attributable to the Group</b>	<b>(1,250.3)</b>	<b>54.1</b>
Opening number of shares	76,234,545	76,234,545
Average number of treasury shares outstanding	(472,327)	(552,021)
<b>Weighted average undiluted number of shares (b)</b>	<b>75,762,218</b>	<b>75,682,524</b>
Net profit/(loss) attributable to the Group from continuing operations per share (in €)	(€16.02)	(€2.36)
Net profit/(loss) attributable to the Group from discontinued operations per share (in €)	(€0.48)	€3.08
<b>BASIC EARNINGS PER SHARE ATTRIBUTABLE TO THE GROUP (in €)</b>	<b>(€16.50)</b>	<b>€0.71</b>

(a) Reclassification of the Healthcare Property Investment business as discontinued operations in accordance with IFRS 5 (see note 3.3).

(b) The weighted average undiluted number of shares is the number of shares at the start of the period plus, as the case may be, the average number of shares related to the capital increase less the average number of treasury shares outstanding.

#### 8.4.2. Diluted earnings per share

<i>(in millions of euros)</i>	2023	2022 Restated (a)
Net profit/(loss) attributable to the Group from continuing operations	(1,213.6)	(178.7)
Net profit/(loss) attributable to the Group from discontinued operations	(36.7)	232.7
<b>Net profit/(loss) attributable to the Group</b>	<b>(1,250.3)</b>	<b>54.1</b>
Weighted average undiluted number of shares	75,762,218	75,682,524
Impact of dilutive instruments (bonus shares)	91,271	132,766
<b>Weighted average diluted number of shares (b)</b>	<b>75,853,489</b>	<b>75,815,290</b>
Diluted net profit/(loss) attributable to the Group from continuing operations per share (in €)	(€16.00)	(€2.36)
Diluted net profit/(loss) attributable to the Group from discontinued operations per share (in €)	(€0.48)	€3.07
<b>DILUTED EARNINGS PER SHARE ATTRIBUTABLE TO THE GROUP (in €)</b>	<b>(€16.48)</b>	<b>€0.71</b>

(a) Reclassification of the Healthcare Property Investment business as discontinued operations in accordance with IFRS 5 (see note 3.3).

(b) The weighted average diluted number of shares is the weighted average undiluted number of shares adjusted for the impact of dilutive instruments (bonus shares).

## Note 9 . Operational information

### 9.1. Income from operating activities

#### ACCOUNTING PRINCIPLES

The Group's revenue breaks down between revenue excluding other income from operating activities and other income from operating activities.

The Group's revenue excluding other income from operating activities consists of:

- ◆ gross rental income from operating leases in which the Group is the lessor and which fall within the scope of IFRS 16. This income is generated by the Commercial Property Investment business (lease income from office properties and business parks);
- ◆ lease income from finance leases in which the Group is the lessor and which fall within the scope of IFRS 16. This income is generated by the Commercial Property Investment business (lease income from property assets leased as part of projects carried out with public-sector partners);
- ◆ income from construction contracts and off-plan sale contracts, generated by the Group's Property Development business, as well as income from services provided by the Group, which fall within the scope of IFRS 15 – Revenue from contracts with customers.

For all leases in which a Group entity is the lessor and, as a result, which generate income, an analysis is performed to determine whether they are operating leases or finance leases. Leases that transfer substantially all risks and rewards incidental to ownership of the underlying asset to the lessee are classified as finance leases; all other leases are classified as operating leases.

#### Gross rental income from operating leases

Gross rental income includes rents and other ancillary income from operating leases.

Lease income is recorded using the straight-line method over the shorter of the entire lease term and the period to the next break option. Consequently, any specific clauses and incentives stipulated in the leases (rent-free periods, progressive rent, lease premiums) are recognised over the shorter of the entire lease term and the period to the next break option, without taking index-linked rent reviews into account. The reference period used is the shorter of the entire lease term and the period to the next break option.

Any expenses directly incurred and paid to third parties to set up a lease are recorded as assets in the consolidated statement of financial position, under the heading "Investment property", and depreciated over the shorter of the entire lease term and the period to the next break option.

Uncollected lease income as of the end of the financial year is recognised in accounts receivable and is tested for impairment in accordance with IFRS 9 as described in note 9.2.3.

Service charges are contractually recharged to tenants. To this end, the Group acts as principal since it controls service charges prior to passing them on to the tenants. As a result, the Group recognises such recharges as income in the "Other income from operating activities" line of the consolidated income statement.

#### Income from finance leases

Income from finance leases includes finance income from property assets leased as part of projects carried out with public-sector partners.

When first recognised, an asset held under a finance lease is presented as a receivable at an amount equal to the net investment in the lease. Such receivable, which includes initial direct costs, is presented in "Accounts receivable" in the consolidated statement of financial position.

Lease income is recognised over the lease term. This income allocation is based on a pattern reflecting a constant periodic return on the net investment in the finance lease. Lease payments received for the period, excluding costs for services, are applied against the gross investment in the lease to reduce both the principal and the unearned income.

Initial direct costs included in the initial measurement of the finance lease receivable reduce the amount of income recognised over the lease term.

#### Income from construction contracts and off-plan sale contracts

The Group builds and sells residential and office properties under contracts with customers. Such contracts include a single performance obligation for a distinct asset. Under such contracts, the customer obtains control of the asset in proportion to the construction work completed, with the exception of the land, whose control is transferred to the customer upon signing the deed of acquisition.

Therefore, income is recognised over time, pro rata on the basis of cumulative costs incurred at the end of the financial year (including the price of land for off-plan sale contracts) and the progress of sales based on units sold, less any income recognised in previous financial years in respect of projects already in the construction phase at the beginning of the year.

The Group recognises a contract asset or contract liability in the consolidated statement of financial position at an amount equal to cumulative income from construction and off-plan sale contracts to date, for which the performance obligation has been satisfied over time, net of any consideration paid by the customer that has been collected to date, in accordance with the contractual payment schedule. If the amount is positive, it is accounted for as a contract asset in the consolidated statement of financial position; if negative, it is accounted for as a contract liability in the consolidated statement of financial position.

When it is probable that total contract costs will exceed total contract revenue, the Group recognises an onerous contract provision in the consolidated statement of financial position.

The Group's income from operating activities breaks down as follows:

<i>(in millions of euros)</i>	2023	2022 Restated (a)
Lease income from operating and finance leases	363.9	364.0
Income from construction and off-plan sale contracts – Property Development	1,073.9	1,059.3
Income from services provided	89.8	31.6
Other income from operating activities	129.3	113.6
<b>Income from operating activities</b>	<b>1,656.9</b>	<b>1,568.5</b>

(a) Reclassification of the Healthcare Property Investment business as discontinued operations in

“Other income from operating activities” mainly relates to service charges recharged to tenants by the Commercial Property Investment Division totalling €121.1 million as of December 31, 2023, compared with €107.1 million as of December 31, 2022.

After taking into account changes during the financial year, which correspond to services rendered and new sales completed during the period, the services not yet rendered under construction contracts and off-plan sale contracts entered into by fully consolidated Property Development companies amounted to €944.1 million as of December 31, 2023. These services will be provided in a more or less linear fashion over the next 24 months.

## 9.2. Components of the working capital requirement

The working capital requirement consists primarily of the following items:

- ◆ inventories and work in progress, accounts receivable, contract assets and miscellaneous receivables on the asset side of the consolidated statement of financial position;
- ◆ accounts payable, contract liabilities and miscellaneous payables on the liability side of the consolidated statement of financial position.

### 9.2.1. Change in working capital requirement

The change in working capital requirement from operating activities in the consolidated cash flow statement can be broken down by segment as follows:

<i>(in millions of euros)</i>	2023	2022
Commercial Property Investment	(31.0)	21.1
Property Development	(40.0)	(144.0)
Healthcare Property Investment (discontinued operations)	(8.6)	(68.0)
<b>TOTAL CASH FLOW FROM COMPONENTS OF THE WORKING CAPITAL REQUIREMENT</b>	<b>(79.5)</b>	<b>(190.8)</b>

The change in working capital requirement of €79.5 million as of December 31, 2023, €70.9 million of which relate to Commercial Property Investment and Property Development, is mainly attributable to:

- ◆ a decrease of €89.6 million in the Property Development Division's contract assets and liabilities;
- ◆ an increase of €48.8 million in the Property Development Division's inventories;
- ◆ a decrease of €31.3 million in other receivables and other payables at Group level.

## 9.2.2. Inventories and work in progress

### ACCOUNTING PRINCIPLES

Inventories primarily consist of land and land banks, work in progress and unsold units from the Property Development business.

Inventories and work in progress are recognised at acquisition or production cost. At each reporting date, they are valued at the lower of their cost and net realisable value.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion or the estimated costs necessary to make the sale.

An impairment loss is recognised if the net realisable value is less than the recognised cost.

(in millions of euros)	Property Development			Total	Commercial Property Investment	Total
	Land bank	Work in progress	Unsold completed units			
Gross value	309.6	538.2	15.2	862.9	0.8	863.8
Impairment loss	(13.5)	(32.2)	(1.8)	(47.5)	(0.0)	(47.6)
<b>NET VALUE AS OF 12/31/2022</b>	<b>296.1</b>	<b>505.9</b>	<b>13.4</b>	<b>815.4</b>	<b>0.8</b>	<b>816.2</b>
Gross value	151.7	655.4	12.7	819.7	0.8	820.5
Impairment loss (a)	(31.9)	(44.1)	(2.3)	(78.3)	(0.0)	(78.4)
<b>NET VALUE AS OF 12/31/2023</b>	<b>119.8</b>	<b>611.2</b>	<b>10.4</b>	<b>741.4</b>	<b>0.8</b>	<b>742.2</b>

(a) Changes in the impairment loss during the financial year reflect the market environment for property development as of December 31, 2023.

## 9.2.3. Accounts receivable and contract assets and liabilities

### ACCOUNTING PRINCIPLES

Accounts receivable are measured at amortised cost in accordance with IFRS 9. They are initially recognised at the invoice amount and tested for impairment.

See note 7.2.4 for further information on the Group's exposure to credit risk.

See note 9.1 for further details on the accounting principles applicable to contract assets and liabilities.

Changes in contract assets and liabilities and accounts receivable over the financial year ended December 31, 2023 were as follows:

(in millions of euros)	12/31/2022	Change for the period	Net change in impairment losses recognised in the income statement	Changes in scope of consolidation (a)	12/31/2023
Construction contracts (advances from customers)	69.0	(7.8)	-	3.9	65.1
Advances, down payments and credit notes to be issued	0.4	(0.1)	-	-	0.3
<b>CONTRACT LIABILITIES</b>	<b>69.4</b>	<b>(7.9)</b>	<b>-</b>	<b>3.9</b>	<b>65.4</b>
Construction and off-plan sale contracts	122.7	81.7	-	-	204.3
<b>CONTRACT ASSETS – NET VALUE</b>	<b>122.7</b>	<b>81.7</b>	<b>-</b>	<b>-</b>	<b>204.3</b>
Accounts receivable – operating leases	51.0	25.7	-	(26.7)	50.0
Financial accounts receivable – finance leases	72.0	(2.2)	-	-	69.8
Accounts receivable from ordinary activities	73.7	6.0	-	(3.3)	76.4
<b>Accounts receivable – Gross value</b>	<b>196.7</b>	<b>29.5</b>	<b>-</b>	<b>(30.0)</b>	<b>196.1</b>
Impairment of receivables from leases	(19.0)	0.0	(6.8)	2.7	(23.1)
Impairment of receivables from ordinary activities	(4.2)	-	0.1	-	(4.1)
<b>Accounts receivable – Impairment</b>	<b>(23.2)</b>	<b>0.0</b>	<b>(6.7)</b>	<b>2.7</b>	<b>(27.2)</b>
<b>ACCOUNTS RECEIVABLE – NET VALUE</b>	<b>173.5</b>	<b>29.5</b>	<b>(6.7)</b>	<b>(27.3)</b>	<b>168.9</b>

(a) The Healthcare Property Investment Division is no longer consolidated (see note 2.1).



Below is a maturity analysis of accounts receivable net of impairment and excluding financial receivables as of December 31, 2023 and December 31, 2022:

(in millions of euros)	Total	Not yet due	< 30 days	Due			
				30 < X < 60 days	60 < X < 90 days	90 < X < 120 days	> 120 days
Gross value	124.7	79.1	3.2	1.6	3.0	7.3	30.6
Impairment	(23.2)	(0.1)	-	(0.0)	(0.1)	(4.5)	(18.4)
<b>NET VALUE AS OF 12/31/2022</b>	<b>101.5</b>	<b>79.0</b>	<b>3.2</b>	<b>1.6</b>	<b>2.9</b>	<b>2.7</b>	<b>12.2</b>
Gross value	126.4	80.6	1.4	5.1	3.0	6.2	30.1
Impairment	(27.2)	(2.0)	(0.1)	(2.6)	(0.3)	(0.9)	(21.4)
<b>NET VALUE AS OF 12/31/2023</b>	<b>99.2</b>	<b>78.7</b>	<b>1.3</b>	<b>2.5</b>	<b>2.7</b>	<b>5.3</b>	<b>8.7</b>

#### 9.2.4. Miscellaneous receivables and payables

Miscellaneous receivables consisted mainly of tax and social security receivables, agency transactions, advances and down payments to suppliers and prepaid expenses. Miscellaneous payables consisted mainly of payables on investment property acquisitions, tax and social security payables, advances from customers, agency transactions and prepaid income.

As an agent, the Group keeps its principals' accounts and represents them in its own consolidated statement of financial position. Specific items are used within "Miscellaneous receivables" and "Miscellaneous payables". The principals' accounts in the consolidated statement of financial position thus represent the position of managed funds and accounts.

As of December 31, 2023 and December 31, 2022, miscellaneous receivables broke down as follows:

(in millions of euros)	12/31/2023			12/31/2022	
	Gross	Impairment losses	Net	Net	
Advances to suppliers	24.2	-	24.2	22.9	
Receivables from asset disposals	0.1	-	0.1	0.1	
Agency transactions	42.4	-	42.4	69.1	
Prepaid expenses	5.7	-	5.7	11.6	
Social security and tax receivables	228.1	-	228.1	240.5	
Other receivables	51.4	(9.4)	42.0	33.7	
<b>TOTAL MISCELLANEOUS RECEIVABLES</b>	<b>351.9</b>	<b>(9.4)</b>	<b>342.5</b>	<b>377.8</b>	

As of December 31, 2023 and December 31, 2022, miscellaneous payables broke down as follows:

(in millions of euros)	12/31/2023	12/31/2022
Advances from customers – Property Investment	59.8	48.5
Payables on asset acquisitions	154.1	167.8
Agency transactions	42.4	69.1
Prepaid income	27.9	31.4
Tax and social security payables excluding income taxes	164.0	187.8
Other payables	37.8	45.3
<b>TOTAL MISCELLANEOUS PAYABLES</b>	<b>486.0</b>	<b>549.9</b>

## 9.3. Lease liabilities

### ACCOUNTING PRINCIPLES

In accordance with IFRS 16:

- ◆ in the consolidated statement of financial position, “Lease liabilities” (current and non-current liabilities) refers to lease commitments under building leases and property leases;
- ◆ in the consolidated income statement, “Other finance income and expenses” includes interest expenses arising from lease liabilities;
- ◆ within the “Financing activities” section of the consolidated cash flow statement, “Repayments of lease liabilities” comprises principal repayments on lease liabilities. Within the “Operating activities” section of the consolidated cash flow statement, “Interest paid” includes interest payments on lease liabilities.

The lease liability is initially measured at the present value of future lease payments. These future lease payments include:

- ◆ fixed lease payments less any lease incentives provided by the lessor;
- ◆ variable lease payments that depend on an index or a rate;
- ◆ residual value guarantees;
- ◆ the price of any purchase options where management is reasonably certain that they will be exercised;
- ◆ early termination penalties where management is reasonably certain that an early termination option entailing significant penalties will be exercised.

The present value of future lease payments is obtained using the Group’s incremental borrowing rate, which varies depending on the remaining lease term.

Lease liabilities are subsequently measured at amortised cost using the effective interest method. In practice, lease liabilities are determined at their net carrying amount plus any interest and less any lease payments made.

Lease liabilities may be remeasured in the course of the reasonably certain lease term in any of the following circumstances:

- ◆ lease modification;
- ◆ an increase or decrease in the assessment of the lease term;
- ◆ an increase or decrease in the assessment of lease payments linked to an index or a rate.

(in millions of euros)	Total lease liabilities including:	Liabilities related to tangible fixed assets	Liabilities related to investment property
<b>12/31/2022</b>	<b>62.9</b>	<b>31.1</b>	<b>31.7</b>
Impact of remeasurement and new leases	12.6	10.8	1.7
Finance expense for the period	2.4	0.8	1.6
Repayment of liabilities (a)	(11.6)	(10.7)	(0.9)
Interest paid (a)	(2.3)	(0.8)	(1.6)
Other changes	0.1	0.1	-
Impact of changes in scope of consolidation (b)	(3.4)	-	(3.4)
<b>12/31/2023</b>	<b>60.4</b>	<b>31.2</b>	<b>29.2</b>
of which maturing in < 1 year	12.2	10.8	1.3
of which maturing in > 1 year and < 5 years	21.0	17.0	4.0
of which maturing in > 5 years	27.3	3.4	23.9

(a) Lease payments amounted to €13.8 million.

(b) The Healthcare Property Investment Division is no longer consolidated (see note 2.1).

In 2023, the expense relating to short-term or low-value leases stood at €1.5 million and €2.9 million, respectively.

## Note 10 . Other non-current assets

### 10.1. Goodwill, other intangible and tangible fixed assets

#### 10.1.1. Goodwill and other intangible fixed assets

##### ACCOUNTING PRINCIPLES

##### Goodwill

For business combinations, goodwill is recognised in the consolidated statement of financial position if the difference between, on the one hand, the fair value of the consideration transferred and, on the other hand, the net of the acquisition-date amounts of the identifiable assets and liabilities assumed measured at fair value is positive (*see note 4*).

Goodwill is an asset with an indefinite useful life and is therefore not amortised.

##### Other intangible fixed assets

Other intangible fixed assets mainly comprise acquired contracts and customer relationships, as well as software. Those fixed assets whose useful lives can be determined are amortised using the straight-line method over their estimated useful lives.

Intangible fixed assets	Useful life
New contracts and customer relationships	Duration of contracts
Other (a)	1 to 3 years

(a) Mainly software

The Group does not hold intangible fixed assets with an indefinite useful life except for goodwill (see above).

##### Impairment tests on goodwill and other intangible fixed assets

##### Goodwill

In accordance with IAS 36, goodwill is tested for impairment at least once a year or more often if there is an indication of impairment. The procedures for carrying out impairment tests are described below:

Indications of impairment include:

- ◆ an event causing a significant decline in the asset's market value;
- ◆ a change in the market environment (technological, economic or legal).

For the Property Development business, goodwill is tested for impairment in the respective group of cash-generating units (CGUs) to which it has been allocated. The fair value of this business is measured as the arithmetic mean of the values obtained with three methods: discounted cash flow (DCF) method, comparable transaction analysis and comparable company analysis. This valuation is based on an independent appraisal.

If the net carrying amount of goodwill becomes higher than its recoverable amount, the difference between those two amounts is recognised as an impairment loss. The recoverable amount is the higher of the fair value less costs of disposal and the value in use (DCF method).

In the DCF valuation method, the cash flows generated by each company over the period of its business plan as well as the cash flows calculated by extending those from the business plan over an additional 10-year period are discounted, and a terminal value calculated by applying a perpetual growth rate to the cash flows is added. The risk-free rate used is the 5-year average yield of the 10-year OAT TEC (variable-rate fungible treasury bond). Three risk premia are added to this risk-free rate: a market risk premium, a size premium and a specific risk premium. The discount rates used are determined before tax.

Reversal of an impairment loss for goodwill is not permitted.

##### Other intangible fixed assets

In accordance with IAS 36, other intangible fixed assets are tested for impairment if there is an indication of impairment. The procedures for carrying out impairment tests are identical to those employed for property lease assets (*see note 10.1.2*).

## Goodwill

As of December 31, 2023, a goodwill impairment test was performed on cash-generating units (CGUs). It indicated the full impairment of the goodwill, since the recoverable amount of these CGUs was below their carrying amount as of that date.

The recoverable amount of the Residential Property Development CGU is its fair value as of December 31, 2023 as determined by an independent valuer based on a new business plan as of December 31, 2023 and an 11.0% discount rate (unchanged compared to December 31, 2022).

## Other intangible fixed assets

	12/31/2022	Acquisitions and construction work	Disposals	Net depreciation and impairment charges	Other changes	12/31/2023
<i>(in millions of euros)</i>						
Gross value	61.2	8.0	(0.4)	-	0.6	69.3
Depreciation	(31.3)	-	0.4	(6.5)	0.0	(37.4)
Impairment losses	(0.5)	-	-	-	-	(0.5)
<b>Other intangible fixed assets</b>	<b>29.4</b>	<b>8.0</b>	<b>(0.0)</b>	<b>(6.5)</b>	<b>0.6</b>	<b>31.5</b>

### 10.1.2. Tangible fixed assets

#### ACCOUNTING PRINCIPLES

##### Tangible fixed assets excluding right-of-use assets relating to property leases

Tangible fixed assets mainly comprise office equipment and fixtures which have been depreciated according to the straight-line method over their useful lives.

##### Right-of-use assets relating to property leases

In accordance with IFRS 16:

- ◆ in the consolidated statement of financial position, “Tangible fixed assets” includes right-of-use assets relating to property leases;
- ◆ in the consolidated income statement, “Depreciation charges net of government investment grants” includes depreciation charges on these assets.

Right-of-use assets relating to property leases are measured initially at cost, which includes the following amounts:

- ◆ lease liabilities measured as described in note 9.3;
- ◆ prepaid lease payments.

These assets are depreciated on a straight-line basis over the course of the reasonably certain lease term.

Right-of-use assets relating to property leases may be remeasured over the reasonably certain lease term in any of the following circumstances:

- ◆ lease modification;
- ◆ an increase or decrease in the assessment of the lease term;
- ◆ an increase or decrease in the assessment of lease payments linked to an index or a rate;
- ◆ impairment losses.

##### Reasonably certain lease term

For each lease falling within the scope of IFRS 16, the lease term is assessed by management in accordance with the procedures provided for under the standard.

The lease term used for each lease is the reasonably certain lease term. The latter is the non-cancellable period of a lease adjusted for the following items:

- ◆ any option to early terminate the lease if the Group is reasonably certain not to exercise that option;
- ◆ any option to extend the lease if the Group is reasonably certain to exercise that option.

##### Impairment test on tangible fixed assets

In accordance with IAS 36, tangible fixed assets are tested for impairment if there is an indication of impairment. The procedures for carrying out impairment tests are described below.

Indications of impairment include:

- ◆ an event causing a significant decline in the asset’s market value;
- ◆ a change in the market environment (technological, economic or legal).

The test is performed either for individual assets or for groups of assets where those assets do not generate cash flows independently.

If the individual net carrying amount of an asset becomes higher than its recoverable amount, the difference between those two amounts is recognised as an impairment loss. The recoverable amount is the higher of the fair value less costs of disposal and the value in use. The value in use is measured based on the present value of the future cash flows expected to arise from the use of the asset.

If there is an indication that an impairment loss recognised in prior periods may no longer exist and the recoverable amount again becomes higher than the net carrying amount, impairment losses on tangible fixed assets or on right-of-use assets relating to property leases that were recognised in previous financial years are reversed, up to the impairment amount initially recognised less any additional depreciation that would have been recorded had no impairment loss been recognised.

<i>(in millions of euros)</i>	12/31/2022	Acquisitions and construction work	Disposals	Impact of depreciation and impairment	Other changes	12/31/2023
Gross value	83.8	8.3	(0.2)	-	(0.5)	91.4
Depreciation	(57.5)	-	0.1	(5.5)	(0.0)	(62.8)
Impairment losses	(2.3)	-	-	0.2	-	(2.2)
<b>Tangible fixed assets excluding right-of-use assets</b>	<b>24.0</b>	<b>8.3</b>	<b>(0.0)</b>	<b>(5.3)</b>	<b>(0.5)</b>	<b>26.4</b>
Gross value of property leases	60.3	10.9	(1.1)	-	(0.2)	69.9
Depreciation of property leases	(30.7)	-	1.0	(10.8)	0.2	(40.4)
<b>Right-of-use assets</b>	<b>29.6</b>	<b>10.9</b>	<b>(0.2)</b>	<b>(10.8)</b>	<b>0.0</b>	<b>29.5</b>
<b>TANGIBLE FIXED ASSETS</b>	<b>53.6</b>	<b>19.2</b>	<b>(0.2)</b>	<b>(16.2)</b>	<b>(0.5)</b>	<b>55.9</b>

## 10.2. Equity-accounted investments

### ACCOUNTING PRINCIPLES

The Group's consolidated statement of financial position includes the Group's share (its ownership interest) of the net assets of joint ventures and associates, which are consolidated using the equity method as described in note 4.

Since the Group considers its investments in joint ventures and associates to be part of its operating activities, the share of profit/(loss) of equity-accounted companies is presented within operating income, in accordance with Recommendation No. 2013-01 of the French Accounting Standards Authority (ANC).

The fair value model for measuring investment property (IAS 40) is also applied to investments in joint ventures proportionately to the Group's stake in these entities.

#### Impairment tests on equity-accounted investments

In accordance with IAS 28, equity-accounted investments are tested for impairment if there is an indication of impairment resulting from a loss event and that loss event has an impact on the estimated future cash flows that can be reliably estimated. Impairment tests are performed in accordance with IAS 36 by treating the investment as a single asset.

If the individual net carrying amount of an investment becomes higher than its recoverable amount, the difference between those two amounts is recognised as an impairment loss. The recoverable amount is the higher of the fair value less costs of disposal and the value in use. The value in use is measured based on the present value of the future cash flows expected to arise from the investment.

If there is an indication that an impairment loss recognised in prior periods may no longer exist and the recoverable amount again becomes higher than the net carrying amount, impairment losses on investments recognised in previous financial years are reversed.

#### 10.2.1. Change in equity-accounted investments

In the consolidated statement of financial position, the change in "Equity-accounted investments" between December 31, 2022 and December 31, 2023 broke down as follows:

<i>(in millions of euros)</i>	12/31/2023			12/31/2022		
	Joint ventures	Associates	Total equity-accounted companies	Joint ventures	Associates	Total equity-accounted companies
<b>OPENING SHARE IN NET ASSETS</b>	<b>126.4</b>	<b>1.9</b>	<b>128.3</b>	<b>131.0</b>	<b>1.7</b>	<b>132.7</b>
Share of profit/(loss)	(3.3)	0.3	(2.9)	13.5	0.4	14.0
Dividends paid	0.5	(1.6)	(1.0)	3.9	(0.2)	3.7
Impact of changes in scope of consolidation and capital	(12.8)	-	(12.8)	(22.2)	0.0	(22.2)
<b>CLOSING SHARE IN NET ASSETS</b>	<b>110.8</b>	<b>0.7</b>	<b>111.5</b>	<b>126.4</b>	<b>1.9</b>	<b>128.3</b>

## 10.2.2. Information on joint ventures and associates

Key information on the financial position of joint ventures is presented below (on a proportionate consolidation basis for the relevant companies). Associates are immaterial to the Group.

	12/31/2023			12/31/2022		
	Commercial Property Investment	Property Development	Total	Commercial Property Investment	Property Development	Total
<i>(in millions of euros)</i>						
Investment property	91.3	-	91.3	100.8	-	100.8
Other assets	25.0	441.4	466.4	23.8	378.3	402.1
<b>TOTAL ASSETS</b>	<b>116.3</b>	<b>441.4</b>	<b>557.7</b>	<b>124.5</b>	<b>378.3</b>	<b>502.9</b>
Financial liabilities	20.7	223.3	244.1	20.1	165.0	185.1
Other liabilities	7.7	195.1	202.8	8.8	182.6	191.4
<b>TOTAL LIABILITIES</b>	<b>28.4</b>	<b>418.4</b>	<b>446.9</b>	<b>28.9</b>	<b>347.6</b>	<b>376.5</b>
<b>NET ASSETS</b>	<b>87.9</b>	<b>23.0</b>	<b>110.8</b>	<b>95.7</b>	<b>30.7</b>	<b>126.4</b>

	2023			2022		
	Commercial Property Investment	Property Development	Total	Commercial Property Investment	Property Development	Total
<i>(in millions of euros)</i>						
Income from operating activities	12.1	165.3	177.5	11.1	184.9	196.0
EBITDA	2.9	10.6	13.5	2.7	22.9	25.5
Operating profit/(loss)	(6.9)	12.5	5.6	(4.8)	22.8	18.0
Finance income/(expense)	(0.9)	(6.5)	(7.4)	(0.4)	(1.9)	(2.3)
Income tax	0.0	(1.4)	(1.4)	-	(2.1)	(2.1)
<b>NET PROFIT/(LOSS)</b>	<b>(7.8)</b>	<b>4.5</b>	<b>(3.3)</b>	<b>(5.2)</b>	<b>18.7</b>	<b>13.5</b>
including depreciation net of government grants	(0.2)	-	(0.2)	(0.2)	(0.1)	(0.3)

## Note 11 . Income tax

### ACCOUNTING PRINCIPLES

Eligible companies of the Group benefit from the specific tax regime for French listed real estate investment companies (SIICs) or the special regime for *sociétés à prépondérance immobilière à capital variable* (SPPICAVs, i.e. French open-ended collective investment undertakings with at least 51% of real estate assets). Ordinary tax rules apply to the other companies of the Group.

The tax expense for the financial year includes:

- ◆ the current exit tax expense for entities under the SIIC tax regime;
- ◆ the current tax expense at the standard rate;
- ◆ deferred tax income or expense;
- ◆ the company value-added contribution (CVAE);
- ◆ the net change in provisions for tax risks relating to corporate tax or CVAE.

#### SIIC tax regime

Icade SA and its eligible subsidiaries have opted for the SIIC tax regime, which provides for:

- ◆ an SIIC segment exempt from tax on current income from leasing activities, capital gains on disposals and dividends received from subsidiaries which have opted for the SIIC tax regime;
- ◆ a segment that is taxable under ordinary tax rules in respect of other operations.

Entities to which the SIIC tax regime applies must pay out:

- ◆ 95% of profits from leasing activities;
- ◆ 70% of capital gains on disposals;
- ◆ 100% of dividends paid by subsidiaries which have opted for the SIIC tax regime.

#### Entry into the SIIC tax regime

At the time of entry into the SIIC tax regime, an exit tax of 19% is levied on any unrealised capital gains relating to investment property. A quarter of the tax amount is payable from December 15 of the financial year on which the entity begins to apply the tax regime and the remainder is spread over the following three financial years.

The exit tax liability is discounted according to its payment schedule on the basis of a market rate plus a premium.

The impact of discounting is deducted from the tax liability and the tax expense initially recognised. At the end of each reporting period until maturity, a finance expense is recognised as an offsetting entry for the unwinding of the discount on the tax liability.

#### Tax at the standard rate

Tax at the standard rate is accounted for in accordance with IAS 12 and calculated:

- ◆ on the portion of profit/(loss) that is taxable at the standard rate for companies that have opted for the SIIC tax regime;
- ◆ on the profit/(loss) of entities that have not opted for the SIIC tax regime (including companies acquired during the financial year which have not yet opted for the SIIC tax regime as of the end of the financial year);
- ◆ on the profit/(loss) of entities acquired during the financial year.

#### Deferred tax

Deferred tax is calculated on any temporary differences that exist at the end of the reporting period between the carrying amount of an asset or liability and its tax base, and on tax loss carry forwards.

Deferred tax assets and liabilities are measured using the tax rates enacted or substantively enacted by the tax authorities as of the end of the reporting period.

Deferred tax assets are only recognised if they are likely to be used to reduce future taxable income. Deferred tax is recognised using the liability method.

The impact of changes in tax rates and tax rules for existing deferred tax assets and liabilities affect the tax expense for the period.

Deferred tax liabilities recognised by the Group in the consolidated statement of financial position are primarily generated by the mismatch between the percentage of completion method and the completed contract method used for the Property Development Division's projects.



## 11.1. Tax expense

The tax expense for the financial years 2023 and 2022 is detailed in the table below:

<i>(in millions of euros)</i>	2023	2022 Restated (a)
Current tax at the standard rate	(0.8)	(10.0)
Deferred tax	11.6	(9.3)
Company value-added contribution (CVAE)	(1.5)	(3.0)
<b>TAX EXPENSE RECOGNISED IN THE INCOME STATEMENT</b>	<b>9.2</b>	<b>(22.3)</b>

(a) Reclassification of the Healthcare Property Investment business as discontinued operations in accordance with IFRS 5 (see note 3.3).

## 11.2. Reconciliation of the theoretical tax rate to the effective tax rate

The theoretical tax expense for the financial year 2023 is calculated by applying the tax rate applicable in France at the end of the reporting period to profit/(loss) before tax. For 2023, the theoretical tax expense was -€345.4 million. The reconciliation of the theoretical tax expense to the effective tax expense is detailed in the table below:

<i>(in millions of euros)</i>	2023
<b>PROFIT/(LOSS) FROM CONTINUING OPERATIONS</b>	<b>(1,329.0)</b>
Tax expense excluding company value-added contribution (CVAE)	10.8
Profit/(loss) of equity-accounted companies subject to corporate tax (a)	(2.4)
<b>PROFIT/(LOSS) BEFORE TAX AND PROFIT/(LOSS) OF EQUITY-ACCOUNTED COMPANIES SUBJECT TO CORPORATE TAX</b>	<b>(1,337.3)</b>
<b>Theoretical tax rate</b>	<b>25.8%</b>
<b>THEORETICAL TAX EXPENSE</b>	<b>345.4</b>
<b>Impact on the theoretical tax expense of:</b>	
- Companies subject to the SIIC tax regime (b)	(322.6)
- Permanent differences	(14.5)
- Change in unrecognised tax assets (tax loss carry forwards)	0.8
- Tax borne by non-controlling interests	1.4
- Other impacts (exit tax, provision for taxes, etc.)	0.1
<b>EFFECTIVE TAX EXPENSE (c)</b>	<b>10.8</b>
<b>Effective tax rate</b>	<b>0.8%</b>

(a) The profit/(loss) of equity-accounted companies directly subject to corporate tax (tax opaque companies) is excluded from the reconciliation since their profit/(loss), net of corporate tax, is included in "Profit/(loss) of equity-accounted companies".

(b) Impact on the theoretical tax expense of profits generated by companies that have opted for the SIIC tax regime and whose profits from the tax-exempt segment do not generate corporate tax.

(c) The effective tax expense is the tax expense recognised in the income statement excluding CVAE.

## 11.3. Deferred tax assets and liabilities

The Group's net deferred tax position as of December 31, 2023 and 2022 broke down as follows by type of deferred tax:

<i>(in millions of euros)</i>	12/31/2023	12/31/2022
<b>Deferred tax relating to temporary differences</b>		
- Provisions for non-deductible assets	4.8	3.0
- Provisions for employee benefit liabilities	1.6	1.9
- Provisions for non-deductible liabilities	4.7	4.6
- Finance leases	(3.7)	(3.7)
- Other (a)	(16.6)	(24.6)
<b>Deferred tax assets related to tax loss carry forwards</b>	<b>6.8</b>	<b>1.2</b>
<b>NET DEFERRED TAX POSITION</b>	<b>(2.6)</b>	<b>(17.6)</b>
Deferred tax assets	18.8	11.0
Deferred tax liabilities	21.4	28.6
<b>NET DEFERRED TAX POSITION</b>	<b>(2.6)</b>	<b>(17.6)</b>

(a) Other sources of deferred tax mainly relate to the difference in profits generated between the percentage of completion method and the completed contract method for some Property Development companies and to tax loss carry forwards.

As of December 31, 2023, unused tax loss carry forwards amounted to €194.3 million.

## Note 12 . Provisions

### 12.1. Provisions

#### ACCOUNTING PRINCIPLES

A provision is recognised if the Group has a present obligation to a third party that arises from past events, the settlement of which is expected to result in an outflow from the Group of resources embodying economic benefits and the value of which can be estimated reliably.

If the settlement date of that obligation is expected to be in more than one year, the present value of the provision is calculated and the effects of such calculation are recorded as finance income/(expense).

Identified risks of any kind, particularly operational and financial risks, are monitored on a regular basis, which makes it possible to determine the amount of provisions deemed necessary.

<i>(in millions of euros)</i>	12/31/2022	Charges	Use	Reversals	Changes in scope of consolidation (a)	Actuarial gains and losses	12/31/2023
Employee benefit liabilities	18.3	0.6	(1.3)	-	(0.8)	(0.4)	16.4
Other provisions	63.7	18.4	(13.9)	(8.7)	-	-	59.5
<b>PROVISIONS FOR LIABILITIES AND CHARGES</b>	<b>82.1</b>	<b>18.9</b>	<b>(15.2)</b>	<b>(8.7)</b>	<b>(0.8)</b>	<b>(0.4)</b>	<b>75.8</b>
Non-current provisions	22.2	0.6	(1.8)	(1.2)	(0.8)	(0.4)	18.5
Current provisions	59.9	18.4	(13.5)	(7.5)	-	-	57.3
including: operating profit/(loss)		15.6	(14.0)	(8.7)			
including: finance income/(expense)		3.4	(1.3)	-			

(a) The Healthcare Property Investment Division is no longer consolidated (see note 2.1).

### 12.2. Contingent liabilities

#### ACCOUNTING PRINCIPLES

A contingent liability is a possible obligation arising from past events where the outcome is uncertain or a present obligation arising from past events whose amount cannot be estimated reliably. Contingent liabilities are not recognised in the consolidated statement of financial position.

As of December 31, 2023, the Group was aware of no contingent liabilities likely to have a material effect on the Group's profits, financial position, assets or business.

## Note 13 . Employee remuneration and benefits

### ACCOUNTING PRINCIPLES

The Group's employees enjoy the following benefits:

- ◆ short-term employee benefits (e.g. paid annual leave or profit-sharing plan);
- ◆ defined contribution post-employment plans (e.g. pension scheme);
- ◆ defined benefit post-employment plans (e.g. lump sum payments on retirement);
- ◆ other long-term employee benefits (e.g. anniversary bonus).

These benefits are recognised in accordance with IAS 19 – Employee benefits.

In addition, corporate officers and certain employees have access to other benefits: share subscription or purchase option plans and bonus share plans. These benefits are recognised in accordance with IFRS 2 – Share-based payment.

### 13.1. Short-term employee benefits

#### ACCOUNTING PRINCIPLES

Short-term employee benefits are employee benefits that the Group is required to pay to its employees before twelve months after the end of the period in which the employees rendered service providing entitlement to these benefits.

They are accounted for as “Miscellaneous payables” in the consolidated statement of financial position until the date they are paid to the employees and recognised as expenses in the consolidated income statement for the reporting period in which service was rendered.

The provision for the employee profit-sharing plan is determined in accordance with the current Group agreement.

## 13.2. Post-employment benefits and other long-term employee benefits

### ACCOUNTING PRINCIPLES

#### Post-employment benefits

Post-employment benefits are employee benefits that the Group is required to pay to its employees after the completion of employment.

##### Defined contribution post-employment plans

Contributions periodically paid under plans which are considered as defined contribution plans, i.e. where the Group has no obligation other than to pay the contributions, are recognised as an expense for the year, when they are due. These plans release the Group from any future obligations.

##### Defined benefit post-employment plans

These benefits are conditional on completing a certain number of years of service within the Group. They include lump sum payments on retirement and other employee benefits which are considered as defined benefit plans (plans under which the Group undertakes to guarantee a defined amount or level of benefit) such as pensions.

They are recognised in the consolidated statement of financial position on the basis of an actuarial assessment of liabilities as of the reporting date performed by an independent actuary.

The provision which is included as a liability in the consolidated statement of financial position is the present value of the obligation less the fair value of plan assets, which are assets held to fund the obligation.

The provision is calculated according to the projected unit credit method and includes the related social security expenses. It takes into account a number of assumptions detailed below:

- ◆ employee turnover rates;
- ◆ rates of salary increases;
- ◆ discount rates;
- ◆ mortality tables;
- ◆ rates of return on plan assets.

Actuarial gains and losses are differences between the assumptions used and reality, or changes in the assumptions used to measure the liabilities and the related plan assets. In accordance with IAS 19, actuarial gains and losses on post-employment benefit plans are recognised in equity for the financial year in which they are measured and included in the consolidated statement of comprehensive income in “Other comprehensive income not recyclable to the income statement”.

In the event of legislative or regulatory changes or agreements affecting pre-existing plans, the Group shall immediately recognise the impact in the income statement in accordance with IAS 19.

#### Other long-term employee benefits

Other long-term employee benefits mainly comprise anniversary bonuses. A provision is recorded in respect of anniversary bonuses, which are measured by an independent actuary based on the likelihood of employees reaching the seniority required for each milestone. These values are updated at the end of each reporting period. For these other long-term benefits, actuarial gains or losses for the financial year are recognised immediately and in full in the income statement.

<i>(in millions of euros)</i>		12/31/2023	12/31/2022
Defined benefit post-employment plans (a)	13.1.	14.2	16.0
Other long-term employee benefits	13.2.	2.2	2.3
<b>TOTAL</b>		<b>16.4</b>	<b>18.3</b>

(a) Includes the impact of France's pension reform, which was not significant for the period, since the increase attributable to the extension of the period worked was mitigated by the effect of discounting.

### 13.2.1. Defined benefit post-employment plans

<i>(in millions of euros)</i>		12/31/2023	12/31/2022
<b>OPENING PROVISION</b>	<b>(1)</b>	<b>16.0</b>	<b>19.9</b>
<b>Impact of changes in scope of consolidation and other changes (a)</b>	<b>(2)</b>	<b>(1.3)</b>	<b>0.2</b>
Cost of services provided during the year (b)		0.6	1.5
Net finance cost for the year		0.5	0.2
<b>Costs for the period</b>	<b>(3)</b>	<b>1.0</b>	<b>1.7</b>
Benefits paid out	(4)	(1.1)	(2.4)
<b>Net expense recognised in the income statement</b>	<b>(5) = (3) + (4)</b>	<b>(0.1)</b>	<b>(0.7)</b>
Actuarial (gains)/losses for the year	(6)	(0.4)	(3.4)
<b>Closing actuarial debt</b>	<b>(7) = (1) + (2) + (5) + (6)</b>	<b>14.2</b>	<b>16.0</b>

For the Group, defined benefit post-employment plans were valued as of December 31, 2023 according to the terms of the Single Group Agreement signed on December 17, 2012.

The following actuarial assumptions were used:

- ♦ discount rate of 3.75% as of December 31, 2023 and 3.08% as of December 31, 2022.  
The discount rate used for the period ended December 31, 2023 is defined based on the “iBoxx € Corporate AA 10+” reference index. This reference index represents the yields of top-rated corporate bonds as of that date;
- ♦ male/female mortality tables:
  - male/female INSEE tables for 2019-2021 as of December 31, 2023,
  - male/female INSEE tables for 2018-2020 as of December 31, 2022;
- ♦ retirement age calculated according to statutory provisions.

Rates of salary increase and employee turnover are defined by job, occupational group and age group. Social security and tax rates on salaries are defined by job and occupational group.

### 13.2.2. Other long-term employee benefits

<i>(in millions of euros)</i>	12/31/2023	12/31/2022
Anniversary bonuses	2.2	2.3
<b>TOTAL</b>	<b>2.2</b>	<b>2.3</b>

### 13.2.3. Sensitivity of net carrying amounts of employee benefit liabilities

The impact of a change in the discount rate on employee benefit liabilities is presented in the table below:

<i>(in millions of euros)</i>			
Change in discount rate	Lump sum payments on retirement, pensions and other benefits	Anniversary bonuses	Total
(1.00)%	1.4	0.2	1.6
(0.50)%	0.7	0.1	0.8
1.00%	(1.2)	(0.1)	(1.4)
0.50%	(0.6)	(0.1)	(0.7)

### 13.2.4. Projected cash flows

Projected cash flows relating to employee benefit liabilities are presented in the table below:

(in millions of euros)

Years	Lump sum payments on retirement, pensions and other benefits	Anniversary bonuses	Total
N+1	1.0	0.2	1.1
N+2	0.5	0.3	0.8
N+3	0.8	0.3	1.0
N+4	1.3	0.2	1.5
N+5	1.1	0.2	1.3
Beyond	16.3	1.7	18.1
<b>TOTAL</b>	<b>21.0</b>	<b>2.8</b>	<b>23.8</b>
Discounting	(6.8)	(0.7)	(7.5)
<b>Liabilities as of 12/31/2023</b>	<b>14.2</b>	<b>2.2</b>	<b>16.3</b>

### 13.2.5. Employee termination benefits

As decided by management, termination benefits relating to the Group's employees (excluding related parties) are not currently covered by any provision.

(in millions of euros)

	12/31/2023	12/31/2022
Potential termination benefits	1.0	0.8
<b>TOTAL UNRECOGNISED</b>	<b>1.0</b>	<b>0.8</b>

## 13.3. Share-based payments

### ACCOUNTING PRINCIPLES

In accordance with IFRS 2, since share subscription or purchase option plans and bonus share plans are equity instruments subject to vesting conditions, they give rise to the recognition of a staff expense in respect of the fair value of services to be rendered during the vesting period, which is spread on a straight-line basis over the vesting period with a corresponding increase in reserves (equity).

The fair value of the financial instrument granted is determined on the grant date and is based on an assessment performed by an independent actuary. This fair value is not adjusted for changes in market parameters. Only the number of share subscription or purchase options is adjusted during the vesting period based on the satisfaction of service conditions or internal performance conditions.

### 13.3.1. Description of share subscription or purchase option plans

The characteristics of share subscription or purchase option plans in place as of December 31, 2023 and changes in financial year 2023 are presented in the following table:

Characteristics of the plans								Changes for the period			
Plans	Grant date	Vesting period	Duration of the plans	Initial strike price <sup>(a)</sup>	Number of options initially granted <sup>(a)</sup>	Strike price after applying the exchange ratio <sup>(b)</sup>	Number of options outstanding as of January 1, 2023	Number of options cancelled	Number of options exercised	Number of options outstanding as of December 31, 2023	Including those exercisable at the end of the period
2012 Plan	<sup>(c)</sup> 04/02/2013	4 years	10 years	21.81	52,915	79.89	6,985	(6,985)	-	-	-
2013 Plan	<sup>(c) (d)</sup> 06/23/2014	4 years	10 years	23.88	106,575	87.47	13,759	-	-	13,759	13,759
2014 Plan	<sup>(c) (d)</sup> 11/12/2014	4 years	10 years	21.83	50,000	79.96	10,237	-	-	10,237	10,237
<b>TOTAL PLANS</b>							<b>30,981</b>	<b>(6,985)</b>	<b>-</b>	<b>23,996</b>	<b>23,996</b>
Weighted average strike price per share (in euros)							<b>83.28</b>			<b>84.27</b>	<b>84.27</b>

(a) The number of shares and strike price at the beginning of the plan are expressed before the exchange ratio has been applied for plans resulting from mergers.

(b) Strike price expressed after the exchange ratio has been applied for plans resulting from mergers.

(c) Plans initially adopted by ANF. After the merger of ANF into Icade, existing plans as of the date of entry into the Icade Group were converted into Icade shares based on the exchange ratio of the merger.

(d) Plans initially adopted by ANF. The vesting period for stock options was 4 years or accelerated in the event of a change in control of the company. Such options vested and became exercisable as a result of Icade's takeover of ANF on October 23, 2017.

### 13.3.2. Description of bonus share plans

The characteristics of bonus share plans in place as of December 31, 2023 are presented in the following table:

Original characteristics of the plans					Changes for the period						As of December 31, 2023		
Plans	Grant date	Vesting period	Duration of the plans	Number of shares granted at the beginning of the plan	Shares granted	Vested shares	Incl. contingent shares	Shares granted	Vested shares	Cancelled shares	Shares granted	Vested shares	Incl. contingent shares
1-2020 Plan <sup>(a)</sup>	12/03/2020	2 years	3 years	32,910	-	26,310	-					-	-
2-2020 Plan <sup>(b)</sup>	12/03/2020	2 years	4 years	65,542	-	54,565	-					26,310	-
1-2021 Plan <sup>(b)</sup>	07/01/2021	2 years	4 years	1,649	1,649	-	1,649			(1,649)		54,565	-
1-2022 Plan <sup>(a)</sup>	04/22/2022	2 years	3 years	44,880	41,160	40	-		120	(4,800)	36,240	160	(e)
2-2022 Plan <sup>(c)</sup>	04/22/2022	2 years	4 years	97,982	90,786	-	90,786		170	(5,552)	85,064	170	(e)
1-2023 Plan <sup>(a)</sup>	07/31/2023	3 years	4 years	21,100	-	-	-	21,100	20	(780)	20,300	20	(e)
2-2023 Plan <sup>(d)</sup>	07/31/2023	3 years	4 years	65,813	-	-	-	65,813	125	(632)	65,056	125	(e)
<b>TOTAL</b>					<b>133,595</b>	<b>80,915</b>	<b>92,435</b>	<b>86,913</b>	<b>435</b>	<b>(13,413)</b>	<b>206,660</b>	<b>81,350</b>	<b>150,120</b>

(a) Plans granted to all permanent employees.

(b) Bonus share awards were subject to performance conditions that were based 50% on an NTA-based TSR and 50% on the performance of Icade's share price relative to the EPRA Europe ex UK Index (assuming no reinvestment of dividends). These awards may be increased by 15% in the event performance exceeds the benchmark.

(c) Bonus share awards are subject to performance conditions that are based 45% on an NTA-based TSR, 40% on the performance of Icade's share price relative to the EPRA Europe ex UK Index (assuming no reinvestment of dividends) and 15% on the reduction in CO<sub>2</sub> emissions in absolute terms (in accordance with SBTi guidelines) compared to their 2019 level. These awards may be increased by 15% in the event performance exceeds the benchmark.

(d) Bonus share awards are subject to performance conditions that are based on (i) changes in net current cash flow (NCCF), (ii) changes in share price, (iii) the reduction in CO<sub>2</sub> emissions measured in absolute terms compared to 2022 based on SBTi guidelines and changes in the gender equality policy. These criteria account for 30%, 40% and 30%, respectively, of the performance shares granted. These grants may be increased by 15% if the performance of one of these indicators exceeds that of the respective benchmark.

(e) Vested early due to the death of some participants.

### 13.3.3. Impact of bonus share plans on the income statement

Taking into account the vesting (based on the length of service in the Group) and performance conditions, bonus share plans represented an expense of €2.9 million for the financial year 2023 (€3.3 million for the financial year 2022).

## 13.4. Staff

The Group's average number of employees, excluding the Healthcare Property Investment Division, as of December 31, 2023 and 2022 is shown in the table below:

	Average number of employees					
	Executives		Non-executives		Total employees	
	12/31/2023	12/31/2022(a)	12/31/2023	12/31/2022(a)	12/31/2023	12/31/2022(a)
Commercial Property Investment	306.4	307.4	70.4	68.4	376.8	375.8
Property Development	500.6	508.8	247.3	274.2	747.9	783.0
<b>TOTAL NUMBER OF EMPLOYEES</b>	<b>807.0</b>	<b>816.2</b>	<b>317.8</b>	<b>342.6</b>	<b>1,124.8</b>	<b>1,158.8</b>

(a) Adjusted for the employees of the Healthcare Property Investment Division which was deconsolidated from the Icade Group's financial statements on July 5, 2023 (see note 2.1).

## Note 14 . Other information

### 14.1. Related parties

#### ACCOUNTING PRINCIPLES

In accordance with IAS 24 – Related party disclosures, a related party is a person or entity that is related to the Company. This may include:

- ◆ a person or a close member of that person's family if that person:
  - has control, or joint control of, or significant influence over the Company,
  - is a member of the key management personnel of the Company or of a parent of the Company;
- ◆ an entity is considered a related entity if any of the following conditions applies:
  - the entity and the Company are members of the same Group,
  - the entity is a joint venture or associate of the Company,
  - the entity is jointly controlled or owned by a member of the key management personnel of the Group,
  - the entity provides key management personnel services to the Company.

A related party transaction is a transfer of resources, services or obligations between a reporting entity and a related party.

#### 14.1.1. Related parties identified by the Company

Transactions between Icade SA and its subsidiaries have been eliminated on consolidation and are not itemised in this note.

Related parties identified by the Company include:

- ◆ Caisse des dépôts (which is the Company's major shareholder and controls the Group) and its affiliated companies;
- ◆ the Company's subsidiaries;
- ◆ joint ventures and associates of the Company;
- ◆ the Company's key management personnel, which consists of the persons who, during or at the end of the reporting period, were directors or members of the Executive Committee of Icade SA.

#### 14.1.2. Related party transactions

Transactions have been concluded under normal market conditions, i.e. comparable to those that would usually take place between independent parties.

#### Remuneration and other benefits for the Company's key management personnel

The remuneration of the Company's key management personnel is presented by type for the financial years 2023 and 2022 in the table below:

<i>(in millions of euros)</i>	12/31/2023	12/31/2022
Short-term benefits (salaries, bonuses, etc.) <sup>(a)</sup>	6.7	5.7
Share-based payments	0.8	0.5
<b>BENEFITS RECOGNISED</b>	<b>7.5</b>	<b>6.2</b>
Termination benefits	1.1	1.5
<b>TOTAL UNRECOGNISED</b>	<b>1.1</b>	<b>1.5</b>
<b>TOTAL</b>	<b>8.6</b>	<b>7.7</b>

*(a) Figures include employer contributions.*

#### Related party receivables and payables

Related party receivables and payables as of December 31, 2023 and 2022 were as follows:

<i>(in millions of euros)</i>	12/31/2023			12/31/2022		
	Parent company	Other	Total	Parent company	Other	Total
Related party receivables	4.1	10.6	14.7	-	17.1	17.1
Related party payables	10.9	138.5	149.4	18.6	150.9	169.5
Guarantees received	9.3	109.6	118.9	17.2	100.5	117.6



## 14.2. Off-balance sheet commitments

### ACCOUNTING PRINCIPLES

Off-balance sheet commitments made and received by the Group represent unfulfilled contractual obligations that are contingent on conditions being met or transactions being carried out after the current financial year.

The Group has three types of commitments: commitments relating to the scope of consolidation, commitments relating to financing activities (mortgages, promises to mortgage property and assignments of claims) and commitments relating to operating activities (including security deposits received for lease payments).

Off-balance sheet commitments received by the Group also include future lease payments receivable under operating leases in which the Group is the lessor and minimum lease payments receivable under finance leases in which the Group is the lessor.

#### 14.2.1. Off-balance sheet commitments

The following tables show the Group's off-balance sheet commitments, both made and received, as of December 31, 2023. The main changes during the period relate to the deconsolidation of the Healthcare Property Investment Division.

#### Commitments made

Off-balance sheet commitments made by the Group as of December 31, 2023 broke down as follows (by type):

	12/31/2023	12/31/2022
<i>(in millions of euros)</i>		
<b>COMMITMENTS RELATING TO THE SCOPE OF CONSOLIDATION</b>	<b>116.5</b>	<b>-</b>
Commitments relating to equity interests sold	116.5	-
<b>COMMITMENTS RELATING TO FINANCING ACTIVITIES</b>	<b>1,155.1</b>	<b>1,426.0</b>
Mortgage financing and lender's liens (a)	743.1	922.8
Promises to mortgage property and assignments of claims	100.0	265.8
Pledged securities, sureties and guarantees (b)	312.0	237.4
<b>COMMITMENTS RELATING TO OPERATING ACTIVITIES</b>	<b>1,679.0</b>	<b>2,104.2</b>
<b>Commitments relating to business development and asset disposals and acquisitions – Office and Healthcare Property Investment Divisions:</b>	<b>185.5</b>	<b>491.1</b>
Residual commitments in construction, property development and off-plan sale contracts	137.7	233.3
Commitments to sell given – Property Development – Land	0.1	-
Commitments to purchase investment property	-	114.5
Commitments to sell investment property	47.7	143.3
<b>Commitments relating to the Property Development business:</b>	<b>1,479.1</b>	<b>1,590.0</b>
Commitments to purchase land	329.7	333.0
Orders for housing units (including taxes)	859.6	851.8
Property development and off-plan sale contracts, Commercial Property Development	277.4	369.1
Demand guarantees given	12.4	36.1
<b>Other commitments made:</b>	<b>14.4</b>	<b>23.0</b>
Other commitments made	14.4	23.0

(a) Including €717.2 million for the Commercial Property Investment business.

(b) Mainly guarantees given by Icade Promotion to financial institutions for its subsidiaries.

## Commitments received

Off-balance sheet commitments received by the Group as of December 31, 2023 broke down as follows (by type):

<i>(in millions of euros)</i>	12/31/2023	12/31/2022
<b>COMMITMENTS RELATING TO THE SCOPE OF CONSOLIDATION</b>	-	0.6
No undisclosed liabilities warranties	-	0.6
<b>COMMITMENTS RELATING TO FINANCING ACTIVITIES</b>	1,906.0	2,260.4
Unused credit lines	1,906.0	2,260.4
<b>COMMITMENTS RELATING TO OPERATING ACTIVITIES</b>	972.4	3,761.4
<b>Commitments relating to business development and asset disposals and acquisitions – Office and Healthcare Property Investment Divisions:</b>	<b>237.4</b>	<b>2,871.6</b>
Commitments to purchase investment property	47.7	143.3
Commitments to sell investment property	-	114.5
Security deposits received for rents from Healthcare assets	-	2,414.7
Security deposits and demand guarantees for rents from Office assets	116.3	104.2
Bank guarantees for construction work	9.4	3.4
Pre-let agreements	63.9	91.5
<b>Commitments relating to the Property Development business:</b>	<b>713.1</b>	<b>871.7</b>
Commitments to sell land	0.1	-
Property development and off-plan sale contracts, Commercial Property Development	271.8	328.7
Demand guarantees received and surety guarantees received – Property Development	111.5	210.0
Commitments to purchase land	329.7	333.0
<b>Other commitments received relating to operating activities:</b>	<b>21.9</b>	<b>18.1</b>
Other commitments received	21.9	18.1

## 14.2.2. Information on leases

The Group is the lessor in a number of operating and finance leases.

### Finance leases

The present value of minimum lease payments receivable by the Group under finance leases was as follows:

<i>(in millions of euros)</i>		12/31/2023	12/31/2022
<b>Existing finance leases at the reporting date</b>			
<b>Total gross initial investment in the lease</b>	<b>A</b>	<b>178.5</b>	<b>178.5</b>
<b>Lease payments due</b>	<b>B</b>	<b>74.6</b>	<b>68.6</b>
Gross initial investment in the lease to be made not later than one year		6.1	6.0
Gross initial investment in the lease to be made later than one year and not later than five years		23.8	23.5
Gross initial investment in the lease to be made later than five years		74.0	80.4
<b>GROSS INVESTMENT IN THE LEASE AT THE REPORTING DATE</b>	<b>C=A-B</b>	<b>103.9</b>	<b>109.9</b>
<b>Earned finance income at the reporting date</b>	<b>D</b>	<b>58.2</b>	<b>54.5</b>
<b>Unearned finance income at the reporting date</b>	<b>E=C-I-D-F</b>	<b>35.0</b>	<b>38.8</b>
<b>Impact of unwinding of discount</b>	<b>F</b>	<b>(23.2)</b>	<b>(20.2)</b>
Present value of unguaranteed residual values accruing to the lessor	<b>G</b>	-	-
Present value of the minimum lease payments receivable not later than one year		2.8	2.9
Present value of the minimum lease payments receivable later than one year and not later than five years		9.8	10.2
Present value of the minimum lease payments receivable later than five years		21.2	23.7
<b>TOTAL PRESENT VALUE OF THE MINIMUM LEASE PAYMENTS RECEIVABLE</b>	<b>H=C-D-E-F-G</b>	<b>33.9</b>	<b>36.8</b>
<b>Net investment in the lease</b>	<b>I</b>	<b>33.9</b>	<b>36.8</b>

### Operating leases

The breakdown of future minimum lease payments receivable by the Group under operating leases was as follows:

<i>(in millions of euros)</i>	12/31/2023	12/31/2022
<b>MINIMUM LEASE PAYMENTS RECEIVABLE UNDER OPERATING LEASES</b>	<b>1,474.0</b>	<b>4,296.0</b>
Not later than one year	330.2	697.7
Later than one year and not later than five years	860.7	2,110.9
Later than five years	283.1	1,487.5

### 14.3. Events after the reporting period

None

### 14.4. Statutory Auditors' fees

	MAZARS				PRICEWATERHOUSECOOPERS AUDIT			
	(in millions of euros)		in %		(in millions of euros)		in %	
	2023	2022	2023	2022	2023	2022	2023	2022
<b>Audit</b>								
Audit, audit opinion, review of separate and consolidated financial statements								
– Issuer	0.4	0.4	38.2%	39.1%	0.4	0.4	39.0%	39.0%
– Fully consolidated subsidiaries	0.7	0.7	59.7%	57.6%	0.7	0.7	59.6%	58.3%
<b>Services other than the audit of financial statements</b>								
– Issuer	0.0	0.0	1.7%	2.6%	0.0	0.0	1.4%	2.5%
– Fully consolidated subsidiaries	0.0	0.0	0.4%	0.7%	-	0.0	0.0%	0.2%
<b>TOTAL</b>	<b>1.1</b>	<b>1.1</b>	<b>100.0%</b>	<b>100.0%</b>	<b>1.1</b>	<b>1.1</b>	<b>100.0%</b>	<b>100.0%</b>

Services other than the audit of financial statements provided by the Board of Statutory Auditors to Icade SA and its subsidiaries primarily include formalities relating to the provision of various certificates and reports on agreed-upon procedures with respect to accounting data and the independent third-party body report on social, environmental and societal disclosures.

## 14.5. Scope of consolidation

The table below shows the list of companies included in the scope of consolidation as of December 31, 2023 and the consolidation method used ("full" for "full consolidation" or "equity" for "equity method").

Full = full consolidation Equity = equity method Decon. = deconsolidated	Legal form	2023			2022
		% ownership	Joint ventures / Associates	Method of consolidation	% ownership
COMMERCIAL PROPERTY INVESTMENT					
ICADE SA	SA	Parent company		Full	Parent company
GIE ICADE MANAGEMENT	GIE	100.00		Full	100.00
OFFICES AND BUSINESS PARKS					
BATI GAUTIER	SCI	100.00		Full	100.00
68 VICTOR HUGO	SCI	100.00		Full	100.00
MESSINE PARTICIPATIONS	SCI	100.00		Full	100.00
1 TERRASSE BELLINI	SCI	33.33	Joint venture	Equity	33.33
ICADE RUE DES MARTINETS	SCI	100.00		Full	100.00
TOUR EQHO	SAS	51.00		Full	51.00
LE TOLBIAC	SCI	100.00		Full	100.00
SAS ICADE TMM	SAS	100.00		Full	100.00
SNC LES BASSINS À FLOTS	SNC	100.00		Full	100.00
SCI LAFAYETTE	SCI	54.98		Full	54.98
SCI STRATEGE	SCI	54.98		Full	54.98
SCI FUTURE WAY	SCI	52.75		Full	52.75
SCI NEW WAY	SCI	100.00		Full	100.00
SCI ORIANZ	SCI	100.00		Full	100.00
POINTE METRO 1	SCI	100.00		Full	100.00
SCI QUINCONCES TERTIAIRE	SCI	51.00		Full	51.00
SCI QUINCONCES ACTIVITES	SCI	51.00		Full	51.00
SNC ARCADE	SNC	100.00		Full	100.00
SNC NOVADIS	SNC	100.00		Full	100.00
SCI AMPHORE	SCI	55.00			
OTHER ASSETS					
BASSIN NORD	SCI	50.00	Joint venture	Equity	50.00
SCI BATIMENT SUD DU CENTRE HOSP PONTOISE	SCI	100.00		Full	100.00
SCI BSM DU CHU DE NANCY	SCI	100.00		Full	100.00
SCI IMMOBILIER HOTELS	SCI	77.00		Full	77.00
SCI BASILIQUE COMMERCE	SCI	51.00	Joint venture	Equity	51.00
OTHER					
ICADE 3.0	SASU	100.00		Full	100.00
CYCLE-UP	SAS	31.69	Joint venture	Equity	31.69
URBAN ODYSSEY	SAS	100.00		Full	100.00
PROPERTY DEVELOPMENT					
RESIDENTIAL PROPERTY DEVELOPMENT					
SCI DU CASTELET	SCI	100.00		Full	100.00
SARL B.A.T.I.R. ENTREPRISES	SARL	100.00		Full	100.00
SARL FONCIERE ESPACE ST CHARLES	SARL	86.00		Full	86.00
MONTPELLIERAINE DE RENOVATION	SARL	86.00		Full	86.00
SCI ST CHARLES PARVIS SUD	SCI	58.00		Full	58.00
MSH	SARL	100.00		Full	100.00
SARL GRP ELLUL-PARA BRUGUIERE	SARL	100.00		Full	100.00
SNC LE CLOS DU MONESTIER	SNC	100.00		Full	100.00
SCI LES ANGLES 2	SCI	75.50		Full	75.50
SNC MARINAS DEL SOL	SNC		Dissolution	Full	100.00
SCI LES JARDINS D'HARMONY	SCI	100.00		Full	100.00
SNC MEDITERRANEE GRAND ARC	SNC	50.00	Joint venture	Equity	50.00
SCI ROYAL PALMERAIE	SCI		Dissolution	Full	100.00
ICADE PROMOTION LOGEMENT	SAS	100.00		Full	100.00
CAPRI PIERRE	SARL	99.92		Full	99.92
SNC CHARLES	SNC	50.00	Joint venture	Equity	50.00

• CONSOLIDATED FINANCIAL STATEMENTS •

	Legal form	2023			2022
		% ownership	Joint ventures / Associates	Method of consolidation	% ownership
SCI TERRASSE GARONNE	SCI		Dissolution	Equity	49.00
SCI MONNAIE – GOUVERNEURS	SCI	70.00		Full	70.00
STRASBOURG R. DE LA LISIERE	SCI	33.00	Joint venture	Equity	33.00
SNC LES SYMPHONIES	SNC	66.70		Full	66.70
SNC LA POSEIDON	SNC	100.00		Full	100.00
MARSEILLE PARC	SCI	50.00	Joint venture	Equity	50.00
LE PRINTEMPS DES ROUGIERES	SARL	96.00		Full	96.00
SCI BRENIER	SCI	95.00		Full	95.00
PARC DU ROY D'ESPAGNE	SNC	50.00	Joint venture	Equity	50.00
SCI JEAN DE LA FONTAINE	SCI	50.00	Joint venture	Equity	50.00
MARSEILLE PINATEL	SNC	50.00	Joint venture	Equity	50.00
SCI LILLE LE BOIS VERT	SCI	50.00	Joint venture	Equity	50.00
SCI RUEIL CHARLES FLOQUET	SCI	50.00	Joint venture	Equity	50.00
SCI VALENCIENNES RESIDENCE DE L'HIPPODROME	SCI	75.00		Full	75.00
SCI BOULOGNE SEINE D2	SCI	17.33	Associate	Equity	17.33
BOULOGNE VILLE A2C	SCI	17.53	Associate	Equity	17.53
BOULOGNE VILLE A2D	SCI	16.94	Associate	Equity	16.94
BOULOGNE VILLE A2E	SCI	16.94	Associate	Equity	16.94
BOULOGNE VILLE A2F	SCI	16.94	Associate	Equity	16.94
BOULOGNE PARC B1	SCI	18.23	Associate	Equity	18.23
BOULOGNE 3-5 RUE DE LA FERME	SCI	13.21	Associate	Equity	13.21
BOULOGNE PARC B2	SCI	17.30	Associate	Equity	17.30
SCI LIEUSAINTE RUE DE PARIS	SCI	50.00	Joint venture	Equity	50.00
BOULOGNE PARC B3A	SCI	16.94	Associate	Equity	16.94
BOULOGNE PARC B3F	SCI	16.94	Associate	Equity	16.94
SCI ROTONDE DE PUTEAUX	SCI		Dissolution		33.33
SAS AD2B	SAS	100.00		Full	100.00
SCI CHATILLON AVENUE DE PARIS	SCI	50.00	Joint venture	Equity	50.00
SCI FRANCONVILLE – 1 RUE DES MARAIS	SCI	49.90	Joint venture	Equity	49.90
ESSEY LES NANCY	SCI	75.00		Full	75.00
SCI LE CERCLE DES ARTS – Housing	SCI	37.50		Full	37.50
LES ARCHES D'ARS	SCI	75.00		Full	75.00
ZAC DE LA FILATURE	SCI	50.00	Joint venture	Equity	50.00
SCI LA SUCRERIE – Housing	SCI	37.50		Full	37.50
SCI LA JARDINERIE – Housing	SCI	37.50		Full	37.50
LES COTEAUX DE LORRY	SARL	50.00	Joint venture	Equity	50.00
SCI LE PERREUX ZAC DU CANAL	SCI	72.50		Full	72.50
SCI Boulogne Ville A3 LA	SCI	17.40	Associate	Equity	17.40
SNC Nanterre MH17	SNC	50.00	Joint venture	Equity	50.00
SNC SOISY AVENUE KELLERMAN	SNC	50.00	Joint venture	Equity	50.00
SNC ST FARGEAU HENRI IV	SNC	60.00		Full	60.00
SCI ORLEANS ST JEAN LES CEDRES	SCI	49.00	Joint venture	Equity	49.00
RUE DE LA VILLE	SNC	99.99		Full	99.99
BEAU RIVAGE	SCI		Dissolution	Full	99.99
RUE DU 11 NOVEMBRE	SCI	100.00		Full	100.00
RUE DU MOULIN	SCI	100.00		Full	100.00
IMPASSE DU FORT	SCI	100.00		Full	100.00
SCI AVENUE DEGUISE	SCI		Dissolution	Full	100.00
LE GRAND CHENE	SCI		Merger		100.00
DUGUESCLIN DEVELOPPEMENT	SAS	100.00		Full	100.00
DUGUESCLIN & ASSOCIES MONTAGNE	SAS	100.00		Full	100.00
CDP THONON	SCI	33.33	Joint venture	Equity	33.33
SCI RESID. SERVICE DU PALAIS	SCI	100.00		Full	100.00

• CONSOLIDATED FINANCIAL STATEMENTS •

	Legal form	% ownership	2023	Method of consolidation	2022
			Joint ventures / Associates		% ownership
SCI RESID. HOTEL DU PALAIS	SCI	100.00		Full	100.00
SCI LE VERMONT	SCI	40.00	Joint venture	Equity	40.00
SCI HAGUENAU RUE DU FOULON	SCI	50.00	Joint venture	Equity	50.00
SNC URBAVIA	SNC	50.00	Joint venture	Equity	50.00
SCI GERTWILLER 1	SCI	50.00		Full	50.00
SCCV LES VILLAS DU PARC	SCCV		Dissolution		100.00
SCI RUE BARBUSSE	SCI	100.00		Full	100.00
ROUBAIX RUE DE L'OUEST	SCCV	50.00	Joint venture	Equity	50.00
SCI LES TERRASSES DES COSTIERES	SCI		Dissolution	Full	60.00
SCI CHAMPS S/MARNE RIVE GAUCHE	SCI	50.00	Joint venture	Equity	50.00
SCI BOULOGNE SEINE D3 PP	SCI	33.33	Associate	Equity	33.33
SCI BOULOGNE SEINE D3 D1	SCI	16.94	Associate	Equity	16.94
SCI BOULOGNE SEINE D3 E	SCI	16.94	Associate	Equity	16.94
SCI BOULOGNE SEINE D3 DEF COMMERCE	SCI	27.82	Associate	Equity	27.82
SCI BOULOGNE SEINE D3 ABC COMMERCE	SCI	27.82	Associate	Equity	27.82
SCI BOULOGNE SEINE D3 F	SCI	16.94	Associate	Equity	16.94
SCI BOULOGNE SEINE D3 C1	SCI	16.94	Associate	Equity	16.94
SCCV SAINTE MARGUERITE	SCCV	50.00	Joint venture	Equity	50.00
SNC ROBINI	SNC	50.00	Joint venture	Equity	50.00
SCCV LES PATIOS D'OR – GRENOBLE	SCCV	80.00		Full	80.00
SCI DES AUBEPINES	SCI	60.00		Full	60.00
SCI LES BELLES DAMES	SCI	66.70		Full	66.70
SCI PLESSIS LEON BLUM	SCI	80.00		Full	80.00
SCCV RICHET	SCCV	100.00		Full	100.00
SCI BOULOGNE PARC B4B	SCI	20.00	Associate	Equity	20.00
SCI ID	SCI	53.00		Full	53.00
SNC PARIS MACDONALD PROMOTION	SNC	100.00		Full	100.00
COEUR DE VILLE	SARL	70.00		Full	70.00
SCI CLAUSE MESNIL	SCCV	50.00	Joint venture	Equity	50.00
ROUEN VIP	SCCV		Dissolution	Full	100.00
OVALIE 14	SCCV	80.00		Full	80.00
SCCV VILLA ALBERA	SCCV	50.00	Joint venture	Equity	50.00
SCI ARKADEA LA ROCHELLE	SCI	100.00		Full	100.00
SCCV FLEURY MEROGIS LOT1.1	SCCV	70.00		Full	70.00
SCCV FLEURY MEROGIS LOT1.2	SCCV	70.00		Full	70.00
SCCV FLEURY MEROGIS LOT3	SCCV	100.00		Full	100.00
SCI L'ENTREPÔT MALRAUX	SCI	65.00		Full	65.00
SCCV CERGY – LES PATIOS D'OR	SCCV	80.00		Full	80.00
MULHOUSE LES PATIOS D'OR	SCCV	40.00	Joint venture	Equity	40.00
SCCV CLERMONT-FERRAND LA MONTAGNE	SCCV	90.00		Full	90.00
SCCV NICE GARE SUD	SCCV	50.00	Joint venture	Equity	50.00
SEP COLOMBES MARINE	SEP	25.00	Joint venture	Equity	25.00
SCI CLAYE SOUILLY – L'OREE DU BOIS	SCI	80.00		Full	80.00
SCI BONDOUFLE – LES PORTES DE BONDOUFLE	SCI	80.00		Full	80.00
SCCV ECOPARK	SCCV	90.00		Full	90.00
SCI FI BAGNOLET	SCI	90.00		Full	90.00
SCI ARKADEA TOULOUSE LARDENNE	SCI	100.00		Full	100.00
SCCV 25 BLD ARMEE DES ALPES	SCCV	50.00	Joint venture	Equity	50.00
SCCV HORIZON PROVENCE	SCCV	58.00		Full	58.00
SCI ARKADEA LYON CROIX ROUSSE	SCI		Dissolution	Equity	70.00
SCCV SETE – QUAI DE BOSCH	SCCV	90.00		Full	90.00
SCCV RIVES DE SEINE – BOULOGNE YC2	SCCV	80.00		Full	80.00
SCI BLACK SWANS	SCI	85.00		Full	85.00

• CONSOLIDATED FINANCIAL STATEMENTS •

	Legal form	% ownership	2023		2022
			Joint ventures / Associates	Method of consolidation	% ownership
SCCV CANAL STREET	SCCV	100.00		Full	100.00
SCCV BLACK SWANS TOUR B	SCCV	85.00		Full	85.00
SCCV ORCHIDEES	SCCV	51.00		Full	51.00
SCCV MEDICADE	SCCV	80.00		Full	80.00
SCI PERPIGNAN LESAGE	SCI	50.00	Joint venture	Equity	50.00
SNC TRIGONES NIMES	SCI	49.00	Joint venture	Equity	49.00
SCCV BAILLY CENTRE VILLE	SCCV	50.00	Joint venture	Equity	50.00
SCCV MONTLHERY LA CHAPELLE	SCCV	100.00		Full	100.00
SCI ARKADEA MARSEILLE SAINT VICTOR	SCI	51.00	Joint venture	Equity	51.00
SCCV SAINT FARGEAU 23 FONTAINEBLEAU	SCCV	70.00		Full	70.00
SCCV CARENA	SCCV	51.00		Full	51.00
SCCV BLACK SWANS TOUR C	SCCV	85.00		Full	85.00
SCI CAEN LES ROBES D'AIRAIN	SCI	60.00		Full	60.00
SCI CAPITAIN BASTIEN	SCI	80.00		Full	80.00
SCCV THERESIANUM CARMELITES	SCCV		Dissolution		65.00
SCI PERPIGNAN CONSERVATOIRE	SCI	50.00	Joint venture	Equity	50.00
SCI LILLE WAZEMMES	SCI	50.00	Joint venture	Equity	50.00
SCCV ANTONY	SCCV	100.00		Full	100.00
SCCV SAINT FARGEAU LEROY BEAUFILS	SCCV	65.00		Full	65.00
SCI ST ANDRE LEZ LILLE – LES JARDINS DE TASSIGNY	SCI	50.00	Joint venture	Equity	50.00
SCCV CARIVRY	SCCV	51.00		Full	51.00
SCCV L'ETOILE HOCHÉ	SCCV	60.00		Full	60.00
SCCV LES PINS D'ISABELLA	SCCV	49.90	Joint venture	Equity	49.90
SCCV LES COTEAUX LORENTINS	SCCV	100.00		Full	100.00
SCCV ROSNY 38-40 JEAN JAURES	SCCV	100.00		Full	100.00
SCCV CARETTO	SCCV	51.00		Full	51.00
SCCV MASSY CHATEAU	SCCV	50.00		Full	50.00
SCCV MASSY PARC	SCCV	50.00	Associate	Equity	50.00
SCCV NEUILLY S/MARNE QMB 10B	SCCV	44.45		Full	44.45
SCCV VITA NOVA	SCCV	70.00		Full	70.00
SCCV NEUILLY S/MARNE QMB 1A	SCCV	44.45	Associate	Equity	44.45
SCCV LE RAINCY RSS	SCCV	50.00	Joint venture	Equity	50.00
SCCV LE MESNIL SAINT DENIS SULLY	SCCV	100.00		Full	90.00
SCCV 1-3 RUE D'HOZIER	SCCV		Dissolution	Equity	45.00
SCCV CUGNAUX – LEO LAGRANGE	SCCV	50.00	Joint venture	Equity	50.00
SCCV COLOMBES MARINE LOT A	SCCV	25.00	Joint venture	Equity	25.00
SCCV COLOMBES MARINE LOT B	SCCV	25.00	Joint venture	Equity	25.00
SCCV COLOMBES MARINE LOT D	SCCV	25.00	Joint venture	Equity	25.00
SCCV COLOMBES MARINE LOT H	SCCV	25.00	Joint venture	Equity	25.00
SCCV LES BERGES DE FLACOURT	SCCV	65.00		Full	65.00
SCCV LE PLESSIS-ROBINSON ANCIENNE POSTE	SCCV	75.00		Full	75.00
SCCV QUAI 56	SCCV	50.00	Joint venture	Equity	50.00
SCCV LE PIAZZA	SCCV	70.00		Full	70.00
SCCV ICAGIR RSS TOURS	SCCV	50.00	Joint venture	Equity	50.00
SSCV ASNIERES PARC B8 B9	SCCV	50.00	Joint venture	Equity	50.00
SSCV SAINT FARGEAU 82-84 Avenue de Fontainebleau	SCCV	70.00		Full	70.00
SAS PARIS 15 VAUGIRARD LOT A	SAS	50.00	Joint venture	Equity	50.00
SCCV PARIS 15 VAUGIRARD LOT C	SCCV	50.00	Joint venture	Equity	50.00
SCCV SARCELLES – RUE DU 8 MAI 1945	SCCV	100.00		Full	100.00
SCCV SARCELLES – RUE DE MONTFLEURY	SCCV	100.00		Full	100.00
SCCV MASSY PARC 2	SCCV	50.00	Associate	Equity	50.00
SCCV CANTEROUX	SCCV	50.00		Full	50.00
SCCV SOHO	SCCV	51.00		Full	51.00

• CONSOLIDATED FINANCIAL STATEMENTS •

	Legal form	2023			2022
		% ownership	Joint ventures / Associates	Method of consolidation	% ownership
SCCV IPK NIMES CRESPON	SCCV	51.00		Full	51.00
SCCV BEARN	SCCV	65.00		Full	65.00
SCCV ASNIERES PARC B2	SCCV	50.00	Joint venture	Equity	50.00
SCCV PERPIGNAN AVENUE D'ARGELES	SCCV	50.00	Joint venture	Equity	50.00
SCCV 117 AVENUE DE STRASBOURG	SCCV	70.00		Full	70.00
SCCV MARCEL PAUL VILLEJUIF	SCCV	60.00		Full	60.00
SCCV MAISON FOCH	SCCV	40.00		Full	40.00
SCCV CHATENAY MALABRY LA VALLEE	SCCV	100.00		Full	100.00
SCCV LOT 2G2 IVRY CONFLUENCES	SCCV	51.00		Full	51.00
SCCV LA PEPINIERE	SCCV	100.00		Full	100.00
SCCV NICE CARRE VAUBAN	SCCV	95.00		Full	95.00
SNC IP1R	SNC	100.00		Full	100.00
SNC IP3M LOGT	SNC	100.00		Full	100.00
SCCV NGICADE MONTPELLIER OVALIE	SCCV	50.00		Full	50.00
SCCV LILLE CARNOT LOGT	SCCV	50.00	Joint venture	Equity	50.00
SCCV NORMANDIE LA REUNION	SCCV	65.00		Full	65.00
SAS AILN DEVELOPPEMENT	SAS	25.00	Joint venture	Equity	25.00
SCCV URBAT ICADE PERPIGNAN	SCCV	50.00	Joint venture	Equity	50.00
SCCV DES YOLES NDDM	SCCV	75.00		Full	75.00
SCCV AVIATEUR LE BRIX	SCCV	50.00	Joint venture	Equity	50.00
SARVILEP	SAS	100.00		Full	100.00
SCCV POMME CANNELLE	SCCV	60.00		Full	60.00
SCCV RS MAURETTES	SCCV	50.00	Joint venture	Equity	50.00
SCCV BRON LA CLAIRIERE G3	SCCV	51.00	Joint venture	Equity	51.00
SCCV BRON LA CLAIRIERE C1C2	SCCV	51.00	Joint venture	Equity	51.00
SCCV BRON LA CLAIRIERE C3C4	SCCV	49.00	Joint venture	Equity	49.00
SCCV BRON LA CLAIRIERE D1D2	SCCV	49.00	Joint venture	Equity	49.00
SCCV LES RIVES DU PETIT CHER LOT 2	SCCV	60.00	Joint venture	Equity	60.00
SCCV ARGENTEUIL LES BUCHETTES	SCCV		Dissolution		100.00
SCCV LES RIVES DU PETIT CHER LOT 4	SCCV	60.00	Joint venture	Equity	60.00
SCCV LES RIVES DU PETIT CHER LOT 5B	SCCV	60.00	Joint venture	Equity	60.00
SCCV URBAN IVRY 94	SCCV	100.00		Full	100.00
SCCV YNOV CAMBACERES	SCCV	51.00		Full	51.00
SCCV DES RIVES DU PETIT CHER LOT 5	SCCV	60.00	Joint venture	Equity	60.00
SCCV DES RIVES DU PETIT CHER LOT 6	SCCV	60.00	Joint venture	Equity	60.00
SCCV MONTPELLIER SW	SCCV	70.00		Full	70.00
SCCV LES JARDINS DE CALIX IPS	SCCV	80.00		Full	80.00
SCCV BOUL DEVELOPPEMENT	SCCV	65.00		Full	65.00
SCCV BILL DEVELOPPEMENT	SCCV	65.00		Full	65.00
SCCV PATIOS VERGERS	SCCV	70.00		Full	70.00
SCCV LILLE PREVOYANCE	SCCV	50.00	Joint venture	Equity	50.00
SCCV BOUSSY SAINT ANTOINE ROCHOPT	SCCV	50.00	Joint venture	Equity	50.00
SCCV IXORA	SCCV	80.00		Full	80.00
SCCV CAP ALIZE	SCCV	80.00		Full	80.00
SCCV HOUILLES JEAN-JACQUES ROUSSEAU	SCCV	50.00	Joint venture	Equity	50.00
SCCV IPSPF CHR1	SCCV	40.00	Joint venture	Equity	40.00
SCCV LORIENT GUESDE	SCCV	80.00		Full	80.00
SCCV BOHRIE D2	SCCV	70.00		Full	70.00
SAS AD VITAM	SAS	100.00		Full	100.00
SCCV MARCEL GROSMENIL VILLEJUIF	SCCV	60.00		Full	60.00
SNC SEINE CONFLUENCES	SNC	50.00	Joint venture	Equity	50.00
SCCV CHATENAY LAVALLEE LOT I	SCCV	50.10		Full	50.10
SCCV QUINCONCES	SCCV	33.33	Joint venture	Equity	33.33



• CONSOLIDATED FINANCIAL STATEMENTS •

	Legal form	2023			2022
		% ownership	Joint ventures / Associates	Method of consolidation	% ownership
SARL BEATRICE MORTIER IMMOBILIER – BMI	SARL	100.00		Full	100.00
SCCV CARTAGENA	SCCV	95.00		Full	95.00
SAS LES HAUTS DE LA VALSIERE	SAS	100.00		Full	50.00
SCCV LE SERANNE	SCCV	50.00	Joint venture	Equity	50.00
SCCV VIADORA	SCCV	30.00	Associate	Equity	30.00
SNC URBAIN DES BOIS	SNC	100.00		Full	100.00
SCCV NANTERRE HENRI BARBUSSE	SCCV	66.67		Full	66.67
SCCV LES PALOMBES	SCCV	50.00	Joint venture	Equity	50.00
SCCV 3 – B1D1 LOGEMENT	SCCV	25.00	Joint venture	Equity	25.00
SCCV 7 – B2A TOUR DE SEINE	SCCV	25.00	Joint venture	Equity	25.00
SCCV 8 – B2A PARTICIPATIF	SCCV	25.00	Joint venture	Equity	25.00
SAS 9 – B2A CITE TECHNIQUE	SAS	25.00	Joint venture	Equity	25.00
SCCV TREVoux ORFÈVRES	SCCV	65.00		Full	65.00
SAS SURESNES LIBERTE	SAS	70.00		Full	70.00
SAS CLICHY 33 MEDERIC	SAS	45.00		Full	45.00
SAS L'OREE	SAS	50.00	Joint venture	Equity	50.00
SCCV CERDAN	SCCV	50.00	Joint venture	Equity	50.00
SCCV DES RIVES DU PETIT CHER LOT 7	SCCV	45.00	Joint venture	Equity	45.00
SAS BREST COURBET	SCCV	50.00	Joint venture	Equity	50.00
SCCV MITTELVEG	SCCV	70.00		Full	70.00
SCCV LES RIVES DU PETIT CHER LOT 8	SCCV	45.00	Joint venture	Equity	45.00
SCCV TERRASSES ENSOLEILLEES	SCCV	50.00	Joint venture	Equity	50.00
SCCV ISSY ESTIENNE D'ORVES	SCCV	85.00		Full	75.00
SCCV CARAIX	SCCV	51.00		Full	51.00
SAS TOULOUSE RUE ACHILE VIADEU	SAS	55.72		Full	55.72
SCCV ARC EN CIEL	SCCV	51.00		Full	51.00
SCCV OUEST VELLEDA	SCCV		Dissolution	Full	75.00
SNC LE BOIS URBAIN	SNC	100.00		Full	100.00
SCCV DOMAINE DE LA CROIX	SCCV	80.00		Full	80.00
SCCV ILE NAPOLEON	SCCV	70.00		Full	70.00
SAS RB GROUP	SAS	65.29		Full	65.29
SARL M&A IMMOBILIER	SARL	65.29		Full	65.29
SCCV LE FORUM-LATTES	SCCV	32.65		Full	32.65
SCCV BLEU PLATINE -SETE	SCCV	45.70		Full	45.70
SCCV LADY MARY-MONT SAINT CLAIR	SCCV	45.70		Full	45.70
SARL KALITHYS	SARL	65.29		Full	65.29
SCCV LADY SAINT CLAIR – SETE	SCCV	65.29		Full	65.29
SCCV BASSA NOVA – PERPIGNAN	SCCV	52.23		Full	52.23
SCCV VILLA HERMES – MANDELIEU	SCCV	65.29		Full	65.29
SCCV HERMES 56 – MONTPELLIER	SCCV	65.29		Full	65.29
SCCV L'OASIS – CASTELNAU	SCCV	65.29		Full	65.29
SCCV VERT AZUR – GRABELS	SCCV	65.29		Full	65.29
SCCV VILLA BLANCHE LUNEL	SCCV	65.29		Full	65.29
SCCV LE PARC RIMBAUD	SCCV	65.29		Full	65.29
SCCV SILVER GARDEN	SCCV	65.29		Full	65.29
SCCV SETE PREMIERE LIGNE	SCCV	65.29		Full	65.29
SCCV LE 9 – MONTPELLIER	SCCV	33.30		Full	33.30
SCCV EUROPE – CASTELNAU	SCCV	32.65	Joint venture	Equity	32.65
SAS RB PARTICIPATIONS	SAS	65.29		Full	65.29
SNC M&A PROMOTION	SNC	65.29		Full	65.29
SCCV LES BAINS – JUVIGNAC	SCCV	65.29		Full	65.29
SCCV LES PINS BLEUS – GRABELS	SCCV	52.23		Full	52.23
SCCV VILLAGE CLEMENCEAU MONTPELLIER	SCCV	52.23		Full	52.23

• CONSOLIDATED FINANCIAL STATEMENTS •

	Legal form	2023		2022	
		% ownership	Joint ventures / Associates	Method of consolidation	% ownership
SCCV 68 AMPERE	SCCV	80.00		Full	80.00
SCCV IPSPF-CHR2	SCCV	40.00	Joint venture	Equity	40.00
SCCV LUNEL FOURQUES	SCCV	51.00		Full	51.00
SCCV VILLENEUVE D'ASCQ – AVENUE DU BOIS	SCCV	50.00	Joint venture	Equity	50.00
SCCV ECHO LES MENUIRES	SCCV	60.00	Joint venture	Equity	60.00
SCCV ACANTHE	SCCV	51.00	Joint venture	Equity	51.00
SAS COLOMBES AURIOL	SAS	51.00	Joint venture	Equity	51.00
SCCV ZAC REPUBLIQUE	SCCV	51.00		Full	51.00
SCCV MEDOC 423	SCCV	49.90	Joint venture	Equity	49.90
SCI ARKADEA LYON GIRONDINS	SCI	100.00		Full	100.00
SCCV BRON CLAIRIERE F1	SCCV	51.00	Joint venture	Equity	51.00
SCCV VILLA LAURES – MONTPELLIER	SCCV	43.55		Full	43.55
SCCV COEUR CARNOLES	SCCV	50.00	Joint venture	Equity	50.00
SCCV ARRAS MICHELET	SCCV	50.00	Joint venture	Equity	50.00
SCCV BRON CLAIRIERE G4	SCCV	49.00	Joint venture	Equity	49.00
SCCV STEEN ST MALO LA FONTAINE	SCCV	33.33	Joint venture	Equity	33.33
SAS STEEN LIBOURNE	SAS	33.33	Joint venture	Equity	33.33
SCCV STEEN DIJON	SCCV	33.33	Joint venture	Equity	33.33
SCCV STEEN PARIS 9 PETRELLE	SCCV	33.33	Joint venture	Equity	33.33
SCCV STEEN ROANNE FOLLEREAU	SCCV	33.33	Joint venture	Equity	33.33
SCCV PHARE D'ISSY	SCCV	75.00		Full	75.00
SEP PEACEFUL	SEP	29.38	Joint venture	Equity	29.38
SCCV 63 DUPONT DES LOGES	SCCV	100.00		Full	
SAS BF3 SAINT RAPHAEL	SAS	20.00		Equity	20.00
SCCV ARCHEVECHE	SCCV	40.00	Joint venture	Equity	40.00
SAS NEUILLY VICTOR HUGO	SAS	54.00		Full	54.00
SNC VILLEURBANNE TONKIN	SNC	55.72		Full	55.72
SCCV MONTIGNY LOTS 1C 5A 5B	SCCV	70.00		Full	
SCCV ILOT DES PLATANES – LATTES	SCCV	29.38	Joint venture	Equity	
SCCV STEEN CHATEAURENARD DENIS PAULEAU	SCCV	33.33	Joint venture	Equity	
SCCV STEEN DOUAI BOULEVARD VAUBAN	SCCV	33.33	Joint venture	Equity	
SCCV STEEN LE CHESNAY	SCCV	33.33	Joint venture	Equity	
SNC M&A CE	SNC	65.29		Full	
SCCV BREST REPUBLIQUE DEVELOPPEMENT	SCCV	50.00	Joint venture	Equity	
SCCV CASTELNAU DAHLIAS	SCCV	90.00		Full	
SCCV SAINT VALERY CAVEE LEVEQUE	SCCV	50.00	Joint venture	Equity	
SCCV SEVRAN ROUGEMONT	SCCV	70.00		Full	
SCCV STEEN ST GILLES RAIMONDEAU	SCCV	33.33	Joint venture	Equity	
SCCV STEEN GAILLON SUR MONTCIENT	SCCV	33.33	Joint venture	Equity	
SCCV LILURA DE L'ADOUR	SCCV	51.00	Joint venture	Equity	
SCCV ZOKO ST ESPRIT	SCCV	51.00	Joint venture	Equity	
SCCV AME ECHO	SCCV	60.00		Full	
SCCV PARIS 12 MESSAGERIES L3 L4	SCCV	100.00		Full	
SCCV LA PLATEFORME RE	SCCV	70.00		Full	
SCCV NANTERRE PARTAGEE	SCCV	35.00	Joint venture	Equity	
SCCV NIMOZA NIMES	SCCV	65.29		Full	
SCCV LE CLOS DES OLIVIERS-MARGUERITTES	SCCV	65.29		Full	
SCCV FORUM II – LATTES	SCCV	39.18		Full	
FONDATION D'ENTREPRISE ICADE PIERRE POUR TOUS	Foundation	100.00		Full	
SAS EQUINOVE	SAS	100.00		Full	
SCCV LA SAUVEGARDE	SCCV	50.10		Full	
SCCV CHOISY B7	SCCV	60.00	Joint venture	Equity	

• CONSOLIDATED FINANCIAL STATEMENTS •

	Legal form	2023			2022
		% ownership	Joint ventures / Associates	Method of consolidation	% ownership
COMMERCIAL PROPERTY DEVELOPMENT					
SNC ICADE PROMOTION TERTIAIRE	SNC	100.00		Full	100.00
PORTES DE CLICHY	SCI		Dissolution	Equity	50.00
SCCV SAINT DENIS LANDY 3	SCCV	50.00	Joint venture	Equity	50.00
SNC GERLAND 1	SNC	50.00	Joint venture	Equity	50.00
SNC GERLAND 2	SNC	50.00	Joint venture	Equity	50.00
CITE SANITAIRE NAZARIENNE	SNC	60.00		Full	60.00
ICAPROM	SNC	45.00	Joint venture	Equity	45.00
SCCV LE PERREUX CANAL	SCCV	100.00		Full	100.00
ARKADEA SAS	SAS	100.00		Full	100.00
CHRYSLIS DEVELOPPEMENT	SAS	35.00	Joint venture	Equity	35.00
MACDONALD BUREAUX	SCCV	50.00	Joint venture	Equity	50.00
SCI 15 AVENUE DU CENTRE	SCI	50.00	Joint venture	Equity	50.00
SAS CORNE OUEST VALORISATION	SAS	25.00	Associate	Equity	25.00
SAS ICADE-FF-SANTE	SAS	65.00		Full	65.00
SCI BOURBON CORNEILLE	SCI	100.00		Full	100.00
SCI ARKADEA FORT DE France	SCI		Dissolution	Full	51.00
SCCV SKY 56	SCCV	50.00	Joint venture	Equity	50.00
SCCV OCEAN COMMERCES	SCCV		Dissolution	Full	100.00
SCCV SILOPARK	SCCV	50.00	Joint venture	Equity	50.00
SCCV TECHNOFFICE	SCCV	50.00	Joint venture	Equity	50.00
SARL LE LEVANT DU JARDIN	SARL	50.67		Full	50.67
SCI ARKADEA RENNES TRIGONE	SCI	51.00	Joint venture	Equity	51.00
SCI ARKADEA LYON CREPET	SCI		Dissolution	Equity	65.00
SCCV LE SIGNAL/LES AUXONS	SCCV	51.00		Full	51.00
SCCV LA VALBARELLE	SCCV	49.90	Joint venture	Equity	49.90
SAS IMMOBILIER DEVELOPPEMENT	SAS	100.00		Full	100.00
SCCV HOTELS A1-A2	SCCV	50.00	Joint venture	Equity	50.00
SCCV BUREAUX B-C	SCCV	50.00	Joint venture	Equity	50.00
SCCV MIXTE D-E	SCCV	50.00	Joint venture	Equity	50.00
SCCV CASABONA	SCCV	51.00		Full	51.00
SCCV GASTON ROUSSEL ROMAINVILLE	SCCV	75.00		Full	75.00
SNC IP2T	SNC	100.00		Full	100.00
SCCV TOURNEFEUILLE LE PIRAC	SCCV	90.00		Full	90.00
SCCV LES RIVES DU PETIT CHER LOT 0	SCCV	60.00	Joint venture	Equity	60.00
SCCV LES RIVES DU PETIT CHER LOT 3	SCCV	60.00	Joint venture	Equity	60.00
SCCV DES RIVES DU PETIT CHER LOT 1	SCCV	60.00	Joint venture	Equity	60.00
SAS NEWTON 61	SAS	40.00	Joint venture	Equity	40.00
SCCV BRON LES TERRASSES L1 L2 L3 N3	SCCV	50.00	Joint venture	Equity	50.00
SAS LA BAUME	SAS	40.00	Joint venture	Equity	40.00
SCCV PIOM 1	SCCV	100.00		Full	100.00
SCCV PIOM 2	SCCV	100.00		Full	100.00
SCCV PIOM 3	SCCV	100.00		Full	100.00
SCCV PIOM 4	SCCV	100.00		Full	100.00
SAS PIOM 5	SAS	100.00		Full	100.00
SCCV COLADVIVI	SCCV	40.00	Associate	Equity	40.00
SCCV PIOM 6	SCCV	100.00		Full	100.00
SCCV 1 – B1C1 BUREAUX	SCCV	25.00	Joint venture	Equity	25.00
SCCV 2 – B1D1 BUREAUX	SCCV	25.00	Joint venture	Equity	25.00
SCCV 4 – COMMERCES	SCCV	25.00	Joint venture	Equity	25.00
SCCV 5 – B1C1 HOTEL	SCCV	25.00	Joint venture	Equity	25.00
SCCV 6 – B1C3 COWORKING	SCCV	25.00	Joint venture	Equity	25.00
SCCV PIOM 7	SCCV	100.00		Full	100.00

• CONSOLIDATED FINANCIAL STATEMENTS •

	Legal form	% ownership	2023	Method of consolidation	2022
			Joint ventures / Associates		% ownership
SCCV PIOM 8	SCCV	100.00		Full	100.00
SCCV PALUDATE GUYART	SCCV	50.00	Joint venture	Equity	50.00
SCCV BRON LES TERRASSES A1 A2 A3 A4	SCCV	50.00	Joint venture	Equity	50.00
SAS 10 COMMERCES B1A4 AND B1B1B3	SAS	25.00	Joint venture	Equity	25.00
SCCV BRON CLAIRIERE B	SCCV	50.00	Joint venture	Equity	50.00
SCCV ECOLE DE LA REPUBLIQUE	SCCV	50.00	Joint venture	Equity	50.00
SCCV STEEN PETREQUIN	SCCV	33.33	Joint venture	Equity	
OTHER PROPERTY DEVELOPMENT					
SARL DOMAINE DE LA GRANGE	SARL	51.00		Full	51.00
RUE CHATEAUBRIAND	SCI	100.00		Full	100.00
SNC DU PLESSIS BOTANIQUE	SNC	100.00		Full	100.00
SARL LAS CLOSES	SARL	50.00	Joint venture	Equity	50.00
SNC DU CANAL ST LOUIS	SNC	100.00		Full	100.00
SNC MASSY VILGENIS	SNC	50.00		Full	50.00
SAS LE CLOS DES ARCADES	SAS	50.00	Joint venture	Equity	50.00
SAS OCEAN AMENAGEMENT	SAS	49.00	Joint venture	Equity	49.00
SNC VERSAILLES PION	SNC	100.00		Full	100.00
SAS GAMBETTA SAINT ANDRE	SAS	50.00	Joint venture	Equity	50.00
SAS MONT DE TERRE	SAS	40.00	Joint venture	Equity	40.00
SNC DU HAUT DE LA TRANCHEE	SNC		Dissolution		100.00
SAS ODESSA DEVELOPPEMENT	SAS	51.00	Joint venture	Equity	51.00
SAS WACKEN INVEST	SAS	51.00	Joint venture	Equity	51.00
SCCV DU SOLEIL	SCCV	50.00	Joint venture	Equity	50.00
SAS MEUDON TASSIGNY	SAS	40.00	Joint venture	Equity	40.00
SAS DES RIVES DU PETIT CHER	SAS	50.00	Joint venture	Equity	50.00
SNC LH FLAUBERT	SNC	100.00		Full	100.00
SAS BREST AMENAGEMENT	SAS	50.00	Joint venture	Equity	50.00
SAS ICADÉ PIERRE POUR TOUS	SAS	100.00		Full	100.00
SAS BONDY CANAL	SAS	51.00	Joint venture	Equity	51.00
SAS HOLDING TOULOUSE TONKIN JHF	SAS	79.60		Full	79.60
SAS JALLANS	SAS	55.72		Full	55.72
SAS CLINIQUE 3	SAS	55.72		Full	55.72
SAS STEEN REHAB	SAS	33.33	Joint venture	Equity	33.33
SCCV 86 FELIX EBOUE	SCCV	100.00		Full	100.00
SAS DE LA BERGERIE	SAS	51.00		Full	51.00
SAS REPENDRE RACINES	SAS	51.00	Joint venture	Equity	51.00
SAS JAURES GALLIENI	SAS	55.00		Full	55.00
SCCV MARSEILLE SMCL	SCCV	15.00		Equity	15.00
SAS HOLDING CITY PARK LEVALLOIS	SAS	100.00		Full	100.00
SAS SAINT PIERRE CENTRE 2025	SAS	70.00	Joint venture	Equity	
SNC LEVALLOIS CITYPARK	SNC	51.00	Joint venture	Equity	
<b>DISCONTINUED OPERATIONS</b>					
<b>HEALTHCARE PROPERTY INVESTMENT</b>					
PRAEMIA HEALTHCARE	SAS		Decon.		58.30
SCI TONNAY INVEST	SCI		Decon.		58.30
SCI PONT DU CHÂTEAU INVEST	SCI		Decon.		58.30
SNC SEOLANES INVEST	SNC		Decon.		58.30
SCI SAINT AUGUSTINVEST	SCI		Decon.		58.30
SCI CHAZAL INVEST	SCI		Decon.		58.30
SCI DIJON INVEST	SCI		Decon.		58.30
SCI COURCHELLETES INVEST	SCI		Decon.		58.30
SCI ORLÉANS INVEST	SCI		Decon.		58.30
SCI MARSEILLE LE ROVE INVEST	SCI		Decon.		58.30

• CONSOLIDATED FINANCIAL STATEMENTS •

	Legal form	2023		2022	
		% ownership	Joint ventures / Associates	Method of consolidation	% ownership
SCI GRAND BATAILLER INVEST	SCI		Decon.		58.30
SCI SAINT CIERES INVEST	SCI		Decon.		58.30
SCI SAINT SAVEST	SCI		Decon.		58.30
SCI BONNET INVEST	SCI		Decon.		58.30
SCI GOULAIN INVEST	SCI		Decon.		58.30
OPPCI ICADE HEALTHCARE EUROPE	SPPICAV		Decon.		59.39
SALUTE ITALIA – FUND	REIF		Decon.		59.39
SAS IHE GESUNDHEIT	SAS		Decon.		63.49
SAS IHE RADENSLEBEN	SAS		Decon.		63.49
SAS IHE NEURUPPIN	SAS		Decon.		63.49
SAS IHE TREUENBRIETZEN	SAS		Decon.		63.49
SAS IHE ERKNER	SAS		Decon.		63.49
SAS IHE KYRITZ	SAS		Decon.		63.49
SAS IHE HENNIGSDORF	SAS		Decon.		63.49
SAS IHE COTTBUS	SAS		Decon.		63.49
SAS IHE BELZIG	SAS		Decon.		63.49
SAS IHE FRIEDLAND	SAS		Decon.		63.49
SAS IHE KLAUSA	SAS		Decon.		63.49
SAS IHE AUENWALD	SAS		Decon.		63.49
SAS IHE KLT GRUNDBESITZ	SAS		Decon.		63.49
SAS IHE ARN GRUNDBESITZ	SAS		Decon.		63.49
SAS IHE BRN GRUNDBESITZ	SAS		Decon.		63.49
SAS IHE FLORA MARZINA	SAS		Decon.		63.49
SAS IHE KOPPENBERGS HOF	SAS		Decon.		63.49
SAS IHE LICHTENBERG	SAS		Decon.		63.49
SAS IHE TGH GRUNDBESITZ	SAS		Decon.		63.49
SAS IHE PROMENT BESITZGESELLSCHAFT	SAS		Decon.		63.49
SAS IHE BREMERHAVEN	SAS		Decon.		63.49
SAS ORESC 7	SAS		Decon.		30.29
SAS ORESC 8	SAS		Decon.		53.39
SAS ORESC 12	SAS		Decon.		30.29
IHE SPAIN 1	SLU		Decon.		58.30
IHE GESTIONE ITALIANA	SRL		Decon.		58.30
IHE SALUD MANAGEMENT	SL		Decon.		58.30
SAS ISIHE 1	SAS		Decon.		58.30
FUNDO DE INVESTIMENTO IMOBILIARIO FECHADO SAUDEINVESTE	-		Decon.		58.83
IHE SPAIN 2	SLU		Decon.		58.30